University of Nebraska Medical Center

DigitalCommons@UNMC
Theses & Dissertations

Graduate Studies

Fall 12-16-2016

Staphylococcus Aureus Biofilms Interfere With Macrophage
Antimicrobial Responses Through Differential Gene Regulation,
Toxin Production, and Purine Metabolism
Tyler D. Scherr
University of Nebraska Medical Center

Follow this and additional works at: https://digitalcommons.unmc.edu/etd
Part of the Immunology and Infectious Disease Commons

Recommended Citation
Scherr, Tyler D., "Staphylococcus Aureus Biofilms Interfere With Macrophage Antimicrobial Responses
Through Differential Gene Regulation, Toxin Production, and Purine Metabolism" (2016). Theses &
Dissertations. 145.
https://digitalcommons.unmc.edu/etd/145

This Dissertation is brought to you for free and open access by the Graduate Studies at DigitalCommons@UNMC. It
has been accepted for inclusion in Theses & Dissertations by an authorized administrator of
DigitalCommons@UNMC. For more information, please contact digitalcommons@unmc.edu.

STAPHYLOCOCCUS AUREUS BIOFILMS INTERFERE WITH MACROPHAGE
ANTIMICROBIAL RESPONSES THROUGH DIFFERENTIAL GENE REGULATION,
TOXIN PRODUCTION, AND PURINE METABOLISM

By
Tyler Scherr

A DISSERTATION

Presented to the Faculty of
The Graduate College of the University of Nebraska Medical Center
In partial fulfillment of the requirements for the degree of
Doctor of Philosophy

Department of Pathology and Microbiology
Under the supervision of Professor Tammy Kielian, Ph.D.
University of Nebraska Medical Center
Omaha, NE
September 2016

1
Table of contents:
A.

Acknowledgements

4

B.

Abbreviations

6

C.

List of Figures and Tables

10

D.

Abstract

14

E.

Chapter 1: Introduction

16

1)

Staphylococcus aureus (S. aureus) biofilm infection

17

a)

Methicillin-resistant S. aureus (MRSA)

17

b)

S. aureus biofilms

18

c)

S. aureus prosthetic joint infections (PJIs)

19

d)

Mouse models of S. aureus prosthetic joint infection (PJI)

20

2)

3)

4)
F.

S. aureus virulence and host immune evasion

21

a)

Accessory gene regulator (agr)

21

b)

Microenvironment modulation

22

Innate immune response to S. aureus infection

23

a)

Innate immune recognition of S. aureus

23

b)

MΦ and PMN response to planktonic S. aureus

25

c)

MΦ and PMN response to S. aureus biofilm

26

Overview of dissertation

27

Chapter 2: Materials and Methods

29

1)

30

Bacterial strains and microbiological techniques

2

G.

H.

2)

Mouse strains

31

3)

Cell culture techniques

33

4)

Immune cell co-culture with S. aureus biofilms in vitro

35

5)

Nebraska Transposon Mutant Library Screens

37

6)

BMDMΦ treatments with biofilm-conditioned medium

39

7)

Orthopedic implant S. aureus biofilm infection

40

8)

Bacterial microarray analysis and qRT-PCR

43

9)

Bacterial Proteomics

45

10)

Bioflim extracellular DNA (eDNA) isolation

46

Chapter 3: Global transcriptome analysis of Staphylococcus aureus biofilms in
response to innate immune cells

49

Abstract

50

Introduction

51

Results

54

Discussion

84

Chapter 4: Staphylococcus aureus biofilms induce macrophage dysfunction through
leukocidin AB and α-toxin

88

Abstract

89

Introduction

90

Results

92

Discussion

118

3
I.

J.

L.

Chapter 5: purB affects eDNA release during Staphylococcus aureus biofilm
development to evade macrophage recognition

123

Abstract

124

Introduction

125

Results

127

Discussion

142

Chapter 6: Discussion and Future Directions

147

Key findings and conclusions

147

Future directions

152

References

156

4
Acknowledgements
I would first like to thank my mentor, Dr. Tammy Kielian, for her constant support, guidance, and
encouragement. I came to UNMC hoping to have the opportunity to work on translational
research; to spend my time researching something that might eventually have a positive impact on
people. Everything Tammy does with her lab is always with the patient in mind, and I couldn’t
have asked for a better mentor. Her scientific curiosity and passion for translational research is
infectious and, through all of the ups and downs of scientific research, I’ve been proud to be a
small part of her lab and almost always looked forward to putting in a full-days’ work there.

I would also like to thank my supervisory committee, Dr. Kenneth Bayles, Dr. Paul Fey, Dr.
Curtis Hartman, Dr. Jessica Snowden, and Dr. Geoffrey Thiele for sharing their time and
expertise in providing invaluable guidance in shaping my educational experience and insightful
suggestions regarding my scientific projects.

Next, I need to thank all of the members of the Kielian lab past and present that I have had the
pleasure working alongside over the past 5 years. Mark Hanke, Cortney Heim, Debbie Vidlak,
Amy Aldrich, and Amanda Angle welcomed me into the lab and patiently showed me the ropes
and helped me considerably with completing my projects and maintaining my sanity. Richa
Hanamsagar, Jane Xiong, Nikolay Karpuk, Maria Burkovetskaya, Rachel Fallet, Jessica Odvody,
Megan Bosch, and Venkata Kakulavarapu have all provided valuable feedback on my research
and/or contributed directly to the success of my experiments. Finally, Casey Gries, Kelsey
Yamada, and Anna Staudacher have more recently been a pleasure to work with and near on the
Staph side of the lab, and I owe each of them a debt of gratitude for their assistance as well.

5
I also owe a big thank you to several members of the Fey, Bayles, Chittezham Thomas, and
Snowden labs past and present for their assistance on various projects: Cortney Halsey, Carolyn
Schaeffer, Austin Nuxoll, Jill Lindgren, Marat Sadykov, Jennifer Endres, Derek Moormeier,
Vijaya Yajjala, Todd Widhelm, Matthew Beaver, Vinai Chittezham Thomas, and Sujata
Chaudhari. Several of our collaborators have also been instrumental to my project, including Dr.
Jeffrey Bose, Dr. Alex Horswill, Dr. Keer Sun, Dr. Victor Torres, and Dr. David James. I also
owe a special thanks to members of the UNMC Proteomics Facility (Dr. Pawel Ciborowski and
Jayme Horning) and the UNMC Flow Cytometry Facility (Dr. Charles Kuszynski, Dr. Phil
Hexley, Victoria Smith, and Sam Wall) for their patience and assistance with several
experiments.

Finally, I would like to thank my family and friends for their unceasing love and support. First
and foremost, to my beautiful wife Joelle, without whose constant support none of this would
have been nearly as successful. Next, my wild son Jax, who gives me a fresh perspective every
day and without whom none of this would be nearly as meaningful. To my parents, who shaped
me and without whom none of this would have been possible. To my family, who provided love
and support throughout my life and balance the past five years, especially my sister, Jennie,
brothers-in-law Ryan and Josh, my parents-in-law Tom and Kerry, and my Perry. And to all of
my UNMC friends who have made this journey in part or full with me (including the BRTP class
of 2011, Intramural Disc Golfers, 2015 GSA Officers, and UNMC Makers); I could have
definitely gotten my Ph.D. without you, but it most definitely would not have been as fun!

6
Abbreviations:
Agr

Accessory gene regulator

AIP

Autoinducing peptide

ANOVA

Analysis of variance

BHI

Brain-heart infusion

BMDMΦ

Bone marrow-derived macrophage

CA-MRSA

Community-acquired Methicillin-resistant Staphylococcus aureus

CFU

Colony forming units

DMEM

Dulbecco’s Modified Eagle’s Medium

DNA

Deoxyribonucleic acid

ECM

Extracellular matrix

eDNA

extracellular DNA

ELISA

Enzyme-linked immunosorbent assay

Erm

Erythromycin

EtOH

Ethanol

FACS

Fluorescence-activated cell sorting

FBS

Fetal bovine serum

Fc

Fragment, crystallizable

FITC

Fluorescein isothocyanate

GFP

Green fluorescent protein

GM-CSF

Granulocyte-macrophage colony-stimulating factor

7
HEPES

4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid

Hla

α-hemolysin

HRP

Horseradish peroxidase

IFN

Interferon

Ig

Immunoglobulin

IL

Interleukin

iNOS

Inducible nitric oxide synthase

i.p.

Intraperitoneal

KO

Knockout

K-wire

Kirschner wire

LAC

Los Angeles County

L-glut

L-glutamine

LTA

Lipoteichoic acid

LukAB

Leukocidin AB

MΦ

Macrophage

MACS

Magnetic-activated cell sorting

M-CSF

Macrophage colony-stimulating factor

MDSC

Myeloid-derived suppressor cell

MRSA

Methicillin-resistant Staphylococcus aureus

MSCRAMM

Microbial surface components recognizing adhesive matrix molecules

MET

Macrophage extracellular trap

8
MyD88

Myeloid differentiation primary response gene 88

NADPH

Nicotinamide adenine dinucleotide phosphate

NET

Neutrophil extracellular trap

NOD2

Nucleotide-binding oligomerization domain-containing protein 2

NOS

Nitric oxide synthase

OD

Optical density

PAMP

Pathogen associated molecular pattern

PBP2a

Penicillin-binding protein 2a

PBS

Phosphate-buffered saline

PCR

Polymerase chain reaction

PE

Phycoerythrin

PerCP

Peridinin-chlorophyll-protein complex

PFA

Paraformaldehyde

PGN

Peptidoglycan

PIA

Polysaccharide intercellular adhesion

PJI

Prosthetic joint infection

PMN

Polymorphonuclear cell

PRR

Pattern recognition receptor

PVL

Panton-Valentine Leukocidin

qRT-PCR

Quantitative real time-polyemerase chain reaction

RNA

Ribonucleic acid

9
ROS

Reactive oxygen species

RPMI

Roswell Park Memorial Institute

S. aureus

Staphylococcus aureus

s.c.

Subcutaneous

SCC

Staphylococcal cassette chromosome

S. epidermidis

Staphylococcus epidermidis

TCR

T cell receptor

TNF

Tumor necrosis factor

TSA

Tryptic soy agar

TSB

Tryptic soy broth

WT

Wild-type

10
List of Figures and Tables
Figure S2.1. Fluorescent microspheres can be used as a surrogate for live S. aureus to assess MΦ
phagocytosis
Figure 3.1. S. aureus biofilm growth states
Figure 3.2. S. aureus biofilm-leukocyte co-culture paradigm
Figure 3.3. Differential responses of innate immune cells to S. aureus biofilms
Figure 3.4. Acute MΦ addition to S. aureus biofilms leads to the transcriptional repression of
numerous genes
Figure 3.5. Classification of genes significantly altered by leukocyte addition in S. aureus
biofilms
Figure 3.6. qRT-PCR validation of down-regulated genes in S. aureus biofilms identified by
microarray analysis
Figure 3.7. agr promotes S. aureus biofilm resistance to PMN challenge
Figure 3.8. Differential responses of MΦs and neutrophils to S. aureus biofilms are cell
autonomous
Supplemental Figure S3.1. PMNs phagocytose S. aureus biofilms throughout the co-culture
period
Table 3.2. Significantly down-regulated genes between 6 day-old S. aureus biofilm versus
biofilm-MΦ co-cultures for a 1 h period
Table 3.3. Differentially expressed genes between 6 day-old S. aureus biofilm versus biofilmMΦ co-cultures for a 24 h period
Table 3.4. Differentially expressed genes between 6 day-old S. aureus biofilm versus biofilmPMN co-cultures for a 1 h period

11
Table 3.5. Differentially expressed genes between 6 day-old S. aureus biofilm versus biofilmPMN co-cultures for a 4 h period
Supplemental Table S3.1. Significantly increased genes between 6 day-old S. aureus biofilm
versus biofilm-MΦ co-cultures for a 1 h period
Supplemental Table S3.2. Significantly increased genes between 4 day-old S. aureus biofilm
versus biofilm-PMN co-cultures for a 1 h period
Figure 4.1. S. aureus biofilms secrete a proteinaceous factor(s) that inhibits MΦ phagocytosis
Figure 4.2. S. aureus biofilm-induced MΦ dysfunction is partially agr-dependent
Figure 4.3. SWATH-MS identifies potential biofilm factors responsible for MΦ dysfunction
Figure 4.4. LukA and Hla secretion is enhanced in S. aureus biofilms
Figure 4.5. LukAB and Hla play significant roles in biofilm-induced MΦ dysfunction
Figure 4.6. S. aureus Hla and LukAB act in concert to promote MΦ dysfunction
Figure 4.7. LukAB and Hla are important for S. aureus biofilm formation in vivo
Figure 4.8. Proposed model for S. aureus biofilm-induced MΦ dysfunction
Supplemental Figure S4.1. Bacterial counts and extracellular protein concentrations of S. aureus
WT planktonic, biofilm, and isogenic mutant biofilms are similar
Supplemental Figure S4.2. Validation of S. aureus Hla action on MΦ dysfunction
Supplemental Figure S4.3. Purified LukAB augments MΦ cytotoxicity
Supplemental Figure S4.4. Characterization of S. aureus biofilm growth in 1% casamino acids
Supplemental Table S4.1. Proteins identified to be in greater abundance in WT S. aureus
biofilm-conditioned medium compared to ∆agr biofilm-conditioned medium

12
Supplemental Table S4.2. Proteins identified to be in greater abundance in WT S. aureus
biofilm-conditioned medium compared to WT planktonic-conditioned medium
Figure 5.1. Genes expressed during S. aureus biofilm growth that influence MΦ NF-κB
activation
Figure 5.2. purB is important for preventing MΦ invasion and phagocytosis of mature S. aureus
biofilms
Figure 5.3. eDNA is increased in S. aureus ΔpurB biofilms
Figure 5.4. S. aureus biofilm eDNA can be detected by MΦs and trigger activity
Figure 5.5. S. aureus purB is important for chronic biofilm establishment
Table 5.1. Genes expressed by S. aureus biofilms that influence MΦ NF-κB activation in vitro
Supplemental Figure S5.1. Predicted purine biosynthetic pathway in S. aureus
Supplemental Figure S5.2. purB activity effects Hla production in S. aureus biofilms
Supplemental Figure S5.3. Adenosine attenuates MΦ activation
Figure 6.1. Mechanisms by which S. aureus biofilms interfere with MΦ antimicrobial responses

13

University of Nebraska Medical Center
Omaha, NE
September, 2016

STAPHYLOCOCCUS AUREUS BIOFILMS INTERFERE WITH MACROPHAGE
ANTIMICROBIAL RESPONSES THROUGH DIFFERENTIAL GENE REGULATION,
TOXIN PRODUCTION, AND PURINE METABOLISM

Tyler Scherr, Ph.D.
University of Nebraska Medical Center, 2015

Advisor: Tammy Kielian, Ph.D.

14
Abstract
Staphylococcus aureus (S. aureus) is an opportunistic pathogen that is a leading cause of both
nosocomial and community-associated infections. Armed with a myriad of virulence factors and
the propensity to form a biofilm on native tissues and implanted medical devices alike, S. aureus
infections represent a very real public health threat, the treatment of which results in an excessive
economic burden. S. aureus biofilm infections are notoriously recalcitrant to antibiotic therapy
and adept at evading and neutralizing the host immune antimicrobial response. Previous studies
from our laboratory have shown that S. aureus biofilms are able to cause persistent infections, in
part, through the reprogramming of the macrophage (MΦ) immune response. While macrophages
are readily able to recognize and respond to S. aureus in a planktonic state, their ability to mount
a functional antimicrobial attack is thwarted upon encountering S. aureus biofilm. We have
observed that MΦs in close proximity to S. aureus biofilms are less phagocytic and skewed
towards an anti-inflammatory profile typified by arginase and IL-10 production. We have
demonstrated that the ability of S. aureus biofilms to cause chronic infections is due, in part, to
TLR2 or TLR9 evasion. However, we have shown that MyD88 signaling does provide some
benefit to the host in combating S. aureus biofilm infections, which may be attributed to IL-1
receptor signaling. To better understand how S. aureus biofilms subvert the MΦ antimicrobial
response, the work described in this dissertation assessed S. aureus transcriptional activity during
co-culture with MΦs, whether S. aureus biofilms inhibit MΦ activity through secreted molecules,
and performed a high-throughput screen of the Nebraska Transposon Mutant Library to identify
key genes involved in dampening the MΦ NF-κB-regulated proinflammatory response. We found
that S. aureus biofilms attenuate their transcriptional activity following MΦ exposure, augment αhemolysin (Hla) and leukocidin AB (LukAB) secretion to inhibit MΦ phagocytosis and induce
cell death, and rely on a functional purine biosynthetic pathway to prevent MΦ invasion and
phagocytosis, in part, through controlling the amount of eDNA available for MΦ recognition at
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the surface of the biofilm extracellular matrix (ECM). Collectively, these studies build upon our
previous observations by identifying key mechanisms whereby S. aureus biofilms are able to
thwart the MΦ antimicrobial response.
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Chapter 1: Introduction
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1)

Staphylococcus aureus (S. aureus) biofilm infection

a)

Methicillin-resistant S. aureus (MRSA)
Staphylococcus aureus (S. aureus) is a gram-positive, opportunistic pathogen that in the

past few decades has become a leading cause of both nosocomial and community-associated
infections (1). S. aureus is the most virulent of the staphylococcus genus, with the ability to cause
a wide range of diseases, from relatively minor skin and soft tissue infections (SSTIs) to more
severe pneumonia and sepsis potentially leading to toxic shock syndrome (2). S. aureus has
remained a successful pathogen throughout the antibiotic era due, in part, to its propensity to
rapidly acquire antibiotic resistance, and methicillin-resistant S. aureus (MRSA) is no exception.
Methicillin, a beta-lactamase insensitive beta-lactam that is bacteriocidal by inhibiting
peptidoglycan synthesis, began being used in the 1950s in response to the emergence of
penicillin-resistant S. aureus (PRSA). However, within ten years MRSA isolates began to emerge
in hospitals across the US, with one of the first known incidences occurring at Boston City
Hospital (3). Through the intervening decades, MRSA continued to slowly spread, but generally
only affected immune compromised patients, until the late 1990s when a dramatic surge in
MRSA rates began (4). It was around this time that community-associated MRSA (CA-MRSA)
began to occur outside of hospitals, inflicting otherwise healthy individuals (5) who, had
historically encountered primarily methicillin-sensitive S. aureus (MSSA) strains.
CA-MRSA infection is now considered a worldwide epidemic and SSTIs are common,
particularly among athletes, children, homeless persons, military personnel, and many other
groups (6). While exact numbers vary from study to study, some reports place the percentage of
CA-MRSA as responsible for over 50% of all CA-S. aureus infections (7). The emergence of
MRSA coincides with the ability of S. aureus to express a low-affinity penicillin binding protein
(PBP) known as PBP2a (3), which is encoded by the mecA gene and carried on a mobile genetic
element known as Staphylococcal Cassette Chromosome (SCC) mec (8), which also contains
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intact or truncated sets of the divergently transcribed regulatory genes, mecR1 and mecI (3). In
the presence of beta-lactams, such as methicillin, mecR1 cleaves mecI bound to the operator
region of the mecA promoter, thereby de-repressing PBP2a production (9). Since methicillin
cannot bind PBP2a, cell wall synthesis is able to proceed and S. aureus is able to replicate in its
presence (3). While both are MRSA, CA-MRSA usually differs from nosocomial MRSA in that it
harbors smaller SCCmec variants, Type IV and V, is less resistant to other types of antibiotics,
produces more toxins including Panton-Valentine Leukocidin (PVL), and most commonly causes
SSTIs (3).
b)

S. aureus biofilms
Many bacteria can form biofilms, which are generally defined as an adherent community

of bacteria encased within a self-produced matrix typically composed of a combination of
exopolysaccharides, proteins, and extracellular DNA (eDNA) (10-12). The biofilm composition
is often dependent on environmental factors, such as nutrient availability and mechanical stress
(11). As biofilms represent a distinct lifestyle, biofilm-associated bacteria exhibit an altered
phenotype from planktonic cells with regard to metabolism, gene expression, and protein
production , undoubtedly in part due to nutrient, pH, and oxygen gradients present throughout the
characteristic tower-like biofilm structures (13). Biofilms represent a communal virulence
determinant to circumvent immune-mediated clearance and establish persistent infection (13-16).
Most medical device-associated biofilm infections are caused by S. epidermidis and S. aureus,
and both species can also establish biofilms on native host surfaces, such as heart and bone tissue
(17-19). The biofilm mode of growth has been recognized as a major mediator of infection,
contributing to an estimated 80% of all infections (20).
Biofilm formation is classically considered to occur in a stepwise fashion, consisting of
initial attachment, cell aggregation (21, 22) and proliferation, accumulation of an ECM and tower
formation, and detachment of cells and biofilm dispersal (10, 23, 24). Initial attachment is
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believed to be largely physico-chemical in nature, due to features such as hydrophobicity during
the process of passive adsorption (10, 24). S. aureus can form biofilms on both native tissue and
abiotic surfaces, and while the specific mechanisms for attachment likely differ between the two
types of surfaces, it is believed to be mainly governed by the interaction of bacteria with human
matrix proteins either present on native tissue or deposited on implanted medical devices shortly
after placement (24). Following initial attachment, S. aureus cells begin to accumulate and
aggregate into multiple layers in a process that is largely mediated by the expression of microbial
surface components recognizing adhesive matrix molecules (MSCRAMMs) (10). As the name
suggests, these are surface-attached proteins (e.g. fibronectin- and fibrinogen-binding
proteins)(25, 26) that help anchor the bacteria to the surface by linking with human matrix
proteins (24). Next, cells began to proliferate and form biofilm structures through the production
of exopolysaccharides (e.g. polysaccharide intercellular adhesion [PIA]) (27-29), proteins (e.g. S.
aureus surface proteins C and G [SasC, G]) (30, 31), and eDNA (10, 24, 32). The formation of
channels and tower-like structures are thought to facilitate nutrient and waste exchange within the
base of the biofilm (13, 23). Finally, upon full maturity biofilm-associated bacteria begin to
detach, facilitating biofilm dispersal in a process influenced by quorum-sensing (QS). QS is a
phenomenon whereby increased bacterial cell density triggers changes in gene expression and, in
S. aureus, is governed, in part, by the accessory gene regulator (agr) system (24).
c)

S. aureus prosthetic joint infections (PJIs)
An increasing world population coupled with increased life expectancies has led to a

progressive rise in primary and revision arthroplasties (33). By 2030, the demand for primary
total hip and knee arthroplasties in the United States alone is estimated to increase by 174% and
673%, respectively, over the number of procedures performed in 2005 (17). Due to its commensal
nature, it has been estimated that 20% of healthy adults are S. aureus carriers, typically in the
nasal cavity, with another 60% experiencing transient carriage (34), placing a vast majority of the
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adult population at increased risk of infection (35). Infection is the major complication of
orthopedic implants, with incidences reportedly between 1-2% for both knee and hip
replacements (36-40), and S. aureus is a leading cause of orthopedic implant infections with
serious morbidity and mortality outcomes (17, 41) in large part due to its ability to form a
biofilm. Biofilm infections are recalcitrant to antibiotics (42, 43), which often necessitates
removal of the infected device or native tissue, and are associated with significant morbidity and
economic impact (17, 44, 45). Indeed, it has been estimated that approximately $1.8 billion is
spent annually in the US for the treatment and clinical management of orthopedic implant-related
infections (46, 47).
While the exact mechanisms of prosthetic infection are still unclear, studies have
indicated that the presence of a foreign body reduces the minimal inoculum of S. aureus required
to cause infection by a factor of greater than 105 (48, 49). Experimental evidence in animal
models, for instance, have shown that an infection can occur with fewer than 100 colony forming
units (CFU) of microorganisms, and despite the use of perioperative antimicrobial prophylaxis,
when a foreign body is present (50). These animal observations have seemingly held true in
human patients as well, with higher relapse of infection following bacteremia in patients with
orthopedic implants, 30-40% of which followed S. aureus bacteremia (51, 52).
d)

Mouse models of S. aureus prosthetic joint infection (PJI)
There are currently two published murine models of S. aureus PJI, both of which explore

static biofilm growth and host-pathogen interactions during a persistent infection in an implantassociated osteomyelitis setting, but which differ slightly in placement of the metal implant and
observed host response. In the mouse tibial implant model, C57BL/6 mice have been shown to
establish a chronic infection resulting in upregulation of IL-2, IL-12p70, TNF-α, IL-1β, IL-6, and
IL-17 (53). In this model, it has been proposed that early activation of the inflammatory response
may not only be ineffective at microbial clearance, but may also be detrimental to the host due to
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collateral tissue damage caused by neutrophil (PMN) activation and inflammatory mediator
influx. In contrast, the early inflammatory response gives way to a chronic anti-inflammatory
milieu during the femur implant model, typified by myeloid-derived suppressor cell (MDSC)
infiltration in part through IL-12p70-mediated recruitment, a dampening of proinflammatory
signaling (e.g. IL-1β and IL-6), an increase in anti-inflammatory signaling (e.g. IL-10) (54-56).
2)

S. aureus virulence and host immune evasion

a)

Accessory gene regulator (agr)
S. aureus regulates protein production via a number of two-component systems,

including a bacterial density-dependent mechanism of cell-to-cell communication known as QS.
QS operates through the secretion and detection of a signal molecule, in this case autoinducing
peptide (AIP), which triggers a cascade of cellular responses (57). In S. aureus, the QS system is
encoded by the agr locus, composed of four co-transcribed genes (agrA, agrC, agrD, and agrB)
encoding a two-component trans-membrane transduction complex, a pro-signaling peptide, and a
membrane transporter (58). In S. aureus, at least four agr allelic genes exist that are characterized
by a specific signaling peptide (numbered I to IV) and it has been observed that the agr activity
within a group inhibits that of the other groups (59). The effector molecule of the agr system is a
regulatory RNA, RNAIII, whose synthesis is dependent on agr activation and driven by the P3
promoter (10). Altogether, the agr system acts as a trigger, switching from the expression of
surface-associated proteins to secreted proteins and has been shown to regulate numerous
virulence factors (e.g. α-toxin, leukocidins, phenol-soluble modulins [PSMs], adhesins, proteases,
etc.) and even play a role in the biofilm maturation process (60, 61). For example, the DNAbinding regulatory protein SarA is critical for biofilm formation and virulence factor expression
in S. aureus and SarA acts, in part, through the accessory gene regulator agr, which can thus be
thought of as an important regulatory switch between planktonic and biofilm lifestyles (62-65).
b)

Microenvironment modulation
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Previous work has characterized numerous secreted virulence factors used by
staphylococci that target specific host cell populations. S. aureus, in particular, utilizes numerous
hemolysins (66), leukocidins (67, 68), and proteases to evade the host immune system (69).
While staphylococci certainly divert resources from secreted to structural proteins during early
biofilm growth, protein secretion is still maintained in biofilms. For example, several reports have
demonstrated that various bacterial biofilm-forming species secrete peptides and full-length
proteins (i.e. Esp) that interfere with biofilm development of competing organisms, presumably to
eliminate competition for a biofilm-friendly niche (70-72). Additionally, studies have
demonstrated evidence of host-biofilm cross-talk involving the QS molecules N-Acyl homoserine
lactones (AHL), presumably to facilitate biofilm formation and bacterial persistence (73, 74).
Therefore, it is likely that staphylococcal biofilms also secrete factors in vivo, perhaps under QS
system regulation, in an attempt to evade immune recognition and clearance. For example, we
have recently shown that S. aureus biofilms are uniquely enriched in Hla and LukAB in an agrdependent manner in vitro and that the ability of S. aureus biofilm-conditioned medium to inhibit
MΦ phagocytosis is partially dependent on an intact biofilm (75). However, the identity of such
molecules remains to be elucidated but could represent future attractive anti-biofilm agents (76).
Besides virulence factors, staphylococci also secrete molecules for nutrient procurement
and cell signaling. For example, siderophores are critical for iron acquisition (77), while several
signaling molecules are important for biofilm remodeling and dispersal, such as AIP (65),
nuclease (78), and PSMs (79). While the primary roles of these molecules are apparently
unrelated to immune interactions, recent evidence suggests the potential for alternative functions.
For example, nuclease, which mediates biofilm dispersal (64, 78), can also participate in
neutrophil extracellular trap (NET) degradation (80). Recently, nuclease in combination with
adenosine synthase has been implicated in the conversion of NETs to leukotoxic deoxyadenosine,
highlighting a clever means whereby S. aureus turns the immune response against itself (81). In
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addition, S. aureus PSM expression is induced following PMN phagocytosis, resulting in PMN
lysis and bacterial escape (79, 82, 83). This process is regulated by the stringent response
characterized by the synthesis of the intracellular signaling alarmone (p)ppGpp (83). Therefore,
the stringent response provides yet another means of staphylococcal adaptation in response to
select immune pressures, something that has previously been well-established in relation to
nutrient availability and metabolism (84-89). Indeed, recent evidence has implicated (p)ppGpp
and di-cyclic NTPs as critical signals in the switch from planktonic to biofilm growth (76, 90).
However, secreted factors are not the only means whereby staphylococcal biofilms could
regulate the host response in an exogenous manner. While bacteria have a plethora of
environmental sensory mechanisms at their disposal, host immune cells are also very sensitive to
their surrounding environment (91-93). Because biofilms represent a large biomass, the sum
metabolic activity of the bacteria themselves would be expected to have an impact on pH and
oxygen levels in the surrounding tissue microenvironment. Indeed, even subtle changes in pH
(92, 94) or oxygen (91) can significantly alter the nature of the immune response. Furthermore,
novel research with fungal and bacterial biofilms has identified a coordinated system of ROS
signaling for biofilm maturation (95). It will be interesting to see what, if any, impact this biofilm
ROS gradient has on the host immune response and whether host-generated ROS can also act as a
signaling molecule within the biofilm to influence target pathways, such as biofilm formation via
QS (76, 95).
3)

Innate immune response to S. aureus infection

a)

Innate immune recognition of S. aureus
The innate immune system is well equipped to recognize foreign invaders through germ-

line encoded pattern recognition receptors (PRRs) that identify broad, highly conserved microbial
patterns known as pathogen-associated molecular patterns (PAMPs) (96). One such class of PRRs
is the Toll-like receptors (TLRs), which are responsible for the recognition of several key PAMPs

24
from both gram-positive and gram-negative bacterial pathogens (97, 98). Of particular
importance to S. aureus infections are TLR2 and TLR9, which recognize PGN and lipoproteins in
the bacterial cell wall and unmethylated CpG motifs characteristic of bacterial DNA, respectively
(99-102). TLR2 is expressed on the outer cell surface where it recognizes its ligands that are
naturally secreted and/or released from growing bacteria. TLR9, on the other hand, is an
intracellular receptor that could engage liberated bacterial DNA following phagocytosis and
degradation in the phagosome. In total, 12 TLRs have been identified in mice and 10 in humans,
each with their own unique ligand specificity (96, 103). While TLRs recognize different bacterial
PAMPs, most utilize a common signaling pathway through myeloid differentiation factor 88
(MyD88) and NF-κB that results in the transcriptional activation of several proinflammatory
cytokines and chemokines (104-107) that are critically important for coordinating an effective
antimicrobial immune response.
Although TLRs have been demonstrated to be critically important in mediating innate
immune recognition and clearance of S. aureus during planktonic growth (101, 108-111), several
recent studies have shown that S. aureus biofilms are able to circumvent TLR2 and TLR9
recognition (15, 56). These findings also agree with the observations that TLR2-deficient patients
show no increased risk of developing post-arthroplasty S. aureus infections (112). While the
mechanism responsible for TLR2/9 evasion by S. aureus biofilms are unknown, this could in part
be explained by ligand inaccessibility via the protective barrier provided by the complex biofilm
ECM (16). However, it is still possible that S. aureus biofilms may be recognized by alternative
PRRs, such as AIM2, DNA-dependent activator of IFN-regulator factors (DAI), and nucleotidebinding oligomerization domain-containing protein 2 (NOD2) (113-116). Additionally, while
TLR2 and TLR9 do not appear to be important for S. aureus biofilm recognition and clearance,
IL-1β has been demonstrated to be critical for controlling early bacterial burdens in PJI (56).
Likewise, studies from our laboratory and others have shown that MyD88 signaling is critical for
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controlling bacterial burdens during S. aureus biofilm infections (15, 117, 118). Interestingly,
both the IL-1 receptor (IL-1R) and TLRs signal through the adaptor MyD88 for the eventual
induction of NF-kB-mediated transcription (16).
b)

MΦ and neutrophil (PMN) response to planktonic S. aureus
The MΦ is a key innate immune responder that resides in nearly all tissues in the body

and arises upon maturation from extravasating monocytes from the peripheral circulation (119121). MΦs are highly plastic in that they can display a spectrum of functional states depending on
their environment. For example, in vitro experimentation has shown that monocytes treated with
granulocyte-macrophage colony-stimulating factor (GM-CSF) and inflammatory stimuli such as
PAMPs give rise to microbicidal M1 MΦs, whereas monocytes treated with macrophage colonystimulating factor (M-CSF) and IL-4 give rise to anti-inflammatory M2 MΦs that function in
tissue repair and fibrosis (122-124). In vivo, however, the situation is believed to be more
complex, with MΦ functionality existing on a dynamic spectrum of polarized states. Previous
work from our laboratory and others has shown that upon encountering S. aureus in a planktonic
state, MΦs become classically activated (M1) and exert their microbicidal effector functions, in
part, through the production of reactive oxygen and nitrogen species, in addition to
proinflammatory cytokines (125-128). MΦs also clear planktonic bacteria by phagocytosis, which
is tightly linked with proinflammatory cytokine and chemokine production to initiate adaptive
immune responses (129-131). Collectively, these innate leukocyte responses, coupled with
complement activation, usually ensure the successful clearance of planktonic staphylococcal
infections in an immune competent host.
The neutrophil (PMN) is typically the most prominent cellular component of the host
innate immune response to bacterial infections (132). PMNs are frequently the first responders to
microbial invaders and, as such, it has been observed that individuals with PMN defects (e.g.
chronic granulomatous disease) are highly susceptible to severe and life-threatening S. aureus
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infections (133). PMNs originate and mature in the bone marrow, maintain immune surveillance
by circulating in the peripheral vasculature, and are rapidly recruited to infected tissues through
chemotactic signals produced by host cells (e.g. IL-8, GRO-alpha, and MIP-2) (134-136) and/or
shed and secreted bacterial molecules (e.g. lipoteichoic acid or n-formyl peptides) (109, 137-141).
Upon encountering a foreign invader, PMNs will attempt to phagocytose the microbes, a process
which can be stimulated by PRRs but greatly enhanced when the pathogens are opsonized with
host serum molecules, including antibodies and cleavage products of the complement cascade
(142-146). Upon phagocytosis, PMNs use both oxygen-dependent (e.g. NADPH-dependent
oxidase) (147-150) and oxygen–independent (e.g. granules containing microbicidal agents such
as cathepsins) (151-154) processes to kill microbes. Recently, PMN and MΦ extracellular traps
(NETs and METs, respectively) have been identified as another means of antimicrobial action
(80, 155-157). This “beyond the grave” mechanism is typified by an extracellular net of DNA
released from dying phagocytes that contains localized islands of lytic enzymes that kill ensnared
extracellular bacteria. Collectively, these innate leukocyte responses, coupled with complement
activation, usually ensure the successful clearance of planktonic staphylococcal infections in an
immune competent host (76).
c)

MΦ and PMN response to S. aureus biofilms
In contrast to planktonic S. aureus infections, a very different scenario has emerged

regarding biofilm infections. Recent studies have demonstrated that staphylococcal biofilms
actively skew host immunity toward an anti-inflammatory, pro-fibrotic response that favors
bacterial persistence (15, 158-160). This is typified by alternatively-activated (M2) MΦs and
arginase-1 (Arg1) activity, resulting in urea and ornithine production, which are involved in
collagen formation and tissue remodeling (127, 161, 162). Our laboratory has shown that MΦs
associated with S. aureus biofilms both in vitro and in vivo have decreased inducible nitric oxide
synthase (iNOS) concomitant with increased Arg1 expression, as well as attenuated cytokine and
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chemokine production (15, 159, 160). Similar findings have been reported in response to S.
epidermidis biofilms (158, 163-165) and biofilms from other bacterial species (166-169),
suggesting a conserved mechanism exists to thwart host immunity to ensure biofilm persistence
(76, 170).
4)

Overview of dissertation
Initial experiments from our laboratory demonstrated that S. aureus biofilms were able to

cause persistent infections, in part, through the reprogramming of the MΦ immune response (15).
Specifically, we observed that MΦs in close proximity to S. aureus biofilms were less phagocytic
and skewed towards an anti-inflammatory M2 profile typified by Arg1 and IL-10 expression (15).
We hypothesized that this was due, in part, to the physical barrier presented by the biofilm ECM,
and that this matrix could be facilitating immune evasion by occluding otherwise recognizable
PAMPs as well as inducing “frustrated phagocytosis”. Additionally, we found that S. aureus
biofilms evade TLR2- and TLR9-mediated recognition in a murine model of biofilm infection
(15). However, we did demonstrate that MyD88 signaling does provide some benefit to the host
in combating S. aureus biofilm infections and that injecting exogenously activated M1 MΦs into
an established biofilm infection can promote clearance in vivo (159, 160).
During the course of my research, I have further identified multiple mechanisms that
contribute to S. aureus biofilm evasion of MΦ antimicrobial activity. First, I determined that S.
aureus biofilm-associated bacteria dampen their transcriptional activity upon encountering MΦs,
perhaps allowing the bacteria to limit the possibility of MΦ detection (171). Next, I observed that
S. aureus biofilm-conditioned medium is able to inhibit MΦ activation and induce MΦ cell death
due to heightened Hla and LukAB production (75). Finally, I performed a high-throughput screen
of the Nebraska Transposon Mutant Library and discovered the importance of purine biosynthesis
towards the ability of S. aureus biofilms to prevent MΦ phagocytosis. My research adds to the
growing literature describing the ability of S. aureus biofilms to circumvent the MΦ antimicrobial
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response and highlights some potential targets for novel treatments and prevention of chronic
biofilm related infections.
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Chapter 2: Materials and Methods
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1) Bacterial strains and microbiological techniques
Bacterial strains
S. aureus USA300 LAC is a community-associated methicillin-resistant (CA-MRSA) strain
isolated from a Los Angeles county (LAC) jail inmate with a SSTI and was also responsible for
the CA-MRSA outbreak of 2002 (172-175). We received the isolate from Dr. Frank DeLeo
(National Institute of Allergy and Infectious Diseases Rocky Mountain Laboratories, Hamilton,
MT) and cured it of its 27 kb LAC-p03 plasmid encoding erythromycin resistance (176) by
screening for spontaneous erythromycin sensitivity as previously described and was designated as
USA300 LAC 13C. For the purposes of this thesis, this wild type strain will be referred to as
USA300 LAC. The isogenic USA300 LAC agr mutant (Δagr) was provided by Dr. Alex
Horswill (University of Iowa Medical Center, Iowa City, IA) (11). The isogenic LAC ∆hla strain
was constructed by an insertion mutation using site-directed mutagenesis with the pE194
erythromycin resistance cassette (ermB) as previously described (177), with a hla complemented
strain (177) and a hla constitutively active strain (178) included to confirm the specificity of toxin
action. The USA300 JE2 Nebraska Transposon Mutant Library (NTML) (179) mutants, ∆lukA/H,
∆lukB/G, ∆lukD, ∆spl, and ∆purB were moved to the USA300 LAC 13C background by
transduction with Φ11 bacteriophage. Allelic replacement mutants of lukA and lukB and
complemented strains were generously provided by Dr. Victor Torres (New York University,
New York, NY). In vitro complementation of the USA300 ∆purB strain was performed by the
introduction of a functional purB gene on the pCM29 plasmid (180) under induction by the sarA
promoter, named pTS1. In vivo complementation of the USA300 ∆purB strain was performed by
the introduction of a functional purB gene with the native promoter on the pKK22 plasmid
generously provided by Dr. Jeffrey Bose (University of Kansas Medical Center, Kansas City,
KS). For confocal imaging, all strains were either transformed with pCM11 (erm10) or pCM29
(ca10) to express GFP driven by the sarA P1 promoter.
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Bacterial storage and preparation
Bacterial strains were stored as glycerol stocks at -80⁰C, struck out on fresh TSA plates
containing antibiotics for selection when necessary, and grown overnight at 37⁰C prior to
experimentation. A new streak plate was prepared for each experiment in an effort to avoid
mutation of bacteria by prolonged storage at 4⁰C. For experimentation, overnight cultures were
grown in the desired medium by selecting a single bacterial colony from the streak plate using a
sterile loop and incubating at 37⁰C overnight for 12-16 h with constant shaking at 250 rpm.
In vitro S. aureus biofilms
Sterile 12-well plates (Falcon, Corning, NY) or sterile 2-well glass chamber slides (Nunc,
Rochester, NY) were treated with 20% human plasma overnight at 4° C to facilitate bacterial
attachment. The following day, plasma coating buffer was removed and each chamber inoculated
with USA300 LAC at an OD600 of 0.05, whereupon bacteria were incubated at 37° C under static
aerobic conditions for a period of up to 6 days to generate mature biofilms. Our prior studies have
demonstrated that 6 day-old S. aureus biofilms propagated in RPMI-1640 are mature based on the
presence of tower structures and thickness (15, 160). Medium was carefully replenished every 24
h, and biofilms were visualized using a Zeiss laser scanning confocal microscope (LSM 510
META; Carl Zeiss, Oberkochen, Germany). Z-stacks were collected from beneath the glass slide
extending to above the point where bacteria could no longer be detected. Three-dimensional
images of biofilms and measurements to demonstrate biofilm thickness were performed using
Zen 2009 and 2012 software (Carl Zeiss).

2) Mouse strains
A breeding colony of C57BL/6 mice was established in Dr. Kielian’s laboratory after purchasing
animals from the National Cancer Institute (Frederick, MD) or Jackson Laboratories (Bar Harbor
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ME). These studies were performed in strict accordance with the recommendations provided in
the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health (NIH)
and were reviewed by the Institutional Animal Care and Use Committee of the University of
Nebraska Medical Center.

BALB/c NF-κB luciferase (NF-κB-luc) reporter mice (Caliper Life Sciences; Hopkinton, MA)
were generously provided by Caliper Life Sciences. These mice produce firefly luciferase under
the control of the mouse NF-κB promoter, allowing for the measurement of luminescence when
cells are provided with the substrate luciferin as an indicator of inflammatory status.

GFP transgenic (Tg) mice (C57BL/6-Tg[CAG-EGFP]) were purchased from The Jackson
Laboratory (Bar Harbor, ME). These mice produce GFP under the control of a chicken beta-actin
promoter and cytomegalovirus enhancer, which makes all of the tissues, with the exception of
erythrocytes and hair, appear green under excitation light.

TLR9 KO mice were obtained from The Jackson Laboratory (Bar Harbor, ME). These mice do
not express TLR9 and are therefore deficient in the ability of their immune cells to recognize
foreign, unmethylated CpG-DNA.

MyD88 KO mice (originally from Dr. S. Akira, Osaka University, Suita, Osaka, Japan) (26) were
purchased from the Centre de La Recherche Scientifique and have been previously backcrossed
with C57BL/6 mice for over 10 generations (29, 34). These mice do not express the adaptor
protein MyD88 which functions downstream of most TLR signaling pathways, connecting
bacterial PAMP recognition to NF-κB activity.
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3) Cell culture techniques
Primary mouse bone marrow-derived macrophage (BMDMΦ) culture
Adult BALB/c NF-κB-luc, C57BL/6 WT, CAG-EGFP, TLR9KO, and MyD88 KO mice were
euthanized with an overdose of inhaled isoflurane (Isothesia, VetUS, Dublin, OH) using a
euthanasia chamber and cervical dislocation as the secondary method of euthanasia. The
abdominal surface of each mouse was washed with an excess of 70% EtOH to minimize
contamination and a subcutaneous incision was made near the midline of the abdomen opening
up the peritoneum. Skin was separated until the hind limbs were exposed and excess muscle was
dissected away, allowing for the hind limbs to be removed at the hip joint and placed in 1X PBS
on ice. Hind limbs were then submerged in 70% EtOH, excess tissue and muscle was removed
with Kimwipes, and clean bones were placed in fresh 1X PBS on ice. The following steps were
performed under aseptic conditions in a biological safety cabinet with sterile autoclaved
instruments. Both ends of the bones were cut with scissors and bone marrow was flushed with
sterile, cold DMEM using a 26-gauge needle into a 50ml conical tube. Once all bones were
flushed, cells were pipetted to disrupt aggregates, filtered through a 70μm cell strainer, and
centrifuged at 1,200 rpm for 5 min at 4⁰C. The supernatant was aspirated and red blood cells
lysed by the addition of 900μl sterile water for 5 sec, followed by 100μl 10X PBS to restore
osmotic pressure. Finally, cells were washed with medium, centrifuged, and counted using trypan
blue (Lonza, Walkersville, Germany) on a hemacytometer. Cells were plated in 175mm2 tissue
culture dishes at a density of 107 cells/plate in 15ml of medium. BMDMΦ medium was composed
of Dulbecco’s modified eagle’s medium (DMEM, 4.5g/L glucose supplemented with 4mM Lglutamine) containing heat-inactivated fetal bovine serum (10% v/v FBS, HyClone, Logan, UT;
inactivated at 55⁰C for 30 min, with mixing at 10 min intervals), 20% conditioned medium from
L929 cells (ATCC) as a source of MΦ colony stimulating factor (M-CSF) (181) or 40ng/ml MCSF (eBioscience Inc., San Diego, CA), 1% v/v HEPES, 1% v/v Glutamine (both HyClone,
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South Logan, UT), 0.1% v/v 50 mM Beta-mercaptoethanol (Fischer Scientific, Pittsburgh, PA)
and antibiotic/antimycotic solution (penicillin, streptomycin, and ampotericin B, final 1% v/v,
Mediatech Inc., Manassas, VA). Medium was changed on cultures at days 2, 4, and 6 after initial
plating and cells were harvested on day 7 for experimentation.
Neutrophil isolation from the mouse bone marrow
Adult C57BL/6 mice were euthanized and bone marrow was isolated as previously described
above and placed on a three-layer Percoll gradient (Amersham Pharmaca, Biotech, Uppsala,
Sweden). After filtration, cells were centrifuged at 400 x g for 10 min at 4⁰C, resuspended in 3 ml
of 78% Stock Isotonic Percoll (SIP, 100% SIP [9 parts Percoll to 1 part 10X PBS] in 1X PBS),
followed by layering 3 ml of 69% and 52% SIP on top. The three-layer gradient was then
centrifuged at 1500 x g for 30 min at 15⁰C with no brake. PMNs were carefully collected from
the 69%/78% interface and upper portion of the 78% layer, washed with PBS, centrifuged at 400
x g for 10 min at 4⁰C, resuspended in 1 ml 1X Lysing Buffer (BD Pharm Lyse, BD Biosciences,
Franklin Lakes, NJ) and incubated at room temperature for 2 min. Lysis was stopped by addition
of HBSS + 10% FBS and cells were centrifuged at 400 x g for 10 min at 4⁰C prior to
resuspsension in 2 ml buffer for magnetic-activated cell sorting (MACS, PBS without Ca, Mg, +
2% FBS), vortexed and counted with trypan blue on a hemacytometer. Magnetic labeling was
performed using a Miltenyi anti-Ly6G MicroBead Kit (Miltenyi Biotec, San Diego, CA)
according to manufacturer’s instructions. Magnetic separation was performed using an MS
column on a MACS Separator. Columns were prepared by rinsing with 500 μl buffer, whereupon
the cell suspension was added to the column. Unlabeled cells were flushed by washing the
column 3X with 500 μl buffer prior to flushing buffer through with a plunger to elute the fraction
of labeled cells into a collection tube. Cells were counted and at least 600,000 Ly6G+ cells were
removed to check purity by flow cytometry, while the remaining cells were immediately used for
experimentation.
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4) Immune cell co-culture with S. aureus biofilms in vitro
Co-cultures for microarray studies
BMDMΦs or PMNs (107 and 106, respectively) were co-cultured with S. aureus biofilms for
various periods to assess their impact on the biofilm transcriptome, which equated to a MOI of
10:1 (bacteria/MΦ) or 100:1 (bacteria/PMN). PMNs or BMDMΦs were incubated with biofilms
in RPMI-1640 supplemented with 10% FBS at 37° C under static aerobic conditions until they
were harvested by mechanical dissociation at two different time points (1 and 24 h for BMDMΦs;
1 and 4 h for PMNs) to collect RNA for microarray analysis.

For visualization of BMDMΦ- or PMN-biofilm interactions, leukocytes were labeled with 5 µM
CellTracker Orange or CellTracker Blue (both from Molecular Probes, San Diego, CA)
depending on the experimental setup. BMDMΦ and PMN cell death was assessed using
Propidium Iodide Staining Solution (eBioscience Inc., San Diego, CA). Leukocyte-biofilm
interactions were visualized using a Zeiss laser scanning confocal microscope (LSM 510 META
or LSM 710), where Z-stacks were collected from beneath the glass slide extending to above the
point where labeled BMDMΦs or PMNs could no longer be detected. Three-dimensional images
and measurements to demonstrate leukocyte invasion into the biofilm were performed using Zen
2009 software and Zeiss LSM Image Browser (both from Carl Zeiss).
Co-cultures for ELISA studies
To determine the effect of S. aureus biofilms on MΦ cytokine secretion profiles, 106 BMDMΦs
were incubated with mature USA300 LAC biofilms or planktonic bacteria for 6 h at 37°C under
static aerobic conditions as previously described above, whereupon supernatants were clarified by
centrifugation and filtration (0.2 µm) to quantitate TNF-α, IL-10, IL-1β (OptiEIA; BD
Biosciences, Franklin Lakes, NJ), and IL-1RA (DuoSet; R & D Systems, Minneapolis, MN)
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production by ELISA. To account for potential interference by S. aureus protein A (Spa) in
ELISA assays, two separate controls were utilized; first, biofilm-conditioned supernatants without
MΦs were tested, which resulted in minimal cytokine signals. Second, conditioned supernatants
from USA300 LAC Δspa biofilm-MΦ co-cultures were also examined and produced similar
results to what was observed for isogenic wild type biofilms (data not shown).
Co-cultures prior to FACS
To evaluate whether MΦs exposed to intact biofilms were refractory to further activation with
well-characterized microbial antigens, BMDMΦs from GFP Tg mice were co-cultured with
USA300 LAC static biofilms or an equivalent number of planktonic bacteria for 2 h as described
above and subsequently dissociated by trituration. Next, the suspension was incubated with the
vital dye 7-aminoactinomycin D (7-AAD; eBioscience, San Diego, CA) and viable BMDMΦs
(GFP+, 7-AAD-) were recovered by fluorescence-activated cell sorting (FACS). A total of 105
biofilm- or planktonic-exposed BMDMΦs were subsequently treated with 10 µg/ml
peptidoglycan (PGN), 0.1 µM CpG oligodeoxynucleotide (ODN), or 1 µg/ml of the synthetic
lipoprotein Pam3CSK4, or left untreated for an additional 24 h, whereupon supernatants were
evaluated for TNF-α and IL-10 production by ELISA (OptiEIA; BD Biosciences).
Co-cultures for eDNA/DNase treatments
For visualization of BMDMΦ-biofilm interactions, BMDMΦs were labeled with 5 μM
CellTracker blue (Molecular Probes, San Diego, CA) and added to biofilms in fresh medium for
4-6 h. Propidium iodide staining solution (eBioscience Inc., San Diego, CA) was used to assess
eDNA as well as MΦ and bacterial cell death. MΦ-biofilm interactions were visualized using a
Zeiss laser scanning confocal microscope (LSM 710 META), where z-stacks were collected from
beneath the glass slide extending to above the point where labeled MΦs could no longer be
detected. Three-dimensional imaging and measurements to demonstrate MΦ invasion and
phagocytosis of biofilm-associated bacteria were performed using Zen 2012 software and the
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Zeiss LSM Image Browser (both from Carl Zeiss). In some experiments, biofilms were pretreated
for 30 min with 100 U/ml DNase (Sigma, St. Louis, MO) or exogenous eDNA isolated from S.
aureus biofilm was added to the surface prior to co-culture. Biofilm height and live/dead
quantitation was performed using COMSTAT (182) via ImageJ.

5) Nebraska Transposon Mutant Library screens
The Nebraska Transposon Mutant Library (NTML) (179) is a collection of sequence-defined
mutants where 1,952 non-essential genes in the S. aureus USA300 LAC genome have been
disrupted by insertion of the mariner-based transposon, bursa aurealis (183). We screened the
NTML to identify genes expressed during biofilm growth that influenced MΦ phagocytosis,
inflammatory activity, and viability as described below. S. aureus mutants that displayed changes
in MΦ activity but still formed a biofilm were selected for further analysis.
BMDMΦ phagocytosis
The NTML was screened using a microtiter plate assay to identify biofilm-associated genes
regulating secreted products that inhibit BMDMΦ phagocytosis. Briefly, starter cultures of
NTML mutants were prepared from glycerol stocks and incubated for 16 h in RPMI-1640
supplemented with 10% FBS and 5 µg/ml erm at 37°C while shaking at 250 rpm under aerobic
conditions. 96-well microtiter plates were pre-coated with 20% human plasma diluted in sterile
carbonate-bicarbonate buffer (Sigma) at 4°C. The following day, plasma coating buffer was
removed and starter cultures were inoculated at a 1:200 dilution and incubated at 37°C under
static aerobic conditions for 4 days. Medium was carefully replenished every 24 h using an
epMotion 5075 LH robotics platform (Eppendorf, Hamburg, Germany) to minimize cross
contamination and prevent disruption of the biofilm structure.
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BMDMΦ s were seeded at 105 cells/well in tissue culture-treated 96-well plates (Becton
Dickinson, Franklin Lakes, NJ) and incubated overnight at 37°C, 5% CO2, whereupon BMDMΦs
were treated for 2 h at 37°C with biofilm-conditioned supernatants diluted 1:2 in fresh RPMI1640/10% FBS, followed by 1 h incubation with 106 yellow-green fluorescent microspheres (2.0
µm particle size; Molecular Probes, San Diego, CA) to assess phagocytic activity. After the 1 h
incubation period, BMDMΦs were washed extensively with sterile PBS to remove any residual
extracellular microspheres and phagocytic activity was assessed as a measure of total
fluorescence using a Victor3V 1420 plate reader (Perkin Elmer, Waltham, MA) or TECAN M200
PRO (Tecan Group Ltd., Mannedorf, Germany) running Magellan 7.0 software (Tecan Austria
GmbH, Grodig, Austria).
BMDMΦ NF-κB activation
The NTML was also screened to identify mutants that affected MΦ NF-κB activation during
biofilm growth. This assay utilized BMDMΦs from NF-κB-luciferase reporter mice (NF-κB-luc
BMDMΦs), where NF-κB promoter activity is detected with the substrate D-luciferin and
quantitated using a luminometer. Static biofilms were grown in luminescence-compatible 96-well
microtiter plates (Perkin Elmer, Waltham, MA) until mature (as described above), whereupon
NF-κB-luc BMDMΦs (105/well) were co-cultured with S. aureus biofilms for 4 h, after which
samples were lysed using ddH2O and 100 µl/well of D-luciferin (15mg/ml; Gold Biotechnology,
St. Louis, MO) was added to detect luciferase expression. Luminescence was quantified using a
Victor3V 1420 plate reader (Perkin Elmer). Positive and negative controls included NF-κB-luc
BMDMΦs treated with 10 µg/ml S. aureus PGN and untreated cells, respectively. Biofilms alone
produced minimal luminescence signal compared to background (data not shown).

6) BMDMΦ treatments with biofilm-conditioned medium
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Preparation of biofilm-conditioned medium
Static biofilms were generated in two-well glass chamber slides (Nunc, Rochester, NY) or 12well plates (Becton Dickinson, Franklin Lakes, NJ) with S. aureus grown in RPMI-1640 medium
supplemented with 1% casamino acids (CAA; Becton Dickinson) as previously described (15,
184, 185). Spent medium was replaced daily, whereupon conditioned medium for experiments
was collected from 6 day-old USA300 LAC biofilms 24 h following the last medium change and
filtered (0.2 µm). For comparisons, planktonic-conditioned medium was prepared by growing an
overnight culture of USA300 LAC to early (12 h) and late (18 h) stationary phase. As no
significant differences in phagocytosis or viability were observed when MΦs were treated with
conditioned medium from either early or late stationary phase cultures (data not shown), early
stationary phase was utilized throughout these studies. Conditioned medium was also collected
from 6 day-old USA300 LAC biofilms that were mechanically disrupted by trituration,
whereupon the suspension was incubated for another 24 h with fresh medium before collection as
described above. Where indicated, biofilm-conditioned medium was treated with 10μg/ml
proteinase K for 1h at 37⁰C to degrade proteins, or treated with either 10 μg/ml polyanethole
sodium sulfanate (PAS) or mechanically disrupted and incubated with 50 μg/ml lysostaphin (both
from Sigma, St. Louis, MO) 24 h prior to collection. In some experiments, fresh RPMI-1640
medium was spiked with 10 μg of purified S. aureus Hla (Sigma) or 25 μg of purified bioactive or
inactive LukAB (186) to examine effects on MΦ phagocytosis and viability. For some
experiments, biofilm-conditioned medium was incubated with rabbit anti-staphylococcal Hla
antiserum or control rabbit serum (both from Sigma) for 30 min prior to MΦ treatment.
BMDMΦ phagocytosis and cell viability assay
BMDMΦs were prepared and labeled with 5 µM CellTracker Blue (CTB; Molecular Probes, San
Diego, CA) as previously described (15, 187). CTB-labeled MΦs were added to sterile 2-well
glass chamber slides (5x106 cells/chamber) and allowed to adhere for 2 h. Next, MΦs were
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exposed to conditioned medium collected from S. aureus biofilms or planktonic cultures for 2 h at
37°C, whereupon red or green fluorescent microspheres (2.0 µm particle size; Molecular Probes)
were added at a concentration of 4.5x1010 microspheres/ml for 1 h to assess phagocytic activity.
Fluorescent microspheres were used instead of intact S. aureus, since pilot studies revealed that
similar results were obtained with both reagents (Supplemental Fig. S2.1). MΦs were treated with
undiluted biofilm- or planktonic-conditioned medium, since a stronger phenotype was observed
under these conditions (Supplemental Fig. S2.1). MΦ phagocytosis was assessed using a Zeiss
510 META laser scanning confocal microscope (Carl Zeiss, Oberkochen, Germany) and
quantitated by the number of phagocytic events observed in at least 8, random fields of view
(63x) using ZEN 2009 software (Carl Zeiss). Data is expressed as either “percent phagocytosis”,
which indicates the percentage of phagocytic MΦs observed and manually counted within a given
experiment, or “total phagocytosed beads/63x field”, where the total number of phagocytic events
within a given experiment was calculated by an ImageJ plugin (ImageJ 1.47v, Wayne Rasband,
NIH, USA) based on an experimentally determined average pixel area and RGB color code
specific to the co-localization of phagocytosis. Pilot studies confirmed that identical results were
obtained with this calculation compared to manual counts (data not shown). While the number of
beads phagocytosed per MΦ was variable within any given incubation condition, we did not
observe any trends in this parameter between treatment groups and, therefore, this was not
quantified. MΦ viability was assessed by propidium iodide staining at the end of the 3 h
incubation period with the total number of viable MΦs quantitated in at least 8 random 63x fields
of view using ZEN 2009 software. Where reported, “total viable MΦs” were enumerated by an
ImageJ plugin based on an experimentally determined average pixel area and RGB color code
specific to viable MΦs and are reported per 63x microscopic field.

7) Mouse model of S. aureus orthopedic implant biofilm infection
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Preparation of inoculum
A single bacterial colony from a fresh streak plate was used to inoculate 25 ml of autoclaved
brain-heart infusion (BHI) broth in a baffled 250 ml flask (10:1 flask:volume ratio) with constant
shaking at 250 rpm at 37⁰C for 12-16 h. The overnight culture was then diluted 1:10 in fresh BHI
in order to estimate the total number of bacteria present by measuring OD600 (BioMate 3S
Spectrophotometer, Thermo Scientific, Waltham, MA). At the same time, 1 ml of the overnight
culture was centrifuged in a 1.5 ml Eppendorf microcentrifuge tube at 14,000 rpm for 5 min at
4⁰C to pellet the bacteria. The supernatant was removed the pellet was resuspended in 1 ml sterile
1X PBS and subsequently washed two more times by centrifuging as previously described. After
washing, the pellet was diluted in sterile PBS to a final estimated concentration of 5x105 cfu/ml
(1x103 cfu/2μl). The actual inoculum concentration was then determined by serial diluting the
washed culture in triplicate to 10-8 and plating 100 μl of the 10-7 and 10-8 dilutions on TSA.
Infection procedure
Age and sex-matched mice (8-10 weeks old) were weighed and anesthetized with
ketamine/xylazine (100 mg/kg and 5 mg/kg, respectively) by i.p. injection prior to the surgical
site being shaved and disinfected with povidone-iodine. A scalpel was then used to make an
incision along the midline of the knee exposing the patella. Next, a medial parapatellar
arthrotomy was performed with the scalpel to access the knee joint, allowing for a lateral
retraction of the patella to expose the entire distal femur. A 26-gauge needle was then used to
bore a hole through the trochlea into the intramedullary canal creating space for the insertion of a
precut and autoclaved 0.8-cm orthopedic-grade Kirschner wire (0.6 mm diameter, Nitinol [nickeltitanium]; Custom Wire Technologies, Port Washington, WI) leaving approximately 1 mm
exposed as an inoculation site. A total of 103 cfu of the USA300 LAC strain was inoculated in 2
μl at the implant tip, and the patella was relocated prior to surgical wound closure with 6-0 metric
absorbable sutures and skin closure with 6-0 metric nylon sutures (both from Covidien,
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Mansfield, MA). Immediately following surgery and again at 24 h post-surgery, all animals
received Buprenex (0.1 mg/kg s.c.; Reckitt Benckiser, Hull, U.K.) for pain management, after
which all mice exhibited normal ambulation with no discernible pain.
Recovery of implant and surrounding tissues
Animals were sacrificed by an overdose of inhaled isoflurane followed by cervical dislocation.
The flank and left leg were then disinfected with 70% EtOH prior to the skin of the left leg being
carefully removed to expose the infected tissue. Excess underlying adipose tissue and muscle was
removed prior to collection of the tissue immediately proximal to the infection site, which was
then weighed and placed in 500 μl homogenization buffer (1X PBS + protease inhibitor cocktail
tablet, Roche, Indianapolis, IN) on ice. The tissue was then dissociated with the blunt end of a
plunger from a 30-cc syringe and filtered through a 35 μm filter (BD Falcon, Bedford, MA).
Next, a 150μl aliquot was removed for quantitation of bacterial burdens and potential assessment
of inflammatory mediator production (e.g. ELISA). The remaining filtrate was further processed
for flow cytometry as described below. Following tissue collection, the knee joint and femur were
collected, weighed, and placed in 500 μl homogenization buffer prior to being homogenized by a
combination of handheld Polytron homogenizer at the highest setting for 30 s and a Bullet
Blender (Next Advance, Averill Park, NY) with a combination of 0.9-2.0 mm diameter blend and
3.2 mm diameter stainless steel beads (Next Advance, Averill Park, NY). Implants were removed
from the femur and vortexed in 500 μl PBS for 5 min at 2000 rpm. Serial dilutions of effluents
from tissue, joint, femur, and implant were plated on TSA and grown overnight at 37⁰C to
determine bacterial colonization. For some experiments, the spleen, heart, and kidneys were
collected as described above to determine dissemination.
Flow cytometry
Characterization of immune infiltrates was performed via Fluorescence-activated cell sorting
(FACS). Animals were sacrificed with an overdose of inhaled isoflurane and tissues were excised
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and processed as previously described above. The tissue filtrate was washed with ice-cold 1X
PBS + 2% FBS and centrifuged at 1200 rpm for 5 min at 4⁰C, after which RBCs were lysed using
BD Pharm lyse (BD Biosciences, San Diego, CA) per the manufacturer instructions. After lysis,
cells were resuspended in 500 μl 1X PBS followed by Fc Block (2 μl/sample, eBioscience, San
Diego, CA) for 20 min at 4⁰C to minimize nonspecific antibody binding. 100 μl of each sample
was pooled and subsequently aliquoted into single color compensation and isotype control tubes
to identify gaiting thresholds and assess the degree of nonspecific staining, respectively. The
remaining 400 μl was divided between two tubes for subsequent staining with two panels (e.g.
innate and T cell) and q.s. to 500 μl with 1X PBS. Cells were then stained for 30 min at 4⁰C
protected from light with directly-conjugated antibodies for multi-color flow cytometry analysis,
prior to being washed with 1X PBS, centrifuged as previously described, and resuspended in 1X
PBS + 1% paraformaldehyde. The innate immune panel included: CD45-APC, Ly6G-PE, Ly6CPerCP-Cy5.5, and F4/80 PE-Cy7. The T cell panel included: CD3ε-APC, CD4-Pacific Blue,
CD8a-FITC, Ly6C-PerCP-Cy5.5, and TCR γδ-PE. All fluorochrome-conjugated antibodies were
purchased from either BD Biosciences or eBioscience. For the exclusion of dead cells, a
Live/Dead Fixable Stain Kit (Life Technologies, Eugene, OR) was also used, following
manufacturer’s instructions. Analysis was performed using BD FACSDiva software with cells
gated on the live CD45+ leukocyte population.

8) Bacterial microarray analysis and qRT-PCR
RNA isolation
At the appropriate intervals after biofilm-leukocyte co-culture, excess medium was removed from
biofilm chambers and 2X the remaining volume of RNAprotect (QIAGEN, Hilden, Germany)
was added. Biofilms were collected from the bottom of the chamber slide using a cell scraper.
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RNA isolated from biofilms alone (i.e. no leukocyte addition) was included as a control for
comparisons. The resulting suspension of biofilm cells was transferred to a tube and sonicated for
5 min to facilitate dispersal. After sonication, cells were pelleted by centrifugation for 5 min and
RNAprotect was decanted. The resulting pellet was resuspended in 700 µl of RLT Buffer
supplemented with β-mercaptoethanol and transferred to a 2 ml FastPrep lysing tube (MP
Biomedicals, Santa Ana, CA). Biofilm cells were lysed in a FastPrep high-speed homogenizer
(MP Biomedicals) for 20 sec on a speed setting of 6. The resulting lysate was incubated for 5 min
on ice and then centrifuged at 14,000 rpm at 4°C for 15 min. RNA was isolated from the clarified
supernatant using a RNeasy mini kit (QIAGEN) and contaminating DNA was removed by oncolumn DNase digestion using the RNase-Free DNase Set (QIAGEN). RNA was isolated from
eight samples for each time point and co-culture condition with three independent experimental
replicates performed to assess the reproducibility of microarray results. RNA quality and quantity
were determined using an Agilent RNA6000 NANO kit and Agilent 2100 Bioanalyzer (Agilent
Technologies, Santa Clara, CA).
RNA labeling and DNA microarray analysis
Following the manufacturer’s recommendations, 75 ng of total RNA from each sample was
amplified using ExpressArt Bacterial mRNA amplification Nano kits (AmpTec GmbH,
Germany) and labeled using BioArray HighYield RNA Transcript Labeling kits (Enzo Life
Sciences, Inc., Farmingdale, NY). Three micrograms of resulting labeled RNA was hybridized to
a S. aureus GeneChip® following the manufacturer’s recommendations for antisense prokaryotic
arrays (Affymetrix, Santa Clara, CA) then washed, stained, and scanned as previously described
(22, 188). Commercially available GeneChips® were used in this study, representing > 3300 S.
aureus ORFs and > 4800 intergenic regions from strains N315, Mu50, NCTC 8325, and COL
(Affymetrix). GeneChip® signal intensity values for each biofilm sample at each replicate time
point (n ≥ 3) were normalized to the median signal intensity value for each GeneChip® and
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averaged using GENESPRING 7.2 software (Agilent Technologies, Redwood City, CA).
Transcripts that demonstrated 1) at least two-fold change in expression; 2) greater than
background signal intensity value and determined to be "Present" by Affymetrix algorithms; and
3) significant by Student's t-test (p value = 0.05) were considered differentially expressed.
Verification of differentially expressed genes by qRT-PCR
A subset of biofilm genes that were differentially regulated after leukocyte co-culture (i.e. sodA,
saeS, saeR, agrB, rsbU, atl, recA, and nuc) was verified by qRT-PCR using Sybr Green. Primers
were designed using Primer 3.0 software and melt-curve analysis was performed at the end of
each amplification run to verify signal specificity. Results are presented as the relative expression
compared to biofilms that were not co-cultured with leukocytes as a reference standard.

9) Bacterial proteomics
Sequential Windowed data-independent Acquisition of the Total High-resolution Mass
Spectra (SWATH-MS)
Conditioned medium from S. aureus WT and Δagr strains grown under biofilm or planktonic
conditions as described above were harvested, treated with a protease inhibitor cocktail (Roche,
Basel, Switzerland), and proteins precipitated with 20% TCA. Relative protein concentrations
were compared between groups using three independent replicates per sample by Sequential
Windowed data-independent Acquisition of the Total High-resolution Mass Spectra (SWATHMS) as previously described (189). A Z-transformation followed by a Z-test was performed on all
positively identified proteins (>98% confidence) between two sample sets at a time (i.e. WT
biofilm vs. Δagr biofilm or WT biofilm vs. WT planktonic) to assess significant differences in
relative protein abundance as previously described (189). Identified proteins were functionally
grouped by UniProt identifier utilizing the DAVID bioinformatics resource 6.7
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(http://david.abcc.ncifcrf.gov/) (190). Protein-protein interactions were predicted using STRING
9.05 (http://string-db.com) (191, 192).
Western blots
Conditioned medium from S. aureus WT and Δagr biofilm and planktonic growth conditions was
sterile-filtered and treated with a protease inhibitor cocktail (Roche) prior to storage at -80⁰C.
Upon thawing, samples were TCA precipitated overnight and suspended in 30 μl of Laemmli
buffer, whereupon 5 μl of each sample was loaded onto a gel, transferred to a PVDF membrane,
and probed for S. aureus LukA and Hla.
Enzyme-linked Immunosorbent Assay (ELISA)
Conditioned medium from WT S. aureus biofilm and planktonic cultures was sterile-filtered
(0.2µm) and analyzed for Hla concentrations by direct ELISA. Briefly, experimental samples or
serial dilutions of purified S. aureus Hla (Sigma), to generate a standard curve, were diluted in
carbonate-bicarbonate buffer and incubated in 96-well ELISA plates overnight at 4⁰C. The
following day, wells were washed extensively with 1X PBS/0.5% Tween and incubated with a
rabbit anti-Hla antibody followed by an anti-rabbit IgG-HRP antibody (both from Sigma) for
detection. Plates were developed using a TMB substrate (Becton Dickinson) with the reaction
halted using stop solution prior to reading at 450nm. Hla concentrations were normalized to total
protein as measured by a Pierce BCA Protein Assay.

10) Bioflim extracellular DNA (eDNA) isolation
Isolation of eDNA from static biofilms grown in 12-well plates was performed as described
previously (32). Briefly, day 6-old mature biofilms were chilled to 4⁰C followed by the addition
of 50 mM EDTA prior to removal of supernatant, resusupended and mechanically disrupted in
TES Buffer (Tris-HCL; pH 8.0/500mM NaCl). Next, a phenol:chloroform:isoamyl alcohol
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(25:24:1) extraction followed by a chloroform/isoamyl alcohol (24:1) extraction was performed
prior to storage overnight at -20⁰C in 100% ice-cold ethanol and 10% 3M NaAcetate. The next
day, the eDNA was pelleted and washed prior to a final resuspension in TE buffer. qRT-PCR was
performed on 1:10 dilutions of each sample with the LightCycler DNA Master SYBR Green I
(Roche) using gyrA.

48
Supplemental Figure S2.1

Fluorescent microspheres can be used as a surrogate for live S. aureus to assess MΦ
phagocytosis. (A) Bone marrow-derived MΦ were incubated for 3 h with fresh medium or
conditioned medium collected from WT biofilms and left undiluted or diluted 1:5 with fresh
medium, whereupon phagocytosis was assessed by the uptake of planktonic S. aureus +
fluorescent microspheres (beads) or microspheres alone. Significant differences are denoted with
asterisks (***, p < 0.001; unpaired two-tailed student’s t-test). Results are representative of at
least two independent experiments.
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Chapter 3: Global transcriptome analysis of Staphylococcus aureus biofilms in response to
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Abstract
The potent phagocytic and microbicidal activities of PMNs and MΦs are among the first
lines of defense against bacterial infections. Yet Staphylococcus aureus is often resistant to innate
immune defense mechanisms, especially when organized as a biofilm. To investigate how S.
aureus biofilms respond to MΦs and PMNs, gene expression patterns were profiled using
Affymetrix microarrays. The addition of MΦs to S. aureus static biofilms led to a global
suppression of the biofilm transcriptome with a wide variety of genes downregulated. Notably,
genes involved in metabolism, cell wall synthesis/structure, and
transcription/translation/replication were among the most highly downregulated, which was most
dramatic at 1 h compared to 24 h following MΦ addition to biofilms. Unexpectedly, few genes
were enhanced in biofilms after MΦ challenge. Unlike co-culture with MΦs, co-culture of S.
aureus static biofilms with PMNs did not greatly influence the biofilm transcriptome.
Collectively, these experiments demonstrate that S. aureus biofilms differentially modify their
gene expression patterns depending on the leukocyte subset encountered.
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Introduction
Staphylococcus aureus produces numerous virulence factors that facilitate its ability to
invade, colonize, disseminate to distant sites, and impede host defenses to cause disease (84,
193). These characteristics can be amplified during biofilm formation, which represents a
complex multicellular community of organisms encased in a matrix composed primarily of
polysaccharides, extracellular DNA (eDNA), and proteins (10-12). S. aureus biofilm infections
are often difficult to treat due to their heterogeneity and altered metabolic and transcriptional
activity (194), which likely contributes to the chronic and recurrent nature of biofilm infections
(159, 195-197). Our recent studies have demonstrated that S. aureus biofilms interfere with
traditional microbial recognition and killing mechanisms by the innate immune system (159,
195). The subversion of these responses is another example of the remarkable success of S.
aureus as a pathogen and it is now clear that biofilm growth represents yet another immune
resistance determinant. However, our understanding of the cross-talk between S. aureus biofilms
and the immune response is limited.
PMNs are important antimicrobial effectors that possess an arsenal of bactericidal
compounds, including defensins, cathelicidins, and lysozyme (156, 198). In terms of their
microbicidal activity, PMNs are most notable for their ability to produce large amounts of
reactive oxygen intermediates catalyzed by NADPH oxidase. In addition, activated PMNs
degranulate and release PMN extracellular traps (NETs), a meshwork of DNA and enzymes that
facilitates the extracellular killing of S. aureus as well as other bacteria (199). However, the short
lifespan of PMNs requires their constant recruitment to sites of infection, and their transcriptional
capacity for inflammatory mediator production is more limited compared to other professional
phagocytes (i.e. MΦs and dendritic cells). MΦs reside in virtually all tissues and also serve as a
critical first line of defense against microbial invasion. In addition, MΦs are a major source of
proinflammatory mediators that are critical for amplifying leukocyte recruitment and activation
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cascades upon bacterial exposure, as well as providing potent phagocytic and antimicrobial
effects (200, 201). Like PMNs, MΦs can form MΦ extracellular traps (METs),which are believed
to exert similar antimicrobial activity (157). Both MΦs and PMNs are also equipped with an
arsenal of pattern recognition receptors that sense invariant motifs expressed across a broad range
of microbial species to trigger inflammatory mediator release (202, 203). Consequently, PMNs
and MΦs represent key antimicrobial effector populations and their interactions with S. aureus
biofilms is likely critical for dictating the outcome of infection. Our previous studies have
demonstrated that S. aureus biofilms impair MΦ phagocytosis and induce cell death (159, 195,
204); however the response of the biofilm itself to these leukocyte populations remains to be
defined.
While considerable progress has been made in defining S. aureus virulence factors and their
regulatory networks, less is known about the organism’s ability to cope with the host immune
response during biofilm growth (205-207). Genome-wide transcriptional profiling of planktonic
S. aureus following PMN exposure has previously been reported (208, 209); however the
transcriptional changes occurring in S. aureus biofilms in response to PMNs or MΦs has not yet
been investigated. We predicted that S. aureus biofilms modify their transcriptome in response to
these leukocyte subsets to subvert immune recognition and killing, thus favoring biofilm
persistence. This possibility was assessed by defining alterations in S. aureus biofilm gene
expression profiles after co-culture with MΦs or PMNs utilizing S. aureus Affymetrix GeneChip®
arrays. Here we report that S. aureus biofilms respond differently to these leukocyte populations,
with kinetic distinctions also observed. For example, MΦ addition induced a generalized
repression of the biofilm transcriptome within 1 h, whereas at a later interval this inhibition had
dissipated, which correlated with the biofilm’s ability to induce MΦ cell death. In contrast, the
biofilm transcriptome remained relatively stable following PMN addition, regardless of the
interval examined. These results indicate that S. aureus biofilms discriminate between leukocyte
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subsets and alter their transcriptional profile accordingly, presumably in favor of avoiding
detection by the host, leading to biofilm persistence.
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Results
Differences in neutrophil and macrophage interactions with S. aureus biofilms in vitro. To
evaluate the impact of leukocyte subsets on S. aureus biofilm transcriptional profiles, biofilms
that were propagated for either 4 or 6 d were selected for analysis based on their differences in
structural maturity (195). Specifically, 4 day-old biofilms were considered more immature in
terms of average thickness (32 µm) and irregular density (Fig. 3.1A and C), whereas 6 day-old
biofilms were classified as more mature based on a relatively uniform average thickness (47 µm)
and a more consistent density (Fig. 3.1B and C).
Previous studies from our group have demonstrated that S. aureus biofilms are capable of
circumventing MΦ phagocytosis and inducing MΦ death (159, 195, 204). Since the goal of this
study was to compare the impact of MΦs versus PMNs on the biofilm transcriptome, side-by-side
comparisons of how both populations interact with the biofilm were required. S. aureus USA300
LAC-GFP static biofilms were grown for 4 or 6 d, whereupon MΦs or PMNs were co-cultured
with biofilms for an additional 1, 4, or 24 h. Three-dimensional confocal microscopy images were
constructed to demonstrate the proximity of MΦs or PMNs from the biofilm surface and extent of
phagocytosis (Fig. 3.2A and 2B, respectively). MΦs incubated with S. aureus biofilms for either a
1 or 24 h period contained few internalized bacteria, a phenomenon that was independent of
biofilm age as we have previously described (Fig. 3.2A and 3.3) (195). In contrast, intracellular
bacteria were readily discernible in PMN biofilm co-cultures at 1, 4, and 24 h (Fig. 3.2B, 3.3, and
Supplemental Fig. 3.1). In addition, the majority of PMNs were found in close association with
the biofilm surface, whereas most MΦs remained distant from the biofilm (Fig. 3.2).
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Figure 3.1

S. aureus biofilm growth states. (A and B) USA300 LAC-GFP was inoculated into sterile 2well glass chamber slides and incubated at 37°C under static aerobic conditions for a period of 4
(A) or 6 (B) days in RPMI 1640 supplemented with 10% FBS with daily medium replacement.
Biofilms were visualized using confocal microscopy (magnification, X63; 1-μm slices), and
representative three-dimensional images were constructed. (C) Quantification of 4- and 6-day-old
biofilm thickness. Significant differences are denoted with asterisks (***, P < 0.001 using an
unpaired two-tailed Student t test; n = 30 biofilms/time point).
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Figure 3.2

S. aureus biofilm-leukocyte co-culture paradigm. USA300 LAC-GFP static biofilms (green)
were grown for 6 days, whereupon BMDMΦs (A) (orange) or bone marrow-isolated PMNs (B)
(blue) were incubated with biofilms for 24 h and 4 h, respectively. Biofilm co-cultures were
visualized using confocal microscopy (magnification, X63; 1-μm slices), and representative
three-dimensional images were constructed. Insets show a higher magnification to highlight the
absence of MΦ phagocytosis (A) and the presence of PMN phagocytosis (B) of staphylococcal
biofilms. Results are representative of two independent experiments examining three individual
biofilms each.
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Figure 3.3

Differential responses of innate immune cells to S. aureus biofilms. S. aureus USA300 LACGFP static biofilms were grown for 6 days and visualized using confocal microscopy (63X
magnification, 1 µm slices). A total of 107 BMDMΦs or 5 x 106 bone marrow-isolated PMNs
were incubated with biofilms for 18-24 h, whereupon the percentage of leukocytes exhibiting
phagocytosis or death, were enumerated. Significant differences are denoted with asterisks (**, p
< 0.005 using an unpaired two-tailed Student’s t-test, n = 3).
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Macrophages and neutrophils induce differential gene expression profiles in S. aureus
biofilms. The disparity between the ability of MΦs and PMNs to phagocytose and invade S.
aureus biofilms suggested that these cell types may differentially influence biofilm transcriptional
activity. To investigate this possibility, Affymetrix S. aureus GeneChip® profiles were compared
between biofilms incubated in the presence or absence of either MΦs or PMNs. Analysis of the
number of differentially expressed genes revealed that MΦs caused the most substantive changes
in the biofilm, primarily at an early time point (i.e. 1 h; Fig. 3.4A, 3.5A, 3.5B, and Tables 3.2-3),
affecting genes involved in metabolism and transcription/translation/replication for both
immature and mature biofilms (Fig. 3.5). Unexpectedly, most biofilm genes were down-regulated
in response to acute MΦ exposure, with the exception of several hypothetical genes and a lone
gene involved in staphyloxanthin biosynthesis (Supplemental Table 3.1). However, the ability of
MΦs to induce global gene repression was transient, as the number of genes altered was
dramatically reduced after a 24 h co-culture period (Figs 3.4A, and Tables 3.2, 3.3, and
Supplemental Fig. 3.1). This is likely attributable to the fact that a large percentage (≥ 55%) of
MΦs are dead approximately 6 h after co-culture with S. aureus biofilms and presumably are no
longer able to produce factor(s) that influence the biofilm transcriptome (195). A subset of genes
identified as differentially expressed by biofilms upon MΦ addition in the microarray analysis
were verified by qRT-PCR (Fig. 3.6).
In comparison to MΦs, PMNs were more limited in their ability to affect S. aureus biofilm
gene transcription (Fig. 3.4B, 3.5C, 3.5D, and Tables 3.4, 3.5, and Supplemental 3.2). Of note,
many genes remained unaltered following MΦ or PMN addition to biofilms, suggesting that these
genes are important for biofilm maintenance in the face of an immune challenge. Nonetheless,
PMNs and MΦs differentially impact the S. aureus biofilm transcriptome as revealed by the
dichotomy in the observed gene expression patterns.
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Figure 3.4

Acute macrophage addition to S. aureus biofilms leads to the transcriptional repression of
numerous genes. The total number of genes significantly up- or down-regulated in response to
MΦ (A) or PMN (B) co-culture in immature (4 day-old) or mature (6 day-old) S. aureus biofilms
is shown, including those encoding for hypothetical proteins.
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Figure 3.5

Classification of genes significantly altered by leukocyte addition in S. aureus biofilms. S.
aureus USA300 LAC-GFP static biofilms were grown for 4 or 6 days, whereupon MΦs (A and
B) or PMNs (C and D) were incubated with biofilms for 1 h. The numbers of genes with defined
functions (grouped into cell wall/membrane, virulence/defense, regulation, metabolism,
transcription/translation/replication, and miscellaneous categories) significantly altered after MΦ
or PMN challenge are shown. Genes encoding for hypothetical proteins were not included.
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Table 3.2. Significantly down-regulated genes between 6 day-old S. aureus biofilm versus
biofilm-macrophage co-cultures for a 1 h period
Category
Virulence/defense
Fold
Change

Common

Locus

Description

-30.01

nuc

SA0860

thermonuclease precursor

-13.84

epiA

SA1878

lantibiotic epidermin precursor

-12.43

SA2525

ABC transporter, ATP-binding protein

-9.54

SAS0388

exotoxin 3
alpha-hemolysin precursor

-6.88

hlY

SA1173

-6.40

hlb

BA000017
SA2003
phospholipase C

-5.59

chp

SAR2036

chemotaxis-inhibiting protein

SA0477

type I restriction-modification system, S subunit, EcoA
family, putative

SA2409

fmhA protein

-3.16

SA2430

ABC transporter, ATP-binding/permease protein

-2.91

SA2445

fmtA-like protein

-2.78

SA1098

metallo-beta-lactamase family protein

-4.99
-4.64

fmhA

-2.73

epiP

SA1874

epidermin leader peptide processing serine protease

-2.39

entK

SA0886

staphylococcal enterotoxin

-2.22

eprH

SA1265

endopeptidase resistance gene

-2.04

set8

SA0384

exotoxin 8

-2.03

epiE

SA1872

epidermin immunity protein F

Fold
Change

Common

Locus

Description

-22.02

isdC

SA1141

NPQTN cell wall surface anchor protein

SA1994

ABC transporter, ATP-binding protein

SA1138

LPXTG cell wall surface anchor protein

SA1779

transglycosylase domain protein

Cell wall

-8.42
-8.24

isdB

-7.69
-7.66

spsB

SA0969

signal peptidase IB

-6.44

isdD

SA1142

hypothetical protein

-6.39

SA1932

transglycosylase domain protein

-6.23

SA0486

staphylococcus tandem lipoprotein
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-5.38

tagX

SA0697

teichoic acid biosynthesis protein X

-4.62

abcA

SA0700

ABC transporter, ATP-binding/permease protein

SA1169

fibrinogen-binding protein precursor-related protein

-4.40
-3.93

srtA

SA2539

sortase

-3.46

opuBB

SA0783

osmoprotectant ABC transporter, permease protein

-3.35

isaB

SA2660

immunodominant antigen B

-3.34

SA0203

iron compound ABC transporter, iron compound-binding protein,
putative

-3.30

SA0611

glycosyl transferase, group 1 family protein

-3.27

SA0242

teichoic acid biosynthesis protein, putative

SA0935

D-alanine-activating enzyme/D-alanine-D-alanyl carrier protein ligase

-2.94

SA1806

cell wall surface anchor family protein

-2.93

SA1043

glycosyl transferase, group 1 family protein

-2.48

SA1951

Mur ligase family protein

-2.27

SA2431

ABC transporter, ATP-binding/permease protein

-3.19

dltA

-2.27

cap1C

SA2685

capsular polysaccharide biosynthesis protein Cap1C

-2.18

dltD

SA0938

DltD protein

-2.13

SA2082

membrane protein, putative

-2.11

SA0119

cell wall surface anchor family protein

Transcription/translation/replication
Fold
Change

Common

Locus

Description

-10.99

SA2089

single-stranded DNA-binding protein family

-9.90

SA1900

DNA repair exonuclease family protein

-7.17

gpxA

SA1325

glutathione peroxidase

-6.75

rbf

SA0725

transcriptional regulator, AraC family

-6.39

norR

SA0746

transcriptional regulator, MarR family

SA2058

PemK family protein

SA1516

ribosomal protein S1

SA2517

transcriptional regulator, MerR family

SA1221

guanylate kinase

-5.68

SA1919

transcriptional regulator, Fur family

-5.53

SA1060

transcriptional regulator, MarR family

-5.49

SA0550

S4 domain protein

-5.44

SA2203

ClpA-related protein

-6.28
-6.18

rpsA

-6.13
-5.85

gmk
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-5.42

recF

SA0004

recF protein

-5.40

SA1732

replication initiation and membrane attachment protein

-5.29

SA1939

phosphotyrosine protein phosphatase

-5.28

SA0305

ABC transporter, permease protein

-4.87

SA0980

transcriptional regulator, LysR family

-4.77

SA2407

lipoprotein, putative

-4.68

SA1803

pseudouridine synthase, family 1

-4.63

SA0028

IS431mec, transposase

-4.62

ctsR

SA0567

transcriptional regulator

-4.51

licT

SA1393

transcriptional antiterminator

SA1997

transcriptional regulator, GntR family

SA1632

ribosomal protein S21

SA2297

monooxygenase family protein

SA1638

heat shock protein

SA2290

transcriptional regulator, AraC family

SA1622

glycyl-tRNA synthetase

SA0552

general stress protein 13

SA2353

transcriptional regulator

-3.72

SA2713

rhodanese-like domain protein

-3.63

SA1897

protein export protein PrsA, putative

-3.62

SA1894

HIT family protein

-3.62

SA0526

DNA polymerase III, delta prime subunit, putative

-4.41
-4.34

rpsU

-4.32
-4.26

grpE

-4.22
-4.13

glyS

-3.97
-3.88

tcaR

-3.56

serS

SA0009

seryl-tRNA synthetase

-3.52

ftsL

SA1023

putative cell division protein

SA2500

MutT/nudix family protein

SA1369

ribosomal protein L33

-3.38

SA2325

transcriptional regulator, LysR family

-3.36

SA1541

transcriptional regulator, Fur family

-3.33

SA2317

phosphosugar-binding transcriptional regulator

-3.29

SA0535

primase-related protein

-3.24

SA1957

RNA methyltransferase, TrmA family

-3.44
-3.43

rpmG

-3.24

rnr

SA0846

exoribonuclease, VacB/RNase II family

-3.23

rpsP

SA1254

ribosomal protein S16

-3.23

czrA

SA2137

transcriptional regulator CzrA

64
-3.23

gidB

SA2736

glucose-inhibited division protein B

-3.20

rpmF

SA1137

ribosomal protein L32

-3.20

nusB

SA1569

N utilization substance protein B

-3.12

SA1794

thioredoxin, putative

-3.05

SA1285

N utilization substance protein A, putative

-3.04

SA1205

cell-division initiation protein, putative

-3.00

SA0563

transcriptional regulator, GntR family

SA1495

DNA polymerase III, epsilon subunit/ATP-dependent helicase

-2.96

SA0432

spoOJ protein

-2.95

SA1107

transcriptional regulator, Cro/CI family

-2.86

SA0540

endoribonuclease L-PSP, putative

SA0970

exonuclease RexB

SA1839

transposase, IS200 family

-2.99

-2.84

dinG

rexB

-2.81
-2.76

recQ

SA1523

ATP-dependent DNA helicase RecQ

-2.67

gltC

SA0513

transcriptional regulatory protein GltC

-2.61

SA1752

CBS domain protein

-2.61

SA2131

Dps family protein

-2.59

SA0314

conserved hypothetical protein

-2.58

miaA

SA1323

tRNA delta(2)-isopentenylpyrophosphate transferase

-2.51

crcB

SA1832

crcB protein

-2.51

SA1065

transcriptional regulator, putative

-2.48

SA1954

exonuclease

-2.45

nrdG

SA2634

anaerobic ribonucleoside-triphosphate reductase activating protein

-2.45

dnaK

SA1637

dnaK protein

-2.45

pcrA

SA1966

ATP-dependent DNA helicase

SA0024

5-nucleotidase family protein

SA1241

ATP-dependent DNA helicase RecG

SA0551

cell-division protein divIC, putative

-2.44
-2.40

recG

-2.39
-2.35

asnS

SA1494

asparaginyl-tRNA synthetase

-2.27

dnaN

SA0002

DNA polymerase III, beta subunit

SA1771

OsmC/Ohr family protein

-2.23
-2.21

htrA

SA1028

serine protease

-2.20

hexB

SA1316

DNA mismatch repair protein

-2.18

rnhC

SA1150

ribonuclease HIII

65
-2.10

parB

-2.09
-2.07

pheT

-2.06

SA2735

chromosome partioning protein, ParB family

SA1153

DNA-dependent DNA polymerase family X

SA1149

phenylalanyl-tRNA synthetase, beta subunit

SA1250

chromosome segregation SMC protein, putative

-2.05

map

SA1946

methionine aminopeptidase, type I

-2.01

mscL

SA1182

large-conductance mechanosensitive channel

Common

Locus

Description

agrD

SA2024

accessory gene regulator protein D

SA2359

sensor histidine kinase

SA2055

anti-sigma B factor

SA1354

sensor histidine kinase, putative

Regulation
Fold
Change
-8.53
-7.97
-6.53

rsbW

-5.85
-5.73

sarZ

SA2384

staphylococcal accessory protein Z

-5.61

rsbV

SA2056

anti-anti-sigma factor RsbV

-5.41

icaR

SA2688

intercellular adhesion regulator

-5.13

sarS

SA0096

staphylococcal accessory regulator S

-4.95

vraR

SA1942

DNA-binding response regulator

-4.91

rsbU

SA2057

sigma factor B regulator protein

-4.82

graS

SA0717

sensor histidine kinase

-4.50

arlS

SA1450

sensor histidine kinase

-4.07

vraS

SA1943

sensor histidine kinase

-3.82

sarY

SA2289

staphylococcal accessory regulator Y

-3.64

sarA

SA0672

staphylococcal accessory regulator A

SA1906

sensor histidine kinase, putative

SA2023

accessory gene regulator protein B

SA1355

DNA-binding response regulator, LuxR family

-3.49
-3.37

agrB

-2.61
-2.53

arlR

SA1451

DNA-binding response regulator

-2.39

agrC

SA2025

accessory gene regulator protein C

Common

Locus

Description

SA2167

iron compound ABC transporter, iron compound-binding protein

SA1143

iron compound ABC transporter, iron compound-binding protein, putative

SA1111

spermidine/putrescine ABC transporter, spermidine/putrescine-binding prot

Metabolism
Fold
Change
-7.97
-7.58
-7.32

isdE

66
-7.31

SA1875

epidermin biosynthesis protein

-6.46

SA1920

D-isomer specific 2-hydroxyacid dehydrogenase family protein

-5.66

SA1592

rhodanese-like domain protein

-5.28

SA2363

L-lactate permease

SA2151

phosphoglucosamine mutase

SA0024

5-nucleotidase family protein

-5.20

epiD

glmM

-5.19
-5.13

nrdF

SA0793

ribonucleoside-diphosphate reductase 2, beta subunit

-5.11

cls1

SA1351

cardiolipin synthetase

-5.08

phoU

SA1420

phosphate transport system protein

-5.06

SA0031

glycerophosphoryl diester phosphodiesterase, putative

-4.97

SA1787

chorismate mutase/phospho-2-dehydro-3-deoxyheptonate aldolase

-4.79

purB

SA1969

adenylosuccinate lyase

-4.73

isdF

SA1144

iron compound ABC transporter, permease protein, putative

SA2459

carboxylesterase

SA2617

alpha-acetolactate decarboxylase

SA1753

universal stress protein family

SA1223

phosphopantothenoylcysteine decarboxylase/phosphopantothenate--cystein

SA2138

cation efflux family protein

-4.62
-4.54

budA

-4.25
-4.19

coaBC

-4.10
-4.08

xpt

SA0458

xanthine phosphoribosyltransferase

-4.06

proC

SA1546

pyrroline-5-carboxylate reductase

-4.00

xseA

SA1568

exodeoxyribonuclease VII, large subunit

-3.92

lacG

SA2180

6-phospho-beta-galactosidase

SA0876

arsenate reductase, putative

-3.71
-3.62

sodA

SA1610

superoxide dismutase

-3.58

zwf

SA1549

glucose-6-phosphate 1-dehydrogenase

SA1588

proline dipeptidase

SA2627

choline dehydrogenase

-3.53

SA2375

transporter, CorA family

-3.47

SA1804

polysaccharide biosynthesis protein

-3.32

SA0666

iron compound ABC transporter, permease protein

-3.58
-3.56

betA

-3.30

gcvH

SA0877

glycine cleavage system H protein

-3.13

cdsA

SA1280

phosphatidate cytidylyltransferase

SA0024

5-nucleotidase family protein

SA1429

aspartate-semialdehyde dehydrogenase

-3.09
-3.03

asd
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-3.02

SA1818

3,4-dihydroxy-2-butanone-4-phosphate synthase/GTP cyclohydrolase II

-3.01

SA0155

cation efflux family protein

-2.98

SA2475

peptide ABC transporter, permease protein, putative

-2.97

SA0712

lipase/esterase

-2.97

SA0687

Na+/H+ antiporter, putative

-2.88

SA2278

acyl-CoA dehydrogenase-related protein

SA1235

ribulose-phosphate 3-epimerase

-2.78

SA0024

5-nucleotidase family protein

-2.76

SA1545

oxidoreductase, short-chain dehydrogenase/reductase family

-2.73

SA1553

glyoxalase family protein

SA0616

glucosamine-6-phosphate isomerase

SA0024

5-nucleotidase family protein

SA2342

magnesium and cobalt transport protein CorA, putative

SA0409

conserved hypothetical protein

SA0251

6-phospho-beta-glucosidase

-2.57

SA1825

N-acetylmuramoyl-L-alanine amidase, family 4

-2.57

SA0200

phosphoglycerate transporter family protein

-2.84

-2.65

rpe

nagB

-2.63
-2.61

corA

-2.57
-2.57

bglA

-2.54

tyrA

SA1401

prephenate dehydrogenase

-2.52

ribD

SA1820

riboflavin biosynthesis protein

-2.46

aroK

SA1596

shikimate kinase

-2.42

arcC

SA1182

carbamate kinase

-2.41

lysA

SA1435

diaminopimelate decarboxylase

-2.40

thrB

SA1364

homoserine kinase

-2.38

cidC

SA2553

pyruvate oxidase

-2.31

SA1814

lysophospholipase, putative

-2.31

SA2303

inositol monophosphatase family protein

SA1693

preprotein translocase, YajC subunit

-2.27

SA0655

oxidoreductase, aldo/keto reductase family

-2.23

SA1109

spermidine/putrescine ABC transporter, permease protein

-2.28

yajC

-2.15

nrdD

SA2635

anaerobic ribonucleoside-triphosphate reductase

-2.13

menE

SA1844

O-succinylbenzoic acid--CoA ligase, putative

-2.13

SA0308

carbohydrate kinase, PfkB family

-2.11

SA2195

M23/M37 peptidase domain protein

-2.08

SA0921

CBS domain protein
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-2.07

epiC

-2.01

SA1876

epidermin biosynthesis protein

SA1309

pyruvate ferredoxin oxidoreductase, beta subunit

Miscellaneous
Fold
Change

Common

-15.57

Locus

Description

SA2526

membrane protein, putative, authentic point mutation

-11.95

isdG

SA1146

conserved hypothetical protein

-9.42

asp23

SA2173

alkaline shock protein 23

-9.15

SA0893

pathogenicity island protein

-8.72

SA0658

HD domain protein

-7.42

SA1439

acylphosphatase

-7.16

SA0821

HD domain protein

-6.87

SA0606

hydrolase, haloacid dehalogenase-like family

-6.33

SA2378

transcriptional regulator, AraC family

-6.30

SA0668

hydrolase, alpha/beta hydrolase fold family

-6.15

SA1573

integrase/recombinase, core domain family, authentic
frameshift

-5.80

SA0602

hydrolase, haloacid dehalogenase-like family

-5.75

SA1365

hydrolase, haloacid dehalogenase-like family

-5.51

SA0318

prophage L54a, integrase

-5.42

SA2666

N-acetylmuramoyl-L-alanine amidase domain protein

-5.20

SA2245

acetyltransferase, GNAT family

-4.77

SA2328

abortive infection protein family

-4.69

SA2159

drug transporter, putative

-4.65

SA0764

glycosyl transferase, group 2 family protein

-4.52

SA0892

pathogenicity island protein, authentic frameshift

-4.49

SA1806

probable ATP-dependent helicase

-4.49

SA0812

degV family protein

-4.46

SA2036

ABC transporter, ATP-binding protein

SA1339

4-oxalocrotonate tautomerase

-4.31

SA1759

universal stress protein family

-4.26

SA2140

lytic regulatory protein, authentic frameshift

-4.24

SA1855

transposase, putative, degenerate

-4.23

SA0716

DNA-binding response regulator

-4.17

SA2142

SAP domain protein

-4.46

dmpI
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-4.15

SA1538

segregation and condensation protein A

-4.02

SA1529

metallo-beta-lactamase superfamily protein

-4.02

SA0181

conserved domain protein

-3.89

SA1941

ribonuclease BN, putative

-3.89

SA2499

helicase, putative

-3.77

SA0630

amino acid permease

-3.76

SA2533

glyoxalase family protein

-3.76

SA0736

acetyltransferase, GNAT family

SA1898

cmp-binding-factor 1

-3.57

SA0747

cobalamin synthesis protein/P47K family protein

-3.44

SA1677

aminotransferase, class V

-3.41

SA0607

azoreductase

-3.38

SA1933

ThiJ/PfpI family protein

-3.34

SA1515

GTP-binding protein, Era/TrmE family

-3.33

SA1287

30S ribosomal protein L7 Ae

-3.30

SA1179

exotoxin 4, putative

SA1155

thioredoxin

-3.24

SA0803

lipoprotein, putative

-3.19

SA1047

conserved domain protein

-3.19

SA1180

exotoxin 3, putative

-3.17

SA0874

nitroreductase family protein

-3.09

SA1207

glyoxalase family protein

-3.03

SA1855

transposase, putative, degenerate

SA2437

bicyclomycin resistance protein

-2.97

SA0891

transcriptional regulator, putative

-2.95

SA2354

membrane protein, putative

SA0023

conserved hypothetical protein

-3.63

-3.30

-3.00

-2.93

scpA

cbf1

trxA

bcr

orfX

-2.89

SAV1941 putative membrane protein

-2.87

SA0978

membrane protein, putative

-2.86

SA1412

hydrolase-related protein

-2.79

SA0553

MesJ/Ycf62 family protein

-2.79

SA1240

DAK2 domain protein

-2.67

SA1189

acetyltransferase (GNAT) family protein

SA2352

tcaA protein

-2.66

tcaA

70
-2.53

SA1708

type III leader peptidase family protein

-2.52

SA0875

thioredoxin, putative

-2.49

SA2339

DNA-3-methyladenine glycosylase

-2.49

SA2499

helicase, putative

-2.47

SA0262

Choloylglycine hydrolase family protein

-2.46

SA2522

DedA family protein

-2.41

SA1644

putative competence protein ComEC/Rec2

-2.40

SA0855

acetyltransferase, GNAT family

-2.39

SA1437

cold shock protein, CSD family

-2.38

SA2018

abortive infection protein family

-2.35

SAV1976 similar to phi PVL ORF 52 homolog

-2.34

SA1615

ATP-dependent RNA helicase, DEAD/DEAH box family

-2.30

SA1751

DHH subfamily 1 protein

-2.28

SA2014

phage terminase family protein

SA1810

integrase

-2.27

SA0595

peptidase, M20/M25/M40 family

-2.26

SA0201

DNA-binding response regulator, AraC family

-2.25

SA0250

PTS system, IIA component

-2.24

SA0744

ABC transporter, ATP-binding protein, MsbA family

SA1010

GTP pyrophosphokinase

-2.19

SA1589

lipoprotein, putative

-2.18

SAV1976 similar to phi PVL ORF 52 homolog

-2.28

-2.23

-2.15

int

relA

fmtC

SA1396

fmtC protein

-2.02

SA2490

similar to N-hydroxyarylamine O-acetyltransferase

-2.02

SA1063

serine/threonine-protein kinase
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Table 3.3. Differentially expressed genes between 6 day-old S. aureus biofilm versus biofilmmacrophage co-cultures for a 24 h period
Category
Upregulated
Metabolism
Fold
change

Common

Locus

Description

11.68

SA0215 propionate CoA-transferase, putative

9.94

SA0214 long-chain-fatty-acid--CoA ligase, putative

5.14

SA0213 acyl-CoA dehydrogenase family protein

4.68

SA0211 acetyl-CoA acetyltransferase

2.88

gltS

SA2340 sodium:glutamate symporter

Virulence/defense
Fold
change

Common

4.23

spa

Locus

Description

SA0095 immunoglobulin G binding protein A precursor

Cell wall
Fold
change

Common

Locus

Description

2.55

pbp1

SA1194 penicillin-binding protein 1

2.46

dat

SA1800 D-alanine aminotransferase

2.37

sdrD

SA0520 Ser-Asp rich fibrinogen-binding, bone sialoprotein-binding protein

Transcription/translation/replication
Fold
change

Common

2.06

glnR

Locus

Description

SA1328 glutamine synthetase repressor

Miscellaneous
Fold
change

Common

2.73

Locus

Description

SA1433 peptidase, M20/M25/M40 family

Category
Downregulated
Metabolism
Fold
Change

Common

Locus

Description

72
-3.85

SA1912

glucosamine-6-phosphate isomerase, putative

-3.04

SA2579

phytoene dehydrogenase

-2.42

SA0921

CBS domain protein

-2.30

SA2369

pyridine nucleotide-disulfide oxidoreductase

-2.27

SA2708

ABC transporter, ATP-binding protein

Transcription/translation/replication
Fold
Change

Common

Locus

-3.41

fabG

SA2482

3-oxoacyl-(acyl carrier protein) reductase, authentic point mutation

-3.23

rpsA

SA1516

ribosomal protein S1

-2.59

hutG

SA2327

formiminoglutamase

SA1753

universal stress protein family

rpmB

SA1238

ribosomal protein L28

Fold
Change

Common

Locus

-3.26

isdC

SA1141

NPQTN cell wall surface anchor protein

SA0764

glycosyl transferase, group 2 family protein

SA0140

capsular polysaccharide biosynthesis protein

-2.56
-2.08

Description

Cell wall

-2.93
-2.20

cap5E

Description

Virulence/defense
Fold
Change

Common

-2.91

Locus

Description

SA1529

metallo-beta-lactamase superfamily protein

-2.76

nuc

SA0860

thermonuclease precursor

-2.67

epiE

SA1872

epidermin immunity protein F

-2.42

SA1797

metallo-beta-lactamase family protein

-2.37

SA2167

iron compound ABC transporter, iron compound-binding protein

Regulation
Fold
Change

Common

Locus

-2.26

arlR

SA1451

DNA-binding response regulator

Fold
Change

Common

Locus

Description

-3.21

asp23

SA2173

alkaline shock protein 23

-3.20

dmpI

SA1339

4-oxalocrotonate tautomerase

Description

Miscellaneous

73
-3.05

SA1038

membrane protein

-2.82

SA2007

peptidase, M20/M25/M40 family, authentic frameshift

-2.68

SA0671

hydrolase, alpha/beta hydrolase fold family

-2.54

SA1576

traG protein, putative

-2.40

SA2434

membrane protein, putative

-2.12

SA1941

ribonuclease BN, putative
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Figure 3.6

qRT-PCR validation of down-regulated genes in S. aureus biofilms identified by microarray
analysis. A subset of genes identified by microarray analysis was confirmed by qRT-PCR
following either a 1 or 24 h co-culture period of MΦs with 4 day-old USA300 LAC static
biofilms. Results are presented as the relative gene expression after MΦ-biofilm co-culture
compared to biofilms that were not incubated with MΦs as a reference standard.
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Table 3.4. Differentially expressed genes between 6 day-old S. aureus biofilm versus biofilmneutrophil co-cultures for a 1 h period
Category
Upregulated
Metabolism
Fold
Change

Common

3.1

Locus

Description

SACOL0200

phosphoglycerate transporter family protein

2.4

pyrE

SACOL1217

orotate phosphoribosyltransferase

2.2

feoB

SACOL2564

ferrous iron transport protein B

SACOL2322

peptidase, M20/M25/M40 family

SACOL1215

carbamoyl-phosphate synthase, large subunit

SACOL0217

ABC transporter, substrate-binding protein

2.2
2.0

carB

2.0
Virulence/defense
Fold
Change

Common

2.0

Locus
SACOL2449

Description
drug transporter, putative

Regulation
Fold
Change

Common

Locus

2.1

lytS

SACOL0245

sensor histidine kinase LytS

SACOL2585

regulatory protein, putative

2.0

Description

Miscellaneous
Fold
Change

Common

Locus

Description

2.7

intergenic upstream of ORF sa_c4971s4276

2.5

intergenic upstream of ORF sa_c7173s10144

2.4

intergenic upstream of ORF sa_c8901s7819

Category
Downregulated
Metabolism
Fold
Change

Common

Locus

Description

-3.7

SACOL2131

Dps family protein

-2.5

SACOL1952

ferritins family protein
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Regulation
Fold
Change

Common

Locus

Description

-2.7

groES

SACOL2017

chaperonin, 10 kDa

-2.4

grpE

SACOL1638

heat shock protein

-2.3

groEL

SACOL2016

chaperonin, 60 kDa

Common

Locus

Miscellaneous
Fold
Change

Description

-2.6

intergenic upstream of ORF sa_c2703s2276

-2.6

intergenic upstream of ORF sa_c7269s10166

-2.2

reverse complement of intergenic upstream of ORF sa_c2703s2276

-2.1

reverse complement of intergenic upstream of ORF sa_c8455s7417

-2.1

intergenic upstream of ORF sa_c8544s7501

Table 3.5. Differentially expressed genes between 6 day-old S. aureus biofilm versus biofilmneutrophil co-cultures for a 4 h period
Category
Upregulated
Metabolism
Fold
Change

Common

Locus

3.4

purK

SACOL1074

phosphoribosylaminoimidazole carboxylase, ATPase subunit

SACOL0240

4-diphosphocytidyl-2C-methyl-D-erythritol synthase, putative

gltB

SACOL0514

glutamate synthase, large subunit

Common

Locus

2.3
2.1

Description

Cell wall
Fold
Change
2.5

SACOL0191

Description
M23/M37 peptidase domain protein

Miscellaneous
Fold
Change

Common

Locus

2.5
2.2
2.1

Description

reverse complement of intergenic upstream of ORF sa_c10613s11068
SAS058

conserved hypothetical protein (all strains, N315)
intergenic downstream of ORF sa_c121s9459
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Increased agr transcription by S. aureus biofilms promotes resistance to neutrophil
challenge. agrA and agrB were both significantly enhanced in 4 day-old S. aureus biofilms
following a 1 h exposure to PMNs (Supplemental Table 3.2). To evaluate the importance of
increased agr transcriptional activity in the face of PMN challenge, we compared the extent of
biofilm phagocytosis and death of PMNs after co-culture with USA300 LAC or its isogenic agr
mutant (Δagr). While Δagr displayed significantly thicker biofilms as previously reported by
others (Fig. 3.7A) (64, 210), PMNs co-incubated with Δagr demonstrated significantly less cell
death and slightly enhanced phagocytosis of biofilm-associated bacteria, although the latter did
not reach statistical significance (Fig. 3.7B). These results suggest that while the physical nature
of the biofilm can limit the extent of phagocytosis, secreted factors also appear to play a role in
evasion of PMN effector functions, at least in vitro; a hypothesis further corroborated by the types
of genes known to be regulated by the agr operon (211, 212) as well as data previously reported
by others (180). This functional study further substantiates our microarray data by illustrating
how the enhanced expression of specific genes may facilitate biofilm evasion of innate immune
mechanisms.
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Figure 3.7

agr promotes S. aureus biofilm resistance to neutrophil challenge. S. aureus USA300 LACGFP wild type (WT) and isogenic Δagr static biofilms were grown for 6 days and visualized
using confocal microscopy (63X magnification, 1 µm slices). (A) Quantification of 4 and 6 dayold biofilm thickness. (B) PMNs (5 x 106) were incubated with biofilms for 20 h, whereupon the
percent of phagocytic and dead PMNs was enumerated. Significant differences are denoted with
asterisks, [(A) ***, p < 0.0001 using an unpaired two-tailed Student’s t-test, n = 60; (B) *, p <
0.05 using an unpaired two-tailed Student’s t-test, n = 3].
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Differential responses of macrophages and neutrophils to S. aureus biofilms are cell
autonomous. To determine whether the differences between MΦs and PMNs to phagocytose
biofilm-associated bacteria could be influenced by one another, both leukocyte populations were
co-cultured with WT USA300 LAC biofilms. The extent of MΦ and PMN invasion into the
biofilm was similar whether cells were added together (Fig. 3.8A) or separately (Fig. 3.8C).
Similarly, MΦs were incapable of phagocytosing biofilm-associated S. aureus whether cocultured with PMNs (Fig. 3.8B) or alone (Fig. 3.8D), whereas PMNs were equally phagocytic
under both conditions (Fig. 3.8B, D). This data demonstrates that the phagocytic ability of PMNs
over MΦs in regard to S. aureus biofilm is cell autonomous and is not influenced by the other
population in vitro.
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Figure 3.8

Differential responses of macrophages and neutrophils to S. aureus biofilms are cell
autonomous. S. aureus USA300 LAC-GFP static biofilms were grown for 6 days and visualized
using confocal microscopy (63X magnification, 1 µm slices). Quantification of invasion or
phagocytosis of MΦs and PMNs (5 x 106 each) cultured either together (A and B) or separately
(C and D) with 6 day-old biofilms at 4 and 24 h. Significant differences are denoted with asterisks
[(A and B) **, p < 0.01 using an unpaired two-tailed Student’s t-test, n = 4; ***, p < 0.0001 using
an unpaired two-tailed Student’s t-test, n = 4; (C and D) *, p < 0.05 using an unpaired two-tailed
Student’s t-test, n = 2; **, p < 0.01 using an unpaired two-tailed Student’s t-test, n =2].
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Supplemental Figure S3.1

Neutrophils phagocytose S. aureus biofilms throughout the co-culture period. USA300 LACGFP static biofilms were grown for 6 days, whereupon bone marrow-isolated PMNs were
incubated with biofilms for 1, 4, or 24 h (A-C, respectively). Biofilm co-cultures were visualized
using confocal microscopy (63X magnification, 1 µm slices) and representative threedimensional images were constructed. Insets are provided at higher magnification to highlight the
presence of intracellular bacteria. Results are representative of at least two independent
experiments.
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Supplemental Table S3.1. Significantly increased genes between 6 day-old S. aureus biofilm
versus biofilm-macrophage co-cultures for a 1 h period
Category
Virulence/Defense
Fold
Change

Common

4.5

Locus
SA2291

Description
staphyloxanthin biosynthesis protein

Miscellaneous
Fold
Change

Common

Locus

Description

2.2

ssr161

Hypothetical

2.2

ssr162

Hypothetical

2.2

ssr169

Hypothetical

2.2

ssr166

Hypothetical

2.2

ssr167

Hypothetical

2.1

ssr168

Hypothetical

2.1

ssr159

Hypothetical

2.1

ssr160

Hypothetical

Supplemental Table S3.2. Significantly increased genes between 4 day-old S. aureus biofilm
versus biofilm-neutrophil co-cultures for a 1 h period
Category
Regulation
Fold
change

Common

Locus

5.6

agrB

SA2381

4.7

agrA

Description
accessory gene regulator protein B

SACOL2026 accessory gene regulator protein A

Virulence/defense
Fold
change

Common

3.6

Locus

Description

SACOL1187 antibacterial protein

Miscellaneous
Fold
change
3.6

Common

Locus
SA1773

Description
hypothetical protein
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3.0

SACOL2565 conserved hypothetical protein

2.0

SACOL2557 conserved domain protein

2.0

SACOL2503 hypothetical protein

Transcription/translation/replication
Fold
change

Common

2.4

glnR

Locus

Description

SACOL1328 glutamine synthetase repressor

Cell Wall
Fold
change

Common

2.4

atl

2.1
2.0

Locus

Description

SACOL1062 bifunctional autolysin
SACOL0507 LysM domain protein

isaA

SACOL2584 Immunodominant antigen A

Metabolism
Fold
change

Common

2.2

abcA

2.1

Locus

Description

SACOL0700 ABC transporter, ATP-binding/permease protein
SACOL1114 Mn2+/Fe2+ transporter, NRAMP family
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Discussion
One facet of S. aureus pathogenesis is the organism’s ability to maintain cellular
homeostasis while enduring immune-mediated stresses (174). S. aureus has been shown to
interfere with virtually every level of the host immune response, including increased resistance to
antimicrobial peptides, impairment of phagocyte recruitment, escape from NETs, resistance to
intracellular killing, and interference with complement function as well as antibody-mediated
opsonization (213). The objective of this study was to examine how relevant innate immune cell
populations, such as PMNs and MΦs, alter the S. aureus biofilm transcriptome. To our
knowledge, there have been no studies to date examining biofilm gene expression profiles after
incubation with innate immune cell populations with any species of bacterial biofilm. Based on
our preliminary data and the fact that PMNs are generally shorter-lived than MΦs, we chose early
(i.e. 1 and 4 h) and late (i.e. 1 and 24 h) time points for biofilm co-cultures, respectively.
Surprisingly, in subsequent experiments, we found that a significant number of PMNs remained
viable at 24 h after biofilm addition; therefore, PMN co-incubation periods were extended in
subsequent confocal experiments.
In the current study, the greatest transcriptional impact on S. aureus biofilms was achieved
during an early (i.e. 1 h) co-culture period with MΦs. This effect was independent of
phagocytosis, since we observed few internalized bacteria within MΦs incubated with S. aureus
biofilms (195, 204). Although numerous genes were repressed following biofilm exposure to
MΦs after 1 h of co-culture, surprisingly many genes remained unaltered. These unaffected genes
are likely important for biofilm maintenance, and may represent an essential core transcriptome
needed to maintain biofilm survival and/or evade host antimicrobial effector mechanisms in the
face of an immune challenge. In contrast, few genes were altered in S. aureus biofilms following
a 24 h exposure to MΦs, which may be explained by changes in MΦ viability following extended
biofilm co-culture periods. Specifically, our previous work demonstrated that most MΦs remain
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viable during a 1 h co-culture period with biofilms; however, by 6 h MΦ viability is significantly
reduced as measured by the live/dead stain 7-aminoactinomycin D (7-ADD)(195). Together,
these findings suggest that S. aureus biofilms rapidly transition into a transcriptionally dormant
mode after MΦ challenge, which is reversed once the pressure of viable MΦs has dissipated. We
cannot exclude the possibility that minor changes in biofilm gene expression could have occurred
following leukocyte addition that were not detected due to limitations in microarray sensitivity. In
addition, although extreme care was taken to ensure rapid processing of biofilms prior to RNA
isolation, it remains possible that some transcriptional changes may have occurred during this
interval due to the short half-life of many bacterial mRNAs (214). However, since we compared
the transcriptional profiles of biofilms alone concurrent with leukocyte co-culture conditions, any
changes in mRNA turnover would be expected to decay at the same rate.
Despite the extensive microbicidal mechanisms employed by PMNs, these cells did not
significantly alter the S. aureus biofilm transcriptome. This was unexpected, since we predicted
that PMN challenge would enhance bacterial virulence factor expression to interfere with
recognition/killing mechanisms. While recent studies have demonstrated the ability of S. aureus
to survive intracellularly within PMNs and, to a lesser extent, MΦs, one would expect this
adaptation to necessitate large scale transcriptional changes (215). One possibility to explain the
discrepancy between MΦs and PMNs in regulating biofilm transcriptional responses is that
PMNs were added to biofilms at a 10-fold reduced density than MΦs. However, our confocal
analysis indicated that PMNs invade the biofilm in greater numbers, remain viable for a longer
period than MΦs, and exhibit phagocytosis. Nonetheless, the latter appears to be futile, since
PMN phagocytosis of S. aureus biofilms does not significantly decrease bacterial numbers in
vitro (204). Additionally, PMNs have not proven to play a key microbicidal role in a S. aureus
catheter-associated biofilm model in vivo, showing minimal impact on bacterial burdens (197,
204).
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While MΦs and PMNs perform many overlapping functions in terms of bactericidal activity,
subtle specialization of labor could potentially account for the S. aureus biofilm transcriptional
differences reported in this study. For example, while PMNs are considered potent phagocytic
effectors against numerous extracellular bacteria, activated MΦs are recognized as a signaling
hub during bacterial infections through their secretion of numerous immune stimulatory and
bactericidal factors (200, 201, 216-218). Therefore, it is possible that S. aureus biofilms are more
responsive to this secreted milieu than physical disruption via phagocytosis, although this remains
speculative.
In addition to producing molecules to circumvent the host immune system, S. aureus biofilms
must adapt to nutrient-limiting conditions encountered during growth. Interestingly, MΦ addition
to S. aureus biofilms repressed numerous metabolism-associated genes, further suggesting that
biofilms transition into a dormant mode to evade immune killing pathways. Correspondingly,
MΦ exposure also lead to the repression of genes implicated in transcription, translation, and
replication as well as cell wall synthesis, which would be expected to conserve energy during a
decreased metabolic state. The repression of cell wall synthesis may also be a mechanism to
evade innate immune recognition.
The agr and sarA regulatory systems are among the many controlling the production of
staphylococcal virulence and defense factors. The agr locus encodes a QS system involved in
RNAIII production, which switches the synthesis of surface and adhesive molecules to toxin and
exoprotein expression (84). SarA is a DNA-binding regulator protein that influences the
expression of multiple genes, including those contributing to virulence and biofilm formation
(188, 219). In this study, sarA transcription was reduced in S. aureus biofilms following MΦ
exposure, which agrees with the generalized decrease in numerous genes regulated by SarA. In
contrast, agr transcription was significantly increased in S. aureus biofilms after PMN addition.
The enhanced expression of agr in this setting allowed us to examine its contribution to PMN
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reactivity using an isogenic agr mutant. The percentage of PMNs exhibiting phagocytic activity
was increased in Δagr biofilms, despite the significant increase in biofilm thickness. This
phenotype may be explained, in part, by alterations in phenol-soluble modulin (PSM) expression.
PSMs are surfactant peptides that have recently been implicated in bacterial biofilm formation
across a number of species, including S. aureus (79). PSM expression is intricately linked to
bacterial density and is agr regulated (79). Based on this evidence, it is reasonable to predict that
although Δagr biofilms are thicker than WT, they are likely less structurally complex and unable
to effectively circumvent PMN invasion. In addition, Δagr biofilms elicited less PMN death,
likely due to the reduced expression of lytic toxins, such as Hla and PSMs, which have been
shown to play key roles in S. aureus pathogenesis (82, 220). There were no significant effects on
MΦ phagocytosis or viability in response to Δagr biofilms (data not shown), implying that
enhanced agr transcription is selective for thwarting aspects of PMN function. This finding
further substantiates a potential selective role for impaired PSM action on PMNs, since its
cytotoxic effects primarily target this cell type(221, 222). Finally, as PSM expression is induced
by the stringent response resulting from the harsh conditions within the phagolysosome (83),
impaired PSM activity provides a potential explanation for the increased intracellular burden of
Δagr biofilms by PMNs. The impressive ability of S. aureus biofilms to adapt to PMN challenge
correlates with the modest transcriptome changes reported in this study.
In conclusion, the changes in S. aureus biofilm transcriptional profiles after leukocyte exposure
reported here provides a comprehensive view of the molecules that may impact S. aureus immune
evasion and survival during biofilm growth. Further investigations into the role of differentially
regulated genes will provide a better understanding of the ability of S. aureus to adapt to
environmental challenges and may provide novel strategies and therapeutic targets for
staphylococcal biofilm infections.
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Chapter 4: Staphylococcus aureus biofilms induce macrophage dysfunction through
leukocidin AB and α-toxin
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Abstract
The MΦ response to planktonic S. aureus involves the induction of proinflammatory,
microbicidal activity. However, S. aureus biofilms can interfere with these responses, in part, by
polarizing MΦs toward an anti-inflammatory, pro-fibrotic phenotype. Here we demonstrate that
conditioned medium from mature S. aureus biofilms inhibited MΦ phagocytosis and induced
cytotoxicity, suggesting the involvement of a secreted factor(s). Iterative testing identified the
active factor(s) to be proteinaceous and partially agr-dependent. Quantitative mass spectrometry
identified Hla and LukAB as critical molecules secreted by S. aureus biofilms that inhibit murine
MΦ phagocytosis and promote cytotoxicity. A role for Hla and LukAB was confirmed using hla
and lukAB mutants and synergy between both toxins was demonstrated with a lukAB/hla double
mutant and verified by complementation. Independent confirmation of the effects of Hla and
LukAB on MΦ dysfunction was demonstrated using an isogenic strain where Hla was
constitutively expressed, a Hla antibody to block toxin activity, and purified LukAB peptide. The
importance of Hla and LukAB during S. aureus biofilm formation in vivo was assessed using a
murine orthopedic implant biofilm infection model, where the lukAB/hla strain displayed
significantly decreased bacterial burdens and increased MΦ infiltrates compared with each single
mutant. Collectively, these findings reveal a critical synergistic role for Hla and LukAB in
promoting MΦ dysfunction and facilitating S. aureus biofilm development in vivo.
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Introduction
Highly opportunistic pathogens possess attributes that facilitate persistent infections, in part,
by shielding themselves from immune-mediated attack (223-225). S. aureus is one such example,
and in addition to its well-known arsenal of virulence determinants, biofilm formation represents
another means to circumvent immune-mediated clearance in the host (15, 16). Biofilms are
heterogeneous bacterial communities encased in a complex matrix composed of extracellular
DNA (eDNA), proteins, and polysaccharides (11, 32, 226, 227). S. aureus has a propensity to
form biofilms on medical devices, such as prostheses and indwelling catheters, and the organism
remains a major cause of health care- and community-associated infections (194, 228, 229).
Many S. aureus virulence factors target innate immune pathways that are elicited during
acute planktonic infection, such as phagocytosis and proinflammatory transcription factor
activation (15, 160, 213, 230). Phagocytosis leads to the killing of extracellular pathogens as well
as proinflammatory cytokine and chemokine production, which collectively orchestrate local and
systemic inflammatory responses and initiate adaptive immunity (129-131). Recent studies have
demonstrated that biofilms formed by various bacterial species interfere with classical host antibacterial effector mechanisms (170, 231-235). With regard to S. aureus, work from our laboratory
and others has shown that biofilms polarize MΦs towards an anti-inflammatory phenotype by
dampening proinflammatory responses and limiting MΦ invasion in vivo (15, 159, 160, 236,
237). This response is considered detrimental to biofilm clearance, since polarized MΦs possess
poor microbicidal activity and instead promote fibrosis (15). Similar findings of MΦ dysfunction
have been reported in response to S. epidermidis biofilms (158, 164, 165), suggesting the
existence of a conserved effort to thwart efficient biofilm recognition and clearance by the host.
However, the molecules responsible for the ability of S. aureus biofilms to attenuate MΦ
proinflammatory responses remain ill-defined.
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The objective of this study was to identify S. aureus biofilm-derived products that induce
MΦ dysfunction and facilitate biofilm persistence. Quantitative mass spectrometry identified Hla
and the bicomponent leukotoxin, LukAB, also known as LukGH, as potential candidates
responsible for inhibiting MΦ phagocytosis and promoting cytotoxicity, which was confirmed
using hla and lukAB mutants. A synergistic effect was demonstrated with a lukAB/hla double
mutant that also revealed decreased biofilm formation in vivo using a murine model of orthopedic
implant biofilm infection. The reduction in MΦ phagocytosis, concomitant with enhanced cell
death, likely facilitates the ability of S. aureus to avoid destructive host responses when organized
as a biofilm.
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Results
S. aureus biofilms secrete a proteinaceous factor(s) that inhibits macrophage phagocytosis.
Our previous studies demonstrated that MΦs are unable to phagocytose S. aureus biofilms (15,
160); however, the mechanism responsible for this phenomenon remained to be identified. While
it is known that the physical size of a biofilm is one factor that impedes phagocytosis (15), we
investigated the possibility that a secreted factor(s) was also involved. In order to assess the effect
of biofilm-conditioned medium on MΦ phagocytosis, we utilized fluorescent microspheres
instead of live bacteria, since live S. aureus actively secretes factors during planktonic growth
that would have been impossible to differentiate from biofilm-derived molecules. Using this
approach, we were able to readily distinguish differences in phagocytosis and viability of murine
MΦs exposed to fresh medium (Fig. 4.1A), S. aureus biofilm-conditioned medium (Fig. 4.1B),
and S. aureus planktonic-conditioned medium (Fig. 4.1C) using confocal microscopy. Of note,
similar effects of S. aureus biofilm-conditioned medium on MΦ phagocytosis were obtained with
fluorescent microspheres and intact S. aureus in pilot studies (Supplemental Fig. S2.1),
supporting the validity of this approach. MΦ phagocytic activity was significantly reduced after
treatment with conditioned medium from intact biofilms of the Methicillin-resistant S. aureus
(MRSA) clinical isolate USA300 LAC (172-175) (Fig. 4.1B and D), revealing a role for an
extracellular factor(s). To determine whether this effect relied on an intact biofilm structure, fresh
medium was added to mature biofilms that were disrupted by trituration, whereupon conditioned
medium was harvested 24 h later. Treatment of MΦs with supernatants collected from disrupted
biofilms had less impact on phagocytosis (Fig. 4.1D), suggesting that the putative extracellular
factor(s) is enriched in intact biofilms, perhaps via a QS system that is disturbed upon destruction
of the biofilm architecture. Similarly, conditioned medium from planktonic organisms was less
effective at blocking MΦ phagocytosis (Fig. 4.1C and D), even when cultures were grown to a
high cell density (i.e. late stationary phase; data not shown), demonstrating the enrichment of this
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secreted factor(s) in intact biofilms. Importantly, these differences did not result from alterations
in bacterial density or secreted protein levels, since titers and extracellular protein concentrations
of intact biofilms, disrupted biofilms, and planktonic cultures were similar (Supplemental Fig.
S4.1 and data not shown).
Whereas little information is currently available regarding the S. aureus biofilm secretome,
the importance of autolysis to biofilm formation has been well-established (20, 32, 78, 238-240).
To determine whether the putative biofilm extracellular factor(s) was actively secreted or a
byproduct of cell lysis, mature biofilms were treated for 24 h with polyanethole sodium sulfanate
(PAS) to inhibit lysis (241) or disrupted by trituration and treated with lysostaphin to artificially
induce lysis. Only biofilm-conditioned medium from PAS-treated supernatants maintained
inhibitory activity (Fig. 4.1F), suggesting that S. aureus biofilms actively secrete molecule(s) that
impede MΦ phagocytosis. To elucidate the chemical nature of secreted inhibitory factor(s),
conditioned medium from intact biofilms was treated with proteinase K prior to MΦ addition.
Proteinase K completely ablated the inhibitory effect of S. aureus biofilm-conditioned medium on
MΦ phagocytosis, implicating the action of a protein(s) in this phenomenon (Fig. 4.1H).
In addition to impaired phagocytosis, our prior report demonstrated that S. aureus biofilms
also induced MΦ cytotoxicity (15). The latter could result from frustrated phagocytosis based on
the inability of MΦs to physically engulf the bulky biofilm structure combined with the action of
secreted toxins, such as Hla or leukocidins with known cytotoxic activity (131, 213, 242).
Exposure of murine MΦs to conditioned medium from intact S. aureus biofilms induced
significant cell death, whereas minimal cytotoxicity was observed following treatment with
medium from either disrupted biofilms or planktonic S. aureus (Fig. 4.1A-C, and E). Similar to
the approach employed for phagocytosis, biofilms were treated with lysostaphin or PAS, where
only lysostaphin prevented the cytotoxic effects of biofilm-conditioned medium (Fig. 1G), again
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revealing the action of an actively secreted protein based on its proteinase K-sensitive nature (Fig.
4.1I).
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Figure 4.1

S. aureus biofilms secrete a proteinaceous factor(s) that inhibits macrophage phagocytosis.
(A-C) Representative 2D confocal images (63x) of BMDMΦ phagocytosis of fluorescent
microspheres (yellow-white) and cell death with propidium iodide stain (red-purple) after
exposure to (A) fresh medium, (B) S. aureus biofilm-conditioned medium, or (C) S. aureus
planktonic-conditioned medium. (D and E) BMDMΦs were exposed to fresh medium or
conditioned medium collected from an intact biofilm, a mature biofilm that was mechanically
disrupted, or a similar number of planktonic S. aureus. After a 3 h treatment period, (D) MΦ
phagocytosis of fluorescent microspheres and (E) cell viability was quantitated by confocal
microscopy. (F and G) Conditioned medium from biofilms treated with either PAS (10 μg/ml) or
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lysostaphin (50 μg/ml) were added to MΦs to assess the relative importance of active biofilm
secretion versus passive release of products via autolysis, respectively, on MΦ (F) phagocytosis
and (G) cell death. (H and I) Biofilm-conditioned supernatants were treated with proteinase K (10
μg/ml) prior to MΦ exposure to assess the chemical nature of the inhibitory molecule(s).
Significant differences are denoted with asterisks (***, p < 0.001; one-way ANOVA followed by
Bonferroni's multiple comparison test). Results are representative of at least two independent
experiments.
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S. aureus biofilm-induced macrophage dysfunction is partially agr-dependent. Our findings
that disrupted biofilms were not as effective at blocking MΦ phagocytosis or inducing
cytotoxicity suggested that QS systems enriched during biofilm formation may regulate the
putative inhibitory molecule(s). The expression of numerous virulence factors in S. aureus,
including secreted proteases, leukocidins, and Hla, is either directly or indirectly influenced by
two-component regulatory systems, such as the agr QS system (243). Agr modulates virulence
factor expression and is an important regulatory switch between planktonic and biofilm lifestyles
in S. aureus (64, 212, 244-246). Conditioned medium from a Δagr biofilm induced minimal MΦ
cell death (Fig. 4.2B), whereas the phagocytic block was significantly attenuated but only
partially influenced by agr (Fig. 4.2). Since the MΦ inhibitory phenotypes upon exposure to S.
aureus biofilms were partially agr-dependent, the Δagr strain was utilized for subsequent
proteomics comparisons with WT biofilms in an attempt to identify secreted proteins enriched
during biofilm growth that were capable of inducing MΦ dysfunction.
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Figure 4.2

S. aureus biofilm-induced macrophage dysfunction is partially agr-dependent. BMDMΦs
were exposed to fresh or conditioned medium from S. aureus WT or isogenic ∆agr biofilms for 2
h, whereupon (A) phagocytosis of fluorescent microspheres and (B) total viable MΦs were
quantitated by confocal microscopy. Significant differences are denoted with asterisks (***, p <
0.001; unpaired two-tailed student’s t-test). Results are representative of at least three
independent experiments.
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Sequential Windowed data-independent Acquisition of the Total High-resolution Mass
Spectra (SWATH-MS) as a tool to identify S. aureus biofilm factors that induce
macrophage dysfunction. We next employed a proteomics approach to identify candidate
molecules that might be responsible for biofilm-mediated MΦ dysfunction. Our proteomics
strategy utilized the ∆agr strain as a comparator with WT biofilm, since the MΦ inhibitory
phenotypes were partially agr-dependent (Fig. 4.2). A second comparison was made between
biofilm and planktonic conditions because the MΦ inhibitory factors were enriched during
biofilm growth (Fig. 4.1). To identify differentially expressed proteins between WT vs. ∆agr
biofilm- and planktonic-conditioned medium, TCA-precipitated proteins were analyzed by
quantitative SWATH-MS (189). As expected, conditioned medium from WT and ∆agr biofilms
displayed vastly different proteomic profiles, with 68 of 153 (44%) proteins significantly
enriched in WT biofilms, 23% of which were either secreted proteases or known virulence
factors, such as Hla (Fig. 4.3A and B; Table S4.1). In contrast, cell wall and structural proteins
were more abundant in ∆agr biofilm-conditioned medium compared to WT (Fig. 4.3A and B).
Similarly, proteomic comparisons between WT biofilm- vs. WT planktonic-conditioned medium
differed significantly, with 108 of 301 (36%) proteins enriched in WT biofilm, including several
secreted virulence factors such as toxins and proteases (Table S4.2). A functional proteomics
network constructed with overlapping hits from both comparisons (WT biofilm vs. ∆agr biofilm
and WT biofilm vs. WT planktonic) identified 17 proteins, including two serine proteases and
two leukocidin components, as candidates to account for the inhibitory effects of biofilmconditioned medium on MΦ function (Fig. 4.3C). Additionally, Hla was significantly enriched in
WT compared to ∆agr biofilms (Table S4.1), which represented another toxin of interest for its
potential role in regulating MΦ dysfunction. Importantly, both Hla and LukAB were significantly
enriched in biofilm- compared to planktonic-conditioned medium (Fig. 4.4), suggesting that these
two proteins may be responsible for biofilm-induced MΦ dysfunction. LukAB is a bi-component
leukotoxin also involved in S. aureus-mediated killing of host phagocytes (67, 247, 248).
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Therefore, Hla and LukAB were the focus of subsequent mechanistic studies as they likely play a
significant role in MΦ dysfunction and death in this setting.
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Figure 4.3

SWATH-MS identifies potential biofilm factors responsible for macrophage dysfunction.
Conditioned supernatants from either S. aureus WT or Δagr strains grown under planktonic or
biofilm conditions were harvested and TCA precipitated for protein isolation in triplicate.
Relative protein concentrations were compared between sample sets by Sequential Windowed
data independent Acquisition of the Total High-resolution Mass Spectra (SWATH-MS). (A) 68
of 153 (44%) identified proteins were significantly enriched in WT vs. Δagr biofilm, with the
largest percentage associated with metabolism and virulence. 85 of 153 (56%) identified proteins
were significantly enriched in Δagr biofilm vs. WT biofilm, with the largest percentage of
proteins falling into the functional category of cell wall proteins. (B) Direct comparison of
significantly expressed proteins in WT vs. Δagr biofilm by functional category, with more refined
groups of metabolism and virulence shown. (C) Functional protein association network of
SWATH-MS identified proteins significantly enriched in WT biofilm-conditioned supernatant vs.
planktonic and Δagr biofilm-conditioned supernatants. For all comparisons, statistical
significance was assessed using a Z-test (p < 0.05).
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Figure 4.4

LukA and Hla secretion is enhanced in S. aureus biofilms. (A) LukA and Hla levels in S.
aureus biofilm- vs. planktonic- conditioned medium were assessed by Western blots. (B)
Quantitation of Hla levels in conditioned medium from WT S. aureus biofilms versus planktonic
bacteria. Significant differences are denoted with asterisks (***, p < 0.001; unpaired two-tailed
student’s t-test). Results are representative of at least two independent experiments.
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LukAB and Hla play significant roles in biofilm-induced macrophage dysfunction. Biofilmconditioned medium from both ∆lukA and ∆lukB strains elicited minimal MΦ death compared to
WT biofilm (Fig. 4.5B). Likewise, the phagocytic block induced by the ∆lukA and ∆lukB strains
was less pronounced than WT biofilm-conditioned medium, although phagocytosis did not return
to baseline levels (Fig. 4.5A). Both ∆lukA and ∆lukB phenotypes could be complemented,
providing direct evidence for LukAB in modulating MΦ survival and phagocytosis (Fig. 4.5A
and B). In contrast, while serine proteases were also noted to be elevated by SWATH-MS,
biofilm-conditioned medium from serine protease mutants (∆spl or Δaur/spl/sspAB/scpA) as well
as another leukocidin mutant (∆lukD) behaved similarly to WT biofilms (data not shown).
Since LukAB did not account for the entire MΦ dysfunction phenotype and SWATH-MS
identified increased Hla levels in WT biofilm-conditioned medium (Table S4.1), we next
examined the contribution of Hla to MΦ dysfunction. Further justification for investigating Hla
stemmed from the vast literature on Hla regulation by the agr QS system (242, 249-251), the
finding that conditioned medium from ∆agr biofilms was less effective at inducing MΦ
dysfunction (Fig. 4.2), and that Hla secretion was significantly increased during biofilm growth
(Fig. 4.4). Hla inserts into host cell membranes and oligomerizes to form pores, leading to cell
death (242, 252). Indeed, MΦ survival was significantly improved following exposure to ∆hla
biofilm-conditioned medium compared to WT biofilm, which was complementable (Fig. 4.5D).
The effects of ∆hla on MΦ phagocytosis were less pronounced, but still reached statistical
significance (Fig. 4.5C). Furthermore, blockade of Hla activity in WT biofilm-conditioned
medium using a Hla neutralizing antibody phenocopied the findings with ∆hla (Fig. 4.5C and D).
Specificity of the Hla antibody was demonstrated by its ability to inhibit the effects of purified
Hla on MΦ survival and viability (Supplemental Fig. S4.3). Additional evidence to support Hla
action was provided by the ability of biofilm-conditioned medium from a S. aureus strain that
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constitutively expresses hla (hlaon) to induce significant MΦ death and inhibit phagocytosis (Fig.
4.5C and D).
Both Hla and LukAB expression were markedly increased in conditioned medium from WT
biofilms compared to planktonic bacteria (Fig. 4.4). Therefore, to assess whether LukAB and Hla
act cooperatively to effect MΦ activity, ∆lukA and ∆lukB biofilm-conditioned media were treated
with a Hla neutralizing antibody (Fig. 4.6). Interestingly, negating Hla action in ∆lukA and ∆lukB
biofilm-conditioned medium significantly improved MΦ phagocytosis compared to supernatants
where Hla was active (Fig. 4.6A). Similar findings were obtained with a ∆lukAB/∆hla mutant
(Fig. 4.6A). Hla blockade in ∆lukA and ∆lukB biofilm-conditioned medium had no additional
effect on MΦ survival, which was not unexpected since viability had nearly been restored with
each of the single mutants to levels observed with fresh medium (Fig. 4.6B). When MΦs were
treated with ∆lukAB biofilm-conditioned medium (that still produces Hla) in combination with
purified LukAB or a point mutant that lacks lytic activity (LukABE323A) (186), only bioactive
LukAB returned both phagocytic inhibition and cytotoxicity to levels observed with WT biofilmconditioned medium (Fig. S4.3). Collectively, these results demonstrate that LukAB acts in
concert with Hla to induce MΦ dysfunction.
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Figure 4.5

LukAB and Hla play significant roles in biofilm-induced macrophage dysfunction. (A and
B) BMDMΦs were exposed to fresh or conditioned medium from S. aureus WT, ∆lukA, ∆lukB,
or chromosomally complemented ∆lukAB (∆lukAB::lukAB) biofilms. After a 3 h treatment
period, (A) phagocytosis of fluorescent microspheres and (B) viable MΦs were quantitated by
confocal microscopy. (C and D) BMDMΦs were exposed to fresh or conditioned medium from S.
aureus WT biofilm + Hla antibody (α-Hla), ∆hla, plasmid complemented ∆hla [∆hla(pHla)], and
constitutively expressed hla (hlaon) biofilms. After a 3 h treatment period, (C) phagocytosis of
fluorescent microspheres and (D) viable MΦs were quantitated by confocal microscopy.
Significant differences are denoted with asterisks (*, p < 0.05; ***, p < 0.001; unpaired two-tailed
student’s t-test). Results are representative of at least three independent experiments.
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Figure 4.6

S. aureus Hla and LukAB act in concert to promote macrophage dysfunction. BMDMΦs
were exposed to fresh or conditioned medium from S. aureus WT or isogenic ∆lukA, ∆lukB and
∆lukAB/hla biofilms + Hla antibody (α-Hla). After a 3 h treatment period, (A) phagocytosis of
fluorescent microspheres and (B) viable MΦs were quantitated by confocal microscopy.
Significant differences are denoted with asterisks (***, p < 0.001; unpaired two-tailed student’s ttest). Results are representative of at least three independent experiments.
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LukAB and Hla are important for S. aureus biofilm formation in vivo. Previous work from our
laboratory has demonstrated that augmenting MΦ proinflammatory activity is critical for biofilm
clearance in vivo (160). Therefore, to determine whether the functional role identified for LukAB
and Hla in mediating MΦ dysfunction in vitro would impact biofilm formation in vivo, we
utilized a murine model of S. aureus orthopedic implant biofilm infection (54, 55, 253). Similar
to our in vitro studies revealing cooperation between LukAB and Hla, the ΔlukAB/Δhla double
mutant displayed the greatest reduction in bacterial burdens in the knee joint, surrounding soft
tissue, and femur at days 3 and 7 post-infection compared to ΔlukAB or Δhla strains (Fig. 4.7AC). Furthermore, MΦ infiltrates were significantly increased in mice infected with ΔlukAB/Δhla
(Fig. 4.7D), although they represent a minor population in this model of orthopedic implant
biofilm infection, which is dominated by myeloid-derived suppressor cells (MDSCs) (54, 55).
Taken together, these results identify LukAB and Hla as important virulence factors for
modulating bacterial persistence and MΦ infiltrates during S. aureus biofilm formation in vivo.
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Figure 4.7

LukAB and Hla are important for S. aureus biofilm formation in vivo. Bacterial burdens
associated with the (A) soft tissue surrounding the knee, (B) knee joint, and (C) femur of mice
infected with WT S. aureus and isogenic ∆hla, ∆lukAB and ∆lukAB/hla strains at days 3 and 7
post-infection (n = 10 mice per strain for each time point). Results are expressed as the number of
CFU per gram of tissue to correct for differences in tissue sampling size. (B) Quantitation of
F4/80+ MΦs infiltrating the soft tissue of mice infected with WT S. aureus and isogenic ∆hla,
∆lukAB and ∆lukAB/hla strains. Significant differences are denoted with asterisks (*, p < 0.05;
**, p < 0.01; ***, p < 0.001; unpaired two-tailed Student’s t-test). Results are combined from two
independent experiments.
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Figure 4.8

Proposed model for S. aureus biofilm-induced macrophage dysfunction. S. aureus biofilms
produce an abundance of LukAB, which can associate with the cell surface as a toxin reservoir or
be actively secreted into the extracellular milieu. Biofilms also secrete Hla that acts
synergistically with LukAB to elicit MΦ dysfunction. Other secreted proteins, such as
lipoproteins, lantibiotics, or siderophores may also impact MΦ phagocytosis.
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Supplemental Figure S4.1

Bacterial counts and extracellular protein concentrations of S. aureus WT planktonic,
biofilm, and isogenic mutant biofilms are similar. (A) All S. aureus strains used in these
studies grew to comparable extents after 6 days of culture in RPMI-1640 supplemented with 1%
CAA as indicated by the number of viable bacteria determined by quantitative culture with results
expressed as colony forming units (CFU) per ml. (B) Quantitation of secreted proteins for each
strain. Data are representative of at least two independent experiments. Strains are abbreviated as
follows: ∆agr = accessory gene regulator mutant; ∆hla = α-hemolysin mutant; ∆hla (pHla) =
plasmid complemented α-hemolysin mutant; hlaon = WT strain constitutively expressing α-toxin;
∆lukA = leukocidin AB component single mutant; ∆lukB = leukocidin AB component single
mutant; ; ∆lukAB::lukAB = chromosomally complemented leukocidin AB double mutant;
∆lukAB/∆hla = leukocidin AB and α-hemolysin double mutant.
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Supplemental Figure S4.2

Validation of S. aureus Hla action on macrophage dysfunction. BMDMΦs were incubated for
2 h with fresh medium alone or fresh medium with purified S. aureus Hla + an isotype control or
Hla antibody (α-Hla). After a 2 h treatment period, (A) MΦ phagocytosis of fluorescent
microspheres and (B) total viable MΦs were quantitated by confocal microscopy. Significant
differences are denoted with asterisks (*, p < 0.05; ***, p < 0.001; unpaired two-tailed student’s
t-test). Results are representative of at least two independent experiments.
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Supplemental Figure S4.3

Purified LukAB augments macrophage cytotoxicity. BMDMΦs were exposed to fresh or
biofilm-conditioned medium from S. aureus WT or isogenic ΔlukAB + purified LukAB or
inactive LukABE323A. After a 3 h treatment period, the (A) percentage of MΦs phagocytosing
fluorescent microspheres and (B) percentage of viable MΦs were quantitated by confocal
microscopy. Significant differences are denoted with asterisks (***, p < 0.001; unpaired twotailed Student’s t-test). Results are representative of at least two independent experiments.
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Characterization of S. aureus biofilm growth in 1% casamino acids. Total numbers of
dispersed (supernatant) vs. biofilm-associated bacteria in RPMI-1640 supplemented with 1%
casamino acids were assessed by serial dilution (CFU/well) throughout the 6 day biofilm
maturation process.

114
Table S4.1 Proteins identified to be in greater abundance in WT S. aureus biofilmconditioned medium compared to ∆agr biofilm-conditioned medium
Magnitude
14.32
4.73
4.09
3.32
2.90
2.72
2.56
2.42
2.1
2.01
25.93
6.92
4.37
3.91
3.63
3.07
2.87
2.50
2.42
2.29
42.01
33.61
24.78
24.78
14.23
9.02
6.48
2.17
11.97
10.59
9.71
6.38
5.09
3.90
3.81
3.09
9.98
6.49
5.92
5.08
2.29
23.69
23.39
6.92
6.09

Category
Translation
Translation
Translation
Translation
Translation
Translation
Translation
Translation
Translation
Translation
Metabolism
Metabolism
Metabolism
Metabolism
Metabolism
Metabolism
Metabolism
Metabolism
Metabolism
Metabolism
Protease
Protease
Protease
Protease
Protease
Protease
Protease
Protease
Virulence
Virulence
Virulence
Virulence
Virulence
Virulence
Virulence
Virulence
Cell Stress
Cell Stress Cell
Stress Cell
Stress Cell
Stress
Other
Other
Other
Other

Protein
RL5
Syn
RL13
RL332
EF-TU
RL27
GatB
RS7
RL16
RL10
CysK
CarB
OtcC
KpyK
Pur8
HutG
Pgk
GlmS
OdpB
Ldh1
SplB
SplD
SspA
SspB
SspP
SplA
SplC
SplE
LukDV/HlgB
HlgA
Hld
Hla
PsmA4
LukB/H
LukA/G
ClfA
Asp23
Ch60
ClpL
OhrL
HchA
Pnp
Lip1
Pbp
PpaC

Identity
Ribosomal protein
Asparagine-tRNA ligase
Ribosomal protein
Ribosomal protein
Elongation factor
Ribosomal protein
Aspartyl/glutamyl-tRNA amidotransferase subunit B
Ribosomal protein
Ribosomal protein
Ribosomal protein
Cysteine synthase
Carbamoyl phosphate synthetase subunit B
Ornithine carbamoyltransferase
Pyruvate kinase
Adenylosuccinate lyase
Formimidoylglutamase
Phosphoglycerate kinase
Glutamine--fructose-6-phosphate aminotransferase
Pyruvate dehydrogenase E1 component subunit beta
L-lactate dehydrogenase 1
Serine-like proteasea
Serine-like protease
Serine protease
Cysteine protease
Cysteine protease
Serine-like protease
Serine-like protease
Serine-like protease
Leukocidin component
Gamma-hemolysin component A
Delta-hemolysin
Alpha-hemolysin
Phenol-soluble modulin alpha 4 peptide
Leukocidin component
Leukocidin component
Clumping factor A
Alkaline shock protein
60 kDa chaperonin
ATP-dependent Clp protease ATP-binding subunit
Organic hydroperoxide resistance protein-like
Molecular chaperone Hsp31 and glyoxalase 3
Polyribonucleotide nucleotidyltransferase
Lipase
Beta-lactam-inducible penicillin-binding protein
Probable manganese-dependent inorganic pyrophosphatase
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5.13
Other
Lip2
Lipase
4.33
Other
Ggi3
Antibacterial protein 3 homolog
4.25
Other
AtpB
ATP synthase subunit beta
3.98
Other
AtpA
ATP synthase subunit alpha
3.84
Other
ButA
Diacetyl reductase
3.72
Other
Ispd2
2-C-methyl-D-erythritol 4-phosphate cytidylyltransferase 2
3.69
Other
Y2518
Uncharacterized hydrolase
3.49
Other
Y2365
Uncharacterized lipoprotein
3.44
Other
Ptg3C
PTS system glucose-specific EIICBA component
3.30
Other
GcsT
Aminomethyltransferase
3.17
Other
FtsZ
Cell division
2.94
Other
PdxS
Pyridoxal biosynthesis lyase
2.83
Other
CatA
Catalase
2.63
Other
Y840
Uncharacterized protein
2.46
Other
DldH
Dihydrolipoyl dehydrogenase
2.45
Other
ClpB
Chaperone protein
2.44
Other
PtgA
Glucose-specific phosphotransferase enzyme IIA component
2.36
Other
MtlD
Mannitol-1-phosphate 5-dehydrogenase
2.21
Other
Y370
Uncharacterized protein
2.20
Other
Y941
NADH dehydrogenase-like protein
2.16
Other
UP355
Uncharacterized protein
2.14
Other
Dbh
DNA-binding protein
2.10
Other
Y1797
Uncharacterized protein
a
Proteins in red were selected for follow-up confirmation with mutant strains
Table S4.2 Proteins identified to be in greater abundance in WT S. aureus biofilmconditioned medium compared to WT planktonic-conditioned medium
Magnitude
36.16
19.56
19.27
15.11
13.88
10.66
10.54
10.16
9.01
8.12
7.95
7.59
7.54
7.47
6.98
6.74
6.71
6.48
5.97

Category
Metabolism
Metabolism
Metabolism
Metabolism
Metabolism
Metabolism
Metabolism
Metabolism
Metabolism
Metabolism
Metabolism
Metabolism
Metabolism
Metabolism
Metabolism
Metabolism
Metabolism
Metabolism
Metabolism

Protein
GlmS
GlnA
PyrB
Dha1
Alf1
Odo1
Kad
DaaA
TpiS
Pur1
Odp2
P5cr
PyrG
HutG
LdhD
AckA
SdrD
Acp
RocA

Identity
Glutamine--fructose-6-phosphate aminotransferase
Glutamine synthetase
Aspartate carbamoyltransferase
Alanine dehydrogenase 1
Fructose-bisphosphate aldolase class 1
2-oxoglutarate dehydrogenase E1 component
Adenylate kinase
D-alanine aminotransferase
Triosephosphate isomerase
Amidophosphoribosyltransferase
Dihydrolipoyllysine-residue acetyltransferase
Pyrroline-5-carboxylate reductase
CTP synthase
Formimidoylglutamase
D-lactate dehydrogenase
Acetate kinase
Serine-aspartate repeat-containing protein D
Acyl carrier protein
1-pyrroline-5-carboxylate dehydrogenase
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4.97
4.86
4.83
4.56
4.00
3.94
3.62
3.56
2.89
2.88
2.83
2.66
2.10
15.61
8.07
7.28
7.20
6.06
4.96
4.84
4.62
4.43
4.30
3.74
3.62
2.81
13.97
9.19
8.05
7.05
6.59
4.03
2.80
2.48
66.31
13.95
7.61
6.05
5.14
4.46
4.19
7.29
5.11
3.35
2.75
2.73
2.06
10.98
2.90
2.73
2.57

Metabolism
Metabolism
Metabolism
Metabolism
Metabolism
Metabolism
Metabolism
Metabolism
Metabolism
Metabolism
Metabolism
Metabolism
Metabolism
Translation
Translation
Translation
Translation
Translation
Translation
Translation
Translation
Translation
Translation
Translation
Translation
Translation
Virulence
Virulence
Virulence
Virulence
Virulence
Virulence
Virulence
Virulence
Redox
Redox
Redox
Redox
Redox
Redox
Redox
Cell Stress
Cell Stress
Cell Stress
Cell Stress
Cell Stress
Cell Stress
Structural
Structural
Structural
Structural

TdcB
Pdp
Hps
K6pf
Mqo2
Pgk
CarB
KpyK
OtcC
PyrC
F16pC
PurM
OdpB
RL29
RL3
RL25
RL14
RL24
RL7
GatB
RS2
RL16
RS15
RL5
RL11
RS7
FnbA
GyrA
LukDV/HlgB
LukB/H
BlaR
HlgC
Emp
Plc
MtlD
Dhe2
Y2305
AhpF
Y542
Adh
Azo1
SodM
RecA
CspA
GrpE
ClpB
ClpC
Atl
IsdC
Omp7
Rot

L-threonine dehydratase catabolic protein
Pyrimidine-nucleoside phosphorylase
3-hexulose-6-phosphate synthase
6-phosphofructokinase
Probable malate:quinone oxidoreductase 2
Phosphoglycerate kinase
Carbomoyl phosphate synthetase subunit B
Pyruvate kinase
Ornithine carbamoyltransferase, catabolic subunit
Dihydroorotase
Fructose-1,6-bisphosphatase class 3
Phosphoribosylformylglycinamidine cyclo-ligase
Pyruvate dehydrogenase E1 component subunit beta
Ribosomal protein
Ribosomal protein
Ribosomal protein
Ribosomal protein
Ribosomal protein
Ribosomal protein
Aspartyl/glutamyl-tRNA amidotransferase subunit B
Ribosomal protein
Ribosomal protein
Ribosomal protein
Ribosomal protein
Ribosomal protein
Ribosomal protein
Fibronectin-binding protein A
DNA gyrase subunit A
Leukocidin componenta
Leukocidin component
Regulatory protein
Gamma-hemolysin component C
Extracellular matrix protein-binding protein
1-phosphatidylinositol phosphodiesterase
Mannitol-1-phosphate 5-dehydrogenase
NAD-specific glutamate dehydrogenase
Putative 2-hydroxyacid dehydrogenase
Alkyl hydroperoxide reductase subunit F
Putative heme-dependent peroxidase
Alcohol dehydrogenase
FMN-dependent NADPH-azoreductase
Superoxide dismutase
Recombinase A
Cold shock protein
Putative stress response protein
Chaperone protein
ATP-dependent Clp protease ATP-binding subunit
Bifunctional autolysin
Iron-regulated surface determinant protein C
77 kDa membrane protein
Repressor of toxin, transcriptional regulator

117
2.35
Structural
IsdH
Iron-regulated surface determinant protein H
2.00
Structural
SarA
Transcriptional regulator
8.33
Protease
SplF
Serine-like protease
5.74
Protease
SplA
Serine-like protease
5.46
Protease
SplE
Serine-like protease
3.91
Protease
Aur
Zinc metalloproteinase aureolysin
3.70
Protease
PepVL
Putative dipeptidase subunit
87.39
Other
RsbW
Serine-protein kinase
18.16
Other
SrrA
Transcriptional regulatory protein
15.64
Other
Dpo3B
DNA polymerase III subunit beta
14.54
Other
PanB
3-methyl-2-oxobutanoate hydroxymethyltransferase
14.02
Other
AtrF2
Putative acetyltransferase
13.22
Other
RpoE
Probable DNA-directed RNA polymerase subunit delta
11.32
Other
Hem3
Porphobilinogen deaminase
11.29
Other
RpoC
DNA-directed RNA polymerase subunit beta'
8.30
Other
AtpB
ATP synthase subunit beta
7.27
Other
GpsB
Cell cycle protein
6.91
Other
IlvE
Probable branched-chain-amino-acid aminotransferase
6.71
Other
HdoX2
Heme oxygenase (staphylobilin-producing) 2
5.82
Other
Y680
Probable transcriptional regulatory protein\
5.75
Other
CodY
GTP-sensing transcriptional pleiotropic repressor
5.50
Other
SceD
Probable transglycosylase
5.46
Other
Np30
30 kDa neutral phosphatase
4.60
Other
ThlA
Probable acetyl-CoA acyltransferase
4.49
Other
Y1696
UPF0297 protein
4.33
Other
RpoA
DNA-directed RNA polymerase subunit alpha
4.27
Other
Rnj1
Ribonuclease J 1
3.94
Other
PdxT
Glutamine amidotransferase subunit
3.93
Other
FtsL
Cell division protein
3.68
Other
Oat2
Ornithine aminotransferase 2
3.56
Other
Gsa2
Glutamate-1-semialdehyde 2,1-aminomutase 2
3.29
Other
Y2518
Uncharacterized hydrolase
3.23
Other
PtgA
Glucose-specific phosphotransferase enzyme IIA component
3.07
Other
Ptg3C
PTS system glucose-specific EIICBA component
3.06
Other
Y752
Uncharacterized protein
2.75
Other
Y968
Uncharacterized protein
2.40
Other
FabF
3-oxoacyl-[acyl-carrier-protein] synthase 2
2.37
Other
Ldh2
L-lactate dehydrogenase 2
a
Proteins in red were selected for follow-up confirmation with mutant strains
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Discussion
S. aureus subverts the host immune response by numerous mechanisms, including increased
resistance to cationic antimicrobial peptides, impairment of phagocyte recruitment, interference
with antibody-mediated opsonization and complement activation, and resistance to intracellular
killing (213). In addition, biofilm formation further protects S. aureus from the host innate
immune response, representing a communal virulence determinant (15, 56, 159). We have
previously demonstrated that biofilm formation shields S. aureus from Toll-like receptor (TLR)
detection and interferes with MΦ activation in vivo (15, 160). Here we explored the genetic basis
of how biofilm growth prevents MΦ phagocytosis. Our earlier study showed that MΦs were
capable of phagocytosing bacteria from mechanically disrupted, but not intact biofilms,
suggesting that the size of the biofilm and/or density of its matrix represents a physical obstacle, a
phenomenon referred to as “frustrated phagocytosis” (15, 254, 255). Here we extend these
findings to demonstrate that S. aureus biofilms also secrete proteinaceous factors that actively
inhibit MΦ phagocytosis and induce cell death. Interestingly, this proteinaceous component was
mainly evident in intact biofilms, as conditioned medium from mechanically disrupted biofilms
or planktonic cultures grown to early or late stationary phase failed to prevent phagocytosis to the
same extent, although bacterial numbers and secreted protein concentrations were similar (Fig.
1D, Supplemental Fig. S4.1, and data not shown). The preferential ability of intact S. aureus
biofilms to inhibit MΦ phagocytosis suggested the involvement of QS mechanisms that are
enriched during biofilm growth and dissipate once the biofilm structure has been disrupted. This
was confirmed by the finding that biofilm-mediated MΦ dysfunction, in particular cell death, was
less pronounced following exposure to conditioned medium from a ∆agr biofilm. These
observations, combined with the fact that conditioned medium from PAS-treated biofilms
maintained inhibitory activity, whereas lysostaphin-treated biofilms did not, strongly implicated
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the importance of active protein secretion by the biofilm (based on proteinase K sensitivity) to
inhibit MΦ phagocytosis and induce cell death.
The identification of candidate proteins responsible for inducing MΦ death and inhibiting
phagocytosis was facilitated with a relatively new quantitative mass spectrometry technique,
namely SWATH-MS (189). After generating a protein library from our combined sample sets
(i.e. WT biofilm, Δagr biofilm, WT planktonic, and Δagr planktonic), comparisons were
performed to identify the most abundant proteins unique to WT biofilm-conditioned medium.
While this list included some proteins undoubtedly released as a result of cell lysis (i.e. metabolic
enzymes and ribosomal subunits), we focused on known secreted toxins and proteases that were
also detected. Of this list, LukB, as well as its partner component LukA, were shown to have a
significant impact on MΦ phagocytosis and viability. LukAB is unique among leukocidins for its
ability to either remain cell wall-associated or released into the extracellular milieu (67, 247,
248). A recent study has shown that human leukocytes are exquisitely sensitive to the cytolytic
actions of LukAB due to its specificity for CD11b (256) mediated by the binding of a specific
glutamic acid residue (323A) (186). While murine leukocytes are less sensitive to LukAB (256,
257), this toxin was still implicated in S. aureus pathogenesis in a murine renal abscess model
(67), which was confirmed in the current study using a murine S. aureus orthopedic implant
biofilm model. Therefore, although human cells display a greater sensitivity to LukAB, it is clear
from our report and work by others that this bi-component leukotoxin is also active towards
murine leukocytes.
In addition to LukAB, Hla also significantly contributed to biofilm-associated murine MΦ
death and phagocytosis. The toxic effects of Hla are well-known and, while a recent publication
has demonstrated the cytoprotective effects of S. aureus Hla within phagosomes (258), it is
important to note that this scenario is not applicable in our studies given that our phagocytosis
assay utilized microspheres and not viable bacteria. This strategy was employed to avoid
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confounds from toxins secreted by live planktonic S. aureus if they were used to measure MΦ
phagocytosis, which could not be discriminated from biofilm-secreted molecules. Interestingly,
the already potent cytolytic effects of S. aureus Hla were enhanced with the addition of purified
bioactive LukAB. Furthermore, treatment of ΔlukA and ΔlukB biofilm-conditioned medium with
a Hla neutralizing antibody significantly dampened the MΦ phagocytic block. These results
suggest a synergistic effect, whereby the presence of LukAB enhances or accelerates Hlamediated MΦ dysfunction, perhaps via enhanced binding, localization to the cell membrane, or
regulating intracellular signaling pathways.
Previous studies have demonstrated the importance of LukAB or Hla for S. aureus
pathogenesis in murine models of renal abscess (67), pneumonia (259, 260), skin infection (261,
262), bacteremia (263, 264), peritonitis (177, 262, 265), and other localized infection models
(242). However, it should be noted that a ΔlukAB single mutant displayed no attenuation of
virulence in murine models of skin infection and bacteremia (257). In support of our in vitro
findings, our study is the first to report that LukAB and Hla cooperate to regulate S. aureus
virulence in a murine orthopedic implant biofilm infection model. While ΔlukAB or Δhla single
mutants displayed decreased bacterial burdens in some tissues, ΔlukAB/Δhla showed the largest
reduction in bacterial numbers when compared to mice infected with the isogenic WT strain. In
further support of this synergistic effect, ΔlukAB/Δhla infected mice displayed the greatest
increase in MΦ infiltrates. While this in vivo data reveals an important synergistic role for LukAB
and Hla during S. aureus biofilm infection, it remains unclear whether these toxins are directly
altering MΦ survival (i.e. via cell lysis) or indirectly tailoring the immune response (i.e. eliciting
tissue damage resulting in altered cytokine signaling to promote MΦ phagocytosis and
proinflammatory activity). However, evidence against the former possibility was revealed by the
finding that biofilm-conditioned medium elicited similar cytotoxic effects towards
proinflammatory (classically activated) and pro-fibrotic (alternatively activated) MΦs (data not
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shown). We also investigated whether biofilm-conditioned medium augmented MΦ CD11b
expression, which binds LukAB, but found no evidence to support this possibility. Another
potential mechanism to link the synergistic effects of Hla and LukAB is the zinc-dependent
metalloproteinase ADAM10, since Hla is known to recognize ADAM10 on the host cell surface
(266). Once bound, Hla augments ADAM10 activity (267), which could result in increased
LukAB dissociation from the bacterial cell surface and, in turn, enhanced Hla activity. However,
it should be noted that this interaction may provide an explanation for our in vivo findings, but
fails to inform the apparent synergistic effect in our in vitro assay, since MΦs were treated with
biofilm-conditioned medium clarified of bacteria. The mechanism whereby LukAB and Hla
influence biofilm formation in vivo is an area of active investigation in our laboratory.
While the effect of S. aureus biofilm-conditioned medium on MΦ viability was largely
LukAB/Hla-dependent, it appears that part of the phagocytic block was not. SWATH-MS
identified other potential candidate proteins that could act in concert with Hla/LukAB to
maximally impair MΦ phagocytosis, including pyrimidine biosynthetic enzymes,
phosphotransferase proteins, pyruvate kinase, and histidine metabolic enzymes. Along these lines,
it is important to recognize that biofilms represent a diverse bacterial population influenced by a
myriad of complex gradients (e.g. nutrient, oxygen, pH,), metabolic activity, and virulence
potential (13, 84, 268, 269). For example, while our studies utilized conditioned medium
collected from static biofilms, a subpopulation of planktonic or “dispersed” cells is also present at
the air-liquid interface. While this cell population was 2-3 log lower than the biofilm
(Supplemental Fig. S4.4), it is probably naïve to disregard their impact; particularly in light of
recent studies demonstrating the secretory potential of biofilm-dispersed cells (270). Based on
this evidence, we posit that S. aureus biofilms prevent MΦ phagocytosis, in part, by inducing cell
death through LukAB and Hla production (Fig. 4.8). However, since the phagocytic block was
still evident even when MΦ viability was restored to 100% following LukAB/Hla inactivation,
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this suggests the action of additional proteins that act together with Hla/LukAB to maximally
inhibit MΦ phagocytic activity (Fig. 4.8).
Collectively, this study demonstrates that S. aureus biofilms have evolved mechanisms to
establish persistent infections, in part, by actively preventing MΦ phagocytosis and eliciting cell
death that is mediated by the synergistic actions of LukAB and Hla. These findings not only
identify a novel interaction for these secreted proteins, but also highlight the layers of redundancy
within the S. aureus virulence repertoire.
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Chapter 5: purB affects eDNA release during Staphylococcus aureus biofilm development to
evade macrophage recognition
Manuscript in preparation
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Abstract
The typical MΦ response to planktonic S. aureus involves the induction of
proinflammatory, microbicidal activity. However, S. aureus biofilms can interfere with antibacterial mechanisms, in part, by polarizing MΦs toward an anti-inflammatory, pro-fibrotic
phenotype. Here we showed that MΦs exposed to S. aureus biofilms failed to induce the
proinflammatory transcription factor NF-κB, which translated into minimal inflammatory
cytokine production. We took advantage of this phenotype to screen the S. aureus Nebraska
Transposon Mutant Library to identify mutants that were no longer able to suppress MΦ NF-κB
activity. Among the top hits was purB, which encodes the enzyme adenylosuccinate lyase and
catalyzes two reactions in the purine metabolic pathway. In addition to no longer inhibiting MΦ
NF-κB activity, purB mutant biofilms were more susceptible to MΦ invasion and phagocytosis in
a MyD88-dependent manner. This was attributed, in part, to increased eDNA in the purB mutant
biofilm matrix that triggered MΦ invasion and phagocytosis of biofilm-associated bacteria via
Toll-like receptor 9 (TLR9). In vivo, the purB mutant displayed significantly decreased bacterial
burdens in a mouse orthopedic implant biofilm infection model concomitant with significantly
increased MΦ infiltrates that was dependent on TLR9 recognition during acute infection.
Collectively, these findings point towards a critical role for purB in facilitating biofilm evasion of
MΦ microbicidal effector functions.
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Introduction
S. aureus is an opportunistic pathogen recognized for its ability to cause both nosocomial
and community-associated infections (223). While S. aureus isolates encode a myriad of
virulence factors, including toxins, proteases, and nutrient acquisition systems that facilitate
colonization of numerous locations throughout the host, biofilm formation is another key
virulence determinant (15, 16). Biofilms are a heterogeneous population of bacteria surrounded
by a self-produced matrix composed of proteins, exopolysaccharides, and eDNA (32, 226, 227).
While the biofilm matrix likely provides some physical barrier from the host immune response,
heterogeneity within the bacterial population induced by signals such as nutrient and oxygen
gradients, likely provides another layer of protection via differential gene expression and protein
production throughout the biofilm proper (76). Indeed, our prior work demonstrated that S.
aureus biofilms alter their transcriptional profiles upon encountering MΦs (Chapter 3) and
biofilms are enriched in toxins that attenuate MΦ phagocytosis and induce cell death (Chapter 4)
(75, 171).
S. aureus has a number of mechanisms for sensing and responding to environmental
stimuli, including several characterized two-component regulatory systems. For example, the agr
QS system regulates the production of surface-associated versus secreted proteins according to
population density (84). In addition, the link between S. aureus metabolism and virulence is an
active area of investigation (86-89). While many connections are still unclear, previous studies
have demonstrated differential gene expression between S. aureus in the planktonic versus
biofilm lifestyles, including differences in metabolic gene expression (22). Interestingly, the
influence of bacterial metabolites on the host immune response is only beginning to be explored
and represents an area of investigation in our laboratory.
The innate immune system is well-equipped to recognize pathogens through a variety of
cell surface and PRRs. One example is the TLR family, which recognizes PAMPs such as
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lipoproteins and PGN in the bacterial cell wall (via TLR2) and unmethylated CpG motifs in
bacterial DNA (via TLR9). Once engaged by their microbial ligand, most TLRs (with the
exception of TLR3) initiate a proinflammatory signaling cascade through the adapter molecule
MyD88, culminating in NF-kB activation and the induction of a robust proinflammatory,
antimicrobial immune response. While PMNs are among the first innate immune responders to
planktonic bacterial infections such as those caused by S. aureus, there has been an increasing
appreciation for the role of resident tissue MΦs in this response. Although PMNs are highly
phagocytic and possess an arsenal of granules rich in antimicrobial peptides and enzymes (156),
MΦs are also professional phagocytes capable of producing high levels of reactive oxygen
species (ROS) and serve a critical role in leukocyte recruitment and activation through
chemokine/cytokine production as well as inducing adaptive immunity by antigen presentation
(125-127, 130).
Our previous work has established that S. aureus biofilms, in contrast to planktonic
organisms, prevent MΦ invasion and phagocytosis of biofilm-associated bacteria and drive MΦs
towards an anti-inflammatory state (15, 160). Recent studies have revealed a synergistic role for
the toxins Hla and LukAB in inhibiting MΦ phagocytosis and inducing cell death (75); however,
other factors are also involved. The purpose of this work was to identify key genes involved in
inhibiting MΦ proinflammatory activity by taking advantage of the NTML to screen for S. aureus
mutants that were still capable of biofilm formation but lost the ability to skew MΦs towards an
anti-inflammatory state, hence transforming them into proinflammatory, phagocytic cells. Our
results identified numerous hits in the purine regulatory pathway. In depth analysis of a purB
mutant (ΔpurB) revealed increased eDNA release at the outer surface of the biofilm that
triggered, in part, TLR9-mediated MΦ activation. In addition, ΔpurB was less virulent in a mouse
orthopedic implant biofilm model that was TLR9-dependent during the early stage of infection.
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Collectively, these findings suggest that S. aureus carefully regulate eDNA levels and
accessibility during biofilm formation to prevent MΦ recognition and proinflammatory activity.
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Results
Genes expressed during S. aureus biofilm growth that influence macrophage NF-κB
activation. Our previous work has shown that MΦs are unable to invade and phagocytose S.
aureus biofilm-associated bacteria and biofilm exposure drives MΦs towards an antiinflammatory phenotype (15, 160). Although our recent report demonstrated a synergistic role for
Hla and LukAB produced during S. aureus biofilm growth in preventing MΦ phagocytosis
(Chapter 4) (75), this study revealed that other proteins are also involved. To identify additional
molecules important for S. aureus biofilms to evade MΦ recognition, we utilized MΦs from NFκB-luciferase reporter mice to screen the NTML (158, 271, 272). NF-κB is a key transcription
factor that drives the expression of numerous cytokines/chemokines and is a widely used readout
of MΦ proinflammatory activity (125, 131, 230). To validate this screening approach, NF-κB
activation was minimal in MΦs exposed to intact S. aureus biofilms, whereas significant NF-κB
induction was observed in response to planktonic bacteria and S. aureus-derived PGN (Fig 5.1A).
The ability of biofilms to attenuate MΦ NF-κB activation is in agreement with significantly
impaired cytokine production (Fig 5.1B). Furthermore, after biofilm exposure, MΦs remain
refractory to subsequent stimulation by PAMPs, showing a reduction in both proinflammatory
and anti-inflammatory cytokines, similar to MΦs exposed to planktonic S. aureus (Fig 5.1C, D).
The NTML screen identified 22 mutants where MΦ NF-κB activity was significantly
increased compared to WT biofilms (Fig 5.1E, Table 5.1). S. aureus mutants were also evaluated
for their ability to form biofilms (Fig 5.1F), since impaired biofilm formation could lead to false
positive hits by the ability of planktonic bacteria to increase NF-κB activity (Fig 5.1A). Of note,
the numbers of mutants identified by our NF-κB screen were of relatively low abundance,
representing only 1.1% of the library, revealing the stringency of the assay, which was
corroborated by the identification of multiple hits within the purine pathway (i.e. purA, purB,
purF, purM, and purS) and other operons (Table 5.1 and data not shown). Of particular interest
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were purB and purA, since they represented the most robust inducers of MΦ NF-κB activity.
purB was selected for further analysis, since its phenotype was slightly larger, it participates in
two steps of the purine metabolic pathway (whereas purA catalyzes a single reaction;
Supplemental Fig. S5.1), and purB expression has been previously shown to be increased during
biofilm growth although functional assessments were not performed (22).
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Figure 5.1

Genes expressed during S. aureus biofilm growth that influence macrophage NF-κB
activation. (A) BMDMΦs from NF-κB-luciferase reporter mice were incubated with fresh
medium (Unstim.), PGN (10 µg/ml), or S. aureus planktonic or biofilm cultures for 4 h,
whereupon luciferase activity (counts per second) was measured as a function of NF-κB
activation and was normalized against PGN stimulated values (set to 100%). (B) MΦs were cocultured with biofilms or planktonic bacteria for 6 h, whereupon supernatants were collected to
quantitate TNF-α, IL-1β, IL-10, and IL-1RA by ELISA (N.D. = not detected). (C) MΦs were
incubated alone (non-exposed MΦ) or co-cultured with biofilms or planktonic bacteria for 2 h,
whereupon MΦs were separated from bacteria by FACS and treated with medium alone (no
treatment), the synthetic lipoprotein Pam3Cys (1 µg/ml), peptidoglycan (PGN; 10 µg/ml), or CpG
oligodeoxynucleotides (ODN; 0.1 µM) for an additional 24 h. At 24 h, supernatants were
collected for TNF-α and (D) IL-10 quantitation by ELISA [(-) = not detected]. (E) BMDMΦs
from NF-κB-luciferase reporter mice were incubated with WT or NTML biofilms for 4 h,
whereupon luciferase activity (counts per second) was measured as a function of NF-κB
activation. Luciferase activity elicited by each mutant was normalized against WT biofilm
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stimulated MΦs, which was set to 100% (solid red line). Red circles represent mutants where NFκB activity was increased (numbers refer to genes listed in Table 1). (F) Crystal violet staining
was utilized as a quantitative assessment of biofilm formation, with each mutant normalized
against WT biofilm, which was set to 100% (solid red line). Significant differences are denoted
by asterisks (*, p < 0.05; **, p < 0.01; ***, p < 0.001; unpaired two-tailed student’s t-test).
Results are representative of at least three independent experiments.
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Table 5.1. Genes expressed by S. aureus biofilms that influence macrophage NF-κB
activation in vitro
% WT

Locus

Gene

Identity

Function

418.05

SAUSA300_1889

purB

adenylosuccinate lyase

417.83

SAUSA300_0017

purA

adenylosuccinate synthetase

282.23

SAUSA300_1095

carA

264.28

SAUSA300_0969

purS

213.39
207.64
192.36

SAUSA300_0957
SAUSA300_2060
SAUSA300_0972

atpA
purF

carbamoyl phosphate synthase small
subunit
phosphoribosylformylglycinamidine
synthase
Hypothetical protein
F0F1 ATP synthase subunit alpha
amidophosphoribosyltransferase

181.38

SAUSA300_1225

175.67

SAUSA300_1467

ipdA

dihydrolipoamide dehydrogenase

157.96

SAUSA300_1105

priA

primosomal protein N

156.74

SAUSA300_0973

purM

155.16
154.37

SAUSA300_0489
SAUSA300_0787

aroD

phosphoribosylaminoimidazole
synthetase
putative cell division protein FtsH
biosynthesis of aromatic amino acids

153.29
151.66

SAUSA300_0086
SAUSA300_0618

Purine
metabolism
Purine
metabolism
Pyrimidine
metabolism
Purine
metabolism
hypothetical
metabolism
Purine
metabolism
Amino acid
metabolism
Amino acid
metabolism
DNA
replication
Purine
metabolism
Protease
Amino acid
metabolism
Hypothetical
Metal transport

147.22

SAUSA300_0538

146.53

SAUSA300_0213

145.23
145.22
142.94

SAUSA300_1754
SAUSA300_2631
SAUSA300_2030

aspartate kinase

splE

Hypothetical protein
ABC transporter substrate-binding
protein
NAD-dependent
epimerase/dehydratase family protein
oxidoreductase; Gfo/Idh/MocA
family
Serine-like protease
Putative N-acetyltransferase
Hypothetical protein

Location
on Fig.
5.1E
17
1
12
11
10
19
9
14
15
13
8
4
7
2
6

Carbohydrate
transport
Oxidoreductase

5

Protease
Metabolites
Hypothetical

16
20
18

3
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purB is important for preventing macrophage invasion and phagocytosis of mature S.
aureus biofilms. To determine whether the ability of the purB mutant to augment MΦ NF-κB
activity translated into increased invasion and phagocytosis of biofilm-associated bacteria, MΦs
were co-cultured with WT, ΔpurB, and ΔpurB complemented USA300 LAC biofilms. Indeed,
MΦ invasion into mature ΔpurB biofilms was significantly increased compared to WT (Fig.
5.2A) concomitant with enhanced phagocytosis (Fig. 5.2B). To confirm that these changes were
not the result of increased planktonic growth of ΔpurB, biofilm formation was assessed. ΔpurB
was capable of biofilm formation and although biofilm height was significantly reduced (Fig.
5.2C), quantitation revealed a minor reduction in bacterial counts (i.e. < 2-fold; Fig. 5.2D). The
increases in MΦ invasion and phagocytosis of ΔpurB biofilms was complementable (Fig. 5.2A,
B), underscoring the importance of purB in inhibiting MΦ activity.
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Figure 5.2

purB is important for preventing macrophage invasion and phagocytosis of mature S.
aureus biofilms. BMDMΦs were co-cultured with mature WT, ΔpurB, or ΔpurB + pTS1 GFP
biofilms for 4-6 h, after which the percentage of MΦs (A) invading or (B) phagocytosing the
biofilms was enumerated using confocal microscopy. (C) Mature GFP biofilms alone were
observed by confocal microscopy to measure average biofilm height, (D) after which mature
biofilms were mechanically disrupted, serially diluted in PBS, and plated to quantitate viable
bacteria. Significant differences are denoted by asterisks (*, p < 0.05; **, p < 0.01; one-way
ANOVA, followed by Bonferroni’s multiple-comparison test). Results are representative of at
least three independent experiments.
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eDNA is increased in S. aureus ΔpurB biofilms. Since the ability of MΦs to invade and
phagocytose biofilms is likely dictated, in part, by the accessibility of immune stimulatory motifs
at the outer biofilm surface, we next focused on the biofilm ECM. As eDNA is required for S.
aureus biofilm development (32) and bacterial DNA is a known TLR9 ligand (101, 102),
USA300 LAC GFP biofilms were stained with PI to visualize eDNA (Fig. 5.3A). The ratio of PI
(eDNA/dead bacteria) to GFP (live) signal was quantitated in z-stacks acquired by confocal
microscopy, which revealed a significant increase in eDNA/dead bacteria in ΔpurB throughout
biofilm maturation (Fig. 5.3B). As PI is not specific for eDNA, but also stains dead cells present
in the biofilm, eDNA was isolated from mature biofilms and the housekeeping gene gyrA was
quantitated by qRT-PCR. Results confirmed that ΔpurB biofilms contained significantly
increased eDNA (Fig. 5.3C) and all ΔpurB phenotypes could be complemented (Fig. 5.3).
Another interesting finding was that more PI staining was observed at the outer surface of ΔpurB
biofilms, presumably making it more accessible to MΦ recognition, compared to the WT and
complemented strains where eDNA was mainly buried at the base of the biofilm (Fig. 5.3A). To
determine whether the failure of MΦs to invade and phagocytose WT biofilms resulted, in part,
from inaccessibility to immune stimulatory eDNA, purified biofilm-derived eDNA was added to
the surface of mature WT biofilms, which phenotypically transformed the MΦ response to what
was observed with ΔpurB, namely increased biofilm invasion and phagocytosis (Fig. 5.3D).
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Figure 5.3

eDNA is increased in S. aureus ΔpurB biofilms. (A) Propidium iodide was added to mature (6
day-old) WT, ΔpurB, or ΔpurB + pTS1 GFP biofilms, visualized by confocal microscopy (X63,
1-μm slices), and representative three-dimensional images were constructed. (B) GFP and PI
signals were quantitated by COMSTAT analysis to determine a PI/GFP signal ratio. (C) eDNA
was collected from mature biofilms and quantitated by performing qRT-PCR with gyrA. (D)
BMDMΦs were co-cultured for 4-6 h with mature WT GFP biofilms alone, biofilms pretreated
for 30 min with 100 U/ml DNase1, and biofilms with additional eDNA added to the surface after
which the percentage of MΦs (D) invading or (E) phagocytosing biofilms was enumerated using
confocal microscopy. Significant differences are denoted by asterisks (*, p < 0.05; **, p < 0.01;
one-way ANOVA, followed by Bonferroni’s multiple-comparison test). Results are
representative of at least three independent experiments.
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S. aureus ΔpurB biofilm eDNA can be detected by MΦs and trigger activation. MΦs are
equipped with a variety of PRRs. Among these are TLRs, including TLR9, which senses bacterial
DNA and signals via the adapter molecule MyD88 to trigger NF-κB activation and
proinflammatory properties (101, 102). Since ΔpurB augmented MΦ NF-κB activation, biofilm
invasion, and phagocytosis, we next investigated whether this was TLR9-dependent based on
increased eDNA in the ΔpurB biofilm matrix and its accessibility at the surface. Again, WT MΦs
displayed significantly increased invasion (Fig. 5.4A) and phagocytosis (Fig. 5.4B) of ΔpurB
biofilms; however, this was diminished upon co-culture of ΔpurB biofilms with TLR9 KO MΦs,
and completely abrogated in the presence of MyD88 KO MΦs (Fig. 5.4A, B). Collectively, these
results suggest that purB is important for regulating eDNA levels and localization in biofilms,
which is partially responsible for the ability of WT biofilms to evade MΦ detection by preventing
TLR9-dependent proinflammatory activity. However, additional MyD88-dependent signaling
receptors are also involved, the identity of which remains to be determined.
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Figure 5.4

S. aureus biofilm eDNA can be detected by MΦs and trigger activation. BMDMΦs from WT,
TLR9 KO, and MyD88 KO mice were co-cultured with mature WT, ΔpurB, or ΔpurB + pTS1
GFP biofilms for 4-6 h, after which the percentage of MΦs (A) invading or (B) phagocytosing the
biofilms was enumerated using confocal microscopy. Significant differences are denoted by
asterisks (*, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001; one-way ANOVA, followed
by Bonferroni’s multiple-comparison test). Results are representative of at least three independent
experiments.
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S. aureus purB is important for chronic biofilm establishment. While the previous results
revealed a role for purB in the ability of S. aureus biofilms to evade MΦ recognition in vitro, we
next assessed the importance of purB in a model of orthopedic implant biofilm infection in WT
and TLR9 KO mice. Interestingly, ΔpurB displayed decreased bacterial burdens in WT mice
beginning at day 7, which became more pronounced over time, with some mice appearing to have
cleared the infection by day 28 (Fig. 5.5A). Decreased biofilm burdens in WT mice infected with
ΔpurB correlated with a significant reduction in anti-inflammatory MDSCs (Fig. 5.5B)
concomitant with increased MΦ infiltrates (Fig. 5.5B). While ΔpurB showed similarly decreased
biofilm burdens in TLR9 KO mice at later time points, concomitant with reduced MDSC and
increased MΦ infiltrates (Fig. 5.5C), importantly, there were no differences in titers between
ΔpurB and WT infected TLR9 KO mice at day 7 (black and grey squares). This suggests that
eDNA recognition in ΔpurB occurs via TLR9 but only during early biofilm development. By
extension, since WT biofilms have less eDNA that is not present at the outer biofilm surface and
accessible to invading MΦs, this may represent a mechanism whereby WT biofilms evade TLR9mediated recognition, in agreement with our earlier report (15). Importantly, the observed
decrease in bacterial burdens at day 14 was complementable (Fig. 5.5D), again underscoring the
specific importance of purB in this in vivo biofilm infection model. Complementation was not
assessed at other time points to limit the number of animals utilized.
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Figure 5.5

S. aureus purB is important for chronic biofilm establishment. (A) Bacterial burdens
associated with the soft tissue surrounding the knee of WT and TLR9 KO mice infected with WT
S. aureus and isogenic ΔpurB strains at days 7, 14, 21, and 28 post-infection. (B) Quantitation of
Ly6GhighLy6C+ MDSCs and F4/80+ MΦs infiltrating the soft tissue of C57BL/6 WT mice infected
WT S. aureus and isogenic ΔpurB strains at days 7, 14, 21, and 28 post-infection. (C)
Quantitation of Ly6GhighLy6C+ MDSCs and F4/80+ MΦs infiltrating the soft tissue of TLR9 KO
mice infected WT S. aureus and isogenic ΔpurB strains at days 7, 14, 21, and 28 post-infection.
(D) Bacterial burdens associated with the soft tissue surrounding the knee of WT and TLR9 KO
mice infected with WT S. aureus and isogenic ΔpurB, and complemented ΔpurB + pKK22:purB
strains at day 14 post-infection. Significant differences are denoted by asterisks (*, p < 0.05; **, p
< 0.01; ***, p < 0.001; one-way ANOVA, followed by Bonferroni’s multiple-comparison test).
Results are representative of at least two independent experiments.
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Supplemental Figure S5.1

Predicted purine biosynthetic pathway in S. aureus. 5-Phospho-alpha-D-ribose 1-diphosphate
(PRPP) is converted to 5-Phosphoribosylamine (PRA) by amidophosphoribosyltransferase
(purF), which is then converted to 5′-Phosphoribosylglycinamide (GAR) by
phosphoribosylamine-glycine ligase (purD), which is then converted to 5′-Phosphoribosyl-Normylglycinamide (FGAR) by phosphoribosylglycinamide formyltransferase 1 (purN), which is
then converted to 2-(Formamido)-N1-(5′-phosphoribosyl)acetamidine (FGAM) by a combination
of phosphoribosylformylglycinamidine synthase (purS), phosphoribosylformylglycinamidine
synthase I (purQ), and phosphoribosylformylglycinamidine synthase II (purL), which is then
converted to Aminoimidazole ribotide (AIR) by phosphoribosylformylglycinamidine cycloligase (purM), which is then converted to (5-Phospho-D-ribosyl)-5-amino-4imidazolecarboxylate (CAIR) by 5-(carboxyamino)imidazole ribonucleotide synthase (purK) and
5-(carboxyamino)imidazole ribonucleotide mutase (purE), which is then converted to 1-(5′Phosphoribosyl)-5-amino-4-(N-succinocarboxamide)-imidazole (SAICAR) by
phosphoribosylaminoimidazole-succinocarboxamide synthase (purC), which is then converted to
1-(5'-Phosphoribosyl)-5-amino-4-imidazolecarboxamide (AICAR) by adenylosuccinate lyase
(purB), which is then converted to 1-(5'-Phosphoribosyl)-5-formamido-4-imidazolecarboxamide
(FAICAR) followed by Inosine monophosphate (IMP) both by
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phosphoribosylaminoimidazolecarboxamide formyltransferase / IMP cyclohydrolase (purH);
which is then converted to adenylosuccinate by adenylosuccinate synthase (purA), which is then
converted to Adenosine monophosphate (AMP) by adenylosuccinate lyase (purB), which can
then be eventually converted into Adenosine triphosphate (ATP) and used as energy, into adenine
or adenosine through adenosine synthase (adsA), or into RNA or DNA as needed.
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Discussion
S. aureus subverts the host immune response by numerous mechanisms, including
increased resistance to cationic antimicrobial peptides, impairment of phagocyte recruitment,
interference with antibody-mediated opsonization and complement activation, and resistance to
intracellular killing (213). In addition, biofilm formation further protects S. aureus from the host
innate immune response, representing a communal virulence determinant (15, 56, 159). The
objective of this study was to identify genes expressed by S. aureus biofilms that contribute to
MΦ dysfunction through the inhibition of NF-κB.
MΦs utilize phagocytic receptors to identify microbes and trigger immune defenses.
Infectious agents that cause persistent infections, such as S. aureus biofilms, must be able to
detect and subvert these defenses. We have previously demonstrated that biofilm formation
protects S. aureus from TLR detection and phagocytosis, reduces proinflammatory cytokine and
chemokine production, decreases inducible NO synthase (iNOS) expression, and interferes with
MΦ activation in vivo (15, 160). We were interested in the genetic basis of how biofilm growth
prevents MΦ phagocytic functions. Previously, we determined that MΦs were capable of
phagocytosing bacteria from mechanically disrupted, but not intact biofilms, suggesting that the
size of the biofilm and/or density of its matrix may form a mechanical obstacle that physically
prevents MΦ phagocytosis, a phenomenon leading to “frustrated phagocytosis” (15, 254, 255).
Subsequent studies revealed that toxins, including Hla and LukAB are also responsible for the
MΦ phagocytic block, but that additional factors are also involved, which is not unexpected given
the arsenal of S. aureus virulence determinants.
In response to planktonic bacteria, MΦs produce numerous proinflammatory mediators,
exhibit potent phagocytic and anti-microbial activity, and are critical for immune cell recruitment
and activation, serving as a first line of defense against microbial invasion (200, 201). However,
we have previously reported that MΦs are polarized towards an alternatively activated, anti-

144
inflammatory, M2 phenotype upon contact with S. aureus biofilms (15, 160). Here we have
extended these findings to demonstrate that prior biofilm exposure makes MΦs refractory to a
subsequent microbial challenge, further highlighting the immune subversive properties of S.
aureus biofilms. Correspondingly, MΦ NF-κB activation was also significantly reduced after
contact with S. aureus biofilms, whereas a strong response was detected after exposure to
planktonic S. aureus or PGN. This indicates that in addition to impaired phagocytosis, another
mechanism utilized by S. aureus biofilms to subvert the host immune response results from the
ability to prevent MΦ NF-κB activation and resultant proinflammatory cytokine secretion.
Indeed, multiple pathogens employ similar strategies to interfere with MΦ microbicidal activity
either by hindering cytokine expression/secretion (273, 274) or by the production of virulence
factors that directly impede NF-κB activation (158, 275).
To identify genes expressed by S. aureus biofilms that inhibit MΦ NF-κB activation, a
screen of the NTML was performed. This approach utilized MΦs from transgenic mice where the
transcription factor NF-κB drives luciferase expression. Several S. aureus mutants in the purine
biosynthetic pathway (i.e. purA, purB, purF, purS, and purM) failed to block MΦ NF-kB
activation, implicating their involvement in thwarting proinflammatory functions. Previous work
demonstrated that S. aureus purine auxotrophs were less virulent in a murine abscess model of
infection (276). Likewise, purine biosynthesis also appears to have broad physiological effects in
S. aureus, including the modification of global patterns of virulence gene expression (276).
Accordingly, we found that ΔpurB biofilms secreted significantly decreased levels of Hla
compared to WT biofilms (Supplemental Fig. S5.2). Not surprisingly, ΔpurA and ΔpurB
displayed the most robust NF-κB activation in our experiments, as these genes represent more
distal steps in the purine biosynthetic pathway for converting inosine monophosphate (IMP) to
adenosine monophosphate (AMP). A major end product of the purine biosynthetic pathway,
AMP, can be converted to adenosine during staphylococcal infections (277). Adenosine is a
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potent extracellular messenger that is abundant at sites of hypoxia, trauma, and inflammation
(278). Moreover, adenosine has strong immunosuppressive effects, such as down-regulating
cytokine production and immune cell receptors, many of which are mediated by its ability to bind
A3 and A2A receptors on leukocytes (278-280). Accordingly, we found that adenosine attenuated
MΦ NF-κB activity in response to PGN stimulation, further indicating that products of the purine
biosynthetic pathway influence MΦ activation (Supplemental Fig. S5.3).
Interestingly, these studies indicate that purine biosynthesis is also important for S.
aureus regulation of eDNA in the outer biofilm matrix. Consistent with our previous studies,
disrupting the ability of MΦs to recognize bacterial eDNA via TLR9 does not alter invasion and
phagocytosis during co-culture with WT biofilms in vitro, nor does it result in a more severe
infection in vivo in association with WT S. aureus (15). However, disrupting purine biosynthesis
via ΔpurB results in increased eDNA, particularly at the biofilm surface, providing an accessible
PAMP for MΦ recognition and activation. While this phenomenon was complementable and
reproducible with the addition of eDNA to the WT S. aureus biofilm surface, we observed a
stronger phenotype in association with MyD88, implying an additive effect of other PAMP(s)
being recognized by other TLRs, the identity of which remains to be determined.
The results of the current study, concomitant with our previous findings, support the
conclusion that S. aureus biofilms have evolved mechanisms to establish persistent infections, in
part, by actively programming MΦs towards an anti-inflammatory phenotype and preventing
phagocytosis, presumably through the production of adenosine. Additionally, S. aureus biofilms
shield the eDNA component of the ECM from MΦ recognition at the biofilm surface, thereby
further evading MΦ detection.
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Supplemental Figure S5.2

purB activity effects Hla production in S. aureus biofilms. Quantitation of Hla levels in
conditioned medium from WT S. aureus biofilms versus isogenic ΔpurB, and complemented
ΔpurB + pTS1 strains. Significant differences are denoted with asterisks (****, p < 0.0001;
unpaired two-tailed student’s t-test). Results are representative of at least two independent
experiments.
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Supplemental Figure S5.3

Adenosine attenuates macrophage activation. Bone marrow-derived macrophages from NFκB-luciferase reporter mice were stimulated with 10 μg/ml peptidoglycan (PGN) for 2 h + 50 μM
adenosine, whereupon luciferase activity was measured as a function of NF-κB activation.
Significant differences are denoted with asterisks (*, p < 0.05; unpaired two-tailed student’s ttest). Results are representative of at least three independent experiments.
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Chapter 6: Discussion and Future Directions
Key Findings and Conclusions:
The phagocytic and microbicidal activities of PMNs and MΦs are among the first lines of
protection from bacterial pathogens. However, S. aureus is often resistant to innate immunity,
especially when ensconced within the confines of the biofilm matrix. While previous studies in
our laboratory have shown that S. aureus biofilms are able to resist clearance by both PMNs and
MΦs, we wondered if this was accomplished by a conserved set of genes or through entirely
different means. In order to answer this question, we examined biofilm gene expression profiles
following co-culture with these two innate immune cell populations. We also compared the
relative ability of PMNs and MΦs to invade and phagocytose biofilm-associated S. aureus. To
our knowledge, this was the first study of its kind with any species of bacterial biofilm.
During co-culture with PMNs, we observed no significant alteration of the S. aureus
biofilm transcriptome at an early or late period (Chapter 3). This was unexpected, especially
taken together with our confocal data indicating that PMNs were readily able to invade the
biofilm matrix and phagocytose biofilm-associated bacteria. While it is known that S. aureus can
survive intracellularly in PMNs (215, 281, 282), PMN phagocytosis did not result in a significant
reduction in viable bacterial numbers in vitro, and one would expect this adaptation to necessitate
major transcriptional changes but this was not observed. While few transcriptional changes were
detected, interestingly agr transcription was significantly increased after PMN addition to
biofilms. agr regulates the production of numerous secreted virulence factors, including phenolsoluble modulins (PSMs), which have been shown to play a role in biofilm maturation and are
known to elicit cytotoxic effects on PMNs (79, 283). In agreement with this finding, we noted
that Δagr biofilms were less able to inhibit PMN invasion and induce PMN cell death, despite
being significantly thicker on average.
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In contrast to PMNs, we observed a significant dampening of the biofilm transcriptome
during early co-culture with MΦs, including numerous metabolism-associated genes. This
transcriptional dormancy was negated at late co-culture periods, likely because a vast majority of
MΦs had already succumbed to cell lysis by biofilm-secreted toxins (Chapter 4). Also in contrast
to PMNs, we were able to document little/no MΦ invasion and phagocytosis of biofilmassociated bacteria, perhaps in part due to successful “cloaking” of the biofilm. This curious
difference in the biofilm transcriptional response to PMNs and MΦs, despite invasion and
phagocytosis by the former and little to none by the latter, could be explained by the presence of a
MΦ secreted molecule being sensed by the biofilm.
As I had now confirmed previous experiments in our laboratory observing an inability of
MΦs to phagocytose biofilm-associated bacteria, the next question was whether molecules in the
biofilm-conditioned milieu contributed to this phagocytic block (Chapter 4). We first
demonstrated that S. aureus biofilm-conditioned medium could inhibit MΦ phagocytosis and
induce cell death, and that it was significantly more inhibitory and lytic than planktonicconditioned medium. Next, we established that the bioactive factors were actively secreted,
proteinaceous in nature, specific to intact biofilms, and at least partially agr-dependent. We then
performed proteomics analysis via SWATH-MS comparing conditioned medium from Δagr with
the WT strain, which identified Hla and LukAB as significantly enriched in WT biofilmconditioned medium. These results were further corroborated by Western Blot, ELISA, and a
series of MΦ treatments using combinations of neutralizing antibodies and Δhla ΔLukAB
mutants. Furthermore, hla and lukAB were found to act synergistically in vitro and in vivo in an
implant-associated biofilm infection model. Taken together, these studies identified a novel
interaction between these secreted proteins and highlighted another layer of redundancy within
the S. aureus virulence secretome.
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Having identified secreted proteins enriched in S. aureus biofilms that hinder macrophage
phagocytosis and induce cell death, we wanted to specifically ask how biofilms are able to skew
macrophages towards an anti-inflammatory, M2 profile. In order to answer this question, we
performed a high-throughput screen of the NTML in which we co-cultured BMDMΦs from NFκB reporter mice with S. aureus single-gene mutants to identify genes involved in inhibiting
proinflammatory, or M1, MΦ activation (Chapter 5). This screen identified over 20 genes, several
of which encode proteins involved in purine biosynthesis, including one of the top hits,
adenolysuccinate lyase (purB). In vitro, ΔpurB biofilms displayed a significantly decreased
ability to inhibit MΦ invasion and phagocytosis of biofilm-associated bacteria, which was
complementable. We next examined differences in biofilm eDNA content and found that ΔpurB
biofilms contained increased amounts of eDNA. Suspecting that increased eDNA at the biofilm
surface may be leading to increased MΦ activation and invasion, we next performed co-cultures
with BMDMΦs from TLR9 and MyD88 KO mice and found that both had a decreased ability to
invade ΔpurB biofilms. Interestingly, however, MyD88 KO MΦs showed the most significant
decrease, indicating a role for additional PAMPs in this co-culture paradigm in addition to the
CpG motifs present in biofilm eDNA that would be recognized by TLR9. Furthermore, we were
able to show that spiking additional eDNA onto WT S. aureus biofilms facilitated increased
invasion. Finally, we demonstrated the importance of purB in the establishment of an infection in
vivo in our murine orthopedic implant model, which we were also able to confirm by
complementation.
In total, my studies have helped identify some key factors that contribute to S. aureus
biofilm evasion of MΦ recognition and inhibition of MΦ antimicrobial activities (Fig. 6.1). These
experiments also serve to further highlight the immense challenge we face in attempting to more
effectively treat, and even prevent, S. aureus biofilm infections. The vast repertoire of virulence
factors and exquisite control over which S. aureus produces them is truly astounding. It is my
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hope that these studies may positively contribute to the ever growing corpus of S. aureus research
that should one day allow us to live in harmony with this commensal turned opportunistic
pathogen.
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Figure 6.1

Mechanisms by which S. aureus biofilms interfere with MΦ antimicrobial responses. 1) S.
aureus biofilms are able to uniquely detect and respond to MΦ over PMN insult by downregulating much of its transcriptional activity. 2) S. aureus biofilms are uniquely enriched over
planktonic cultures in Hla, LukAB, adenosine, and other factors that contribute to macrophage
antimicrobial inhibition and cell death. 3) S. aureus biofilms are able to regulate eDNA
expression in a purB-dependent manner thereby further preventing MΦ detection via TLR9.
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Future Directions:
Proteomics on innate immune cell and S. aureus biofilm co-cultures
While transcriptional profiling of the S. aureus biofilm after co-culture with either PMNs
or MΦs was novel and informative, a translational assessment of biofilm protein production could
help confirm some of the earlier data and pinpoint shifts in actual protein production in response
to immune insults. In addition, it would be exciting to simultaneously measure protein production
fluctuations from the PMN and MΦ populations after encountering a biofilm. This data collection
could also begin to shed light on potential players in host-pathogen crosstalk and could be
performed using SWATH-MS mass spectrometry. Significant S. aureus protein hits could be
isolated, purified, and used to treat both immune cell populations in vitro to assess the impact on
antimicrobial activity via phagocytic assay, qRT-PCR, and/or Western Blot. Similarly, individual
PMN or MΦ protein hits could be used to treat biofilms to assess the impact on metabolic and
transcriptional activity as measured by qRT-PCR and confocal microscopy via reporter constructs
of key genes. Finally, it may also be interesting to perform immune cell co-cultures with
planktonic S. aureus to gain a fuller understanding of how biofilms alter the innate immune
response. To my knowledge, this would be a completely novel study and should be feasible by
careful identification of bacterial and eukaryotic proteins via consultation with separately
acquired reference libraries.

Identify biofilm proteins that directly inhibit macrophage phagocytosis
Although the effect of S. aureus biofilm-conditioned medium on MΦ viability was
largely Hla/LukAB-dependent, part of the phagocytic block was not. While SWATH-MS
identified other potential candidate proteins including pyrimidine biosynthetic enzymes,
phosphotransferases, pyruvate kinase, histidine metabolic enzymes, and serine-like proteases,
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these were all identified in a comparison between WT and Δagr mutant biofilms and part of the
phagocytic block was not agr-dependent. However, we know this phenotype is protein-dependent
as treatment of the biofilm-conditioned medium with Proteinase K fully reversed the phagocytic
block. With this in mind, other two-component regulators could be tested, in conjunction with
neutralizing Hla and LukAB antibody, to identify a regulator of the protein of interest. Upon
identification, SWATH-MS could be performed as before with the new comparator to identify the
protein(s) involved in directly inhibiting MΦ phagocytosis. Alternatively, a phagocytic screen of
the NTML could be performed assessing the inhibitory effect of conditioned medium from every
mutant biofilm after treatment with the neutralizing antibodies. This study could lead to the
identification of a novel drug target, as we have previously shown that, once activated and
phagocytic, MΦs are capable of decreasing bacterial burdens in an established biofilm infection
in vivo.

Assess agr activity across various medium formulations
Though my original co-culture experiments were performed with RPMI-1640
supplemented with 10% FBS, the MS proteomics studies required supplementation with 1%
casamino acids, since the proteins in FBS would have masked the detection of most bacterial
proteins. Importantly, pilot studies demonstrated similar biofilm formation between FBS and
casamino acids and no adverse effects on MΦ function or viability. However, I have observed
apparently increased levels of sarAP1 promoter activity during biofilm growth in casamino acids
as determined by fluorescence intensity of the sarAP1-GFP plasmid used to visualize the biofilm,
even when normalized for any differences in culturable bacteria. In addition, I have measured
significantly increased levels of Hla production in biofilms grown in casamino acids by ELISA,
even when normalized for any differences in total protein production. As agr regulates numerous
virulence factors including Hla, it would be interesting to note any significant differences in its
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activity between the two media formulations. I could also include more traditional
microbiological media formulations (e.g. TSB), with the expectation that it may promote even
greater agr activity than casamino acids, since it is more nutrient-rich. These studies could be
very interesting and help inform medium selection for in vitro experimentation, particularly when
attempting to draw correlations between growth in media and growth during infection in a
patient. Finally, it would be very interesting to identify any molecules present in the FBS that
inhibit agr activity, as these could potentially be used therapeutically. What about examining
changes when grown in dilute blood to mimic colonization/growth during wound formation?

Characterize the ΔpurB blood agar phenotype
During my experiments with ΔpurB, I noticed that the mutant had a significant growth
defect on TSA + 10% sheep blood in that it was unable to form single, isolated colonies, although
growth was observed in concentrated areas of bacterial lawns. Curiously, this phenotype
disappears after a few days of static biofilm growth in vitro or after 7 days of infection in the in
vivo model of orthopedic implant biofilm infection. In order to determine the responsible genes, I
could perform transcriptomics comparing ΔpurB with the WT strain pre- and post- in vitro or in
vivo biofilm growth. Alternatively, I could perform DNA sequencing to look for any mutations
that may be occurring during these growth conditions that suddenly confer growth on blood agar.
S. aureus infections are challenging to treat as it seems to be uniquely adapted to
circumvent the host antimicrobial response, with the ability to colonize multiple sites on the
human body with ease. Furthermore, S. aureus seems equally adept at benignly living on the
human body as a commensal or chronically persisting inside the body as a pathogen. While many
scientists are attempting to prevent S. aureus infections through the development of vaccines
targeting key virulence factors or through manipulating the bacterial virulence factor regulatory
pathways themselves, the diversity of states in which S. aureus can survive (e.g. planktonic vs
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biofilm, proliferative vs persister) has made the identification of a common denominator to target
unclear. What is becoming clearer, however, is that a multifactorial approach, combining some
form of antibiotics with an immunostimulatory boost, will likely be required. Therefore, there is a
continued pressing need to better understand all of the ways in which S. aureus biofilms thwart
innate immunity.
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